IPCS INCHEM Home



    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY




    ENVIRONMENTAL HEALTH CRITERIA 210



    PRINCIPLES FOR THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM
    EXPOSURE TO CHEMICALS



    This report contains the collective views of an international group
    of experts and does not necessarily represent the decisions or the
    stated policy of the United Nations Environment Programme, the
    International Labour Organisation, or the World Health
    Organization.


    Published under the joint sponsorship of the United Nations
    Environment Programme, the International Labour Organisation, and the
    World Health Organization, and produced within the framework of the
    Inter-Organization Programme for the Sound Management of Chemicals.




    World Health Organization
    Geneva, 1999


         The International Programme on Chemical Safety (IPCS),
    established in 1980, is a joint venture of the United Nations
    Environment Programme (UNEP), the International Labour Organisation
    (ILO), and the World Health Organization (WHO).  The overall
    objectives of the IPCS are to establish the scientific basis for
    assessment of the risk to human health and the environment from
    exposure to chemicals, through international peer review processes, as
    a prerequisite for the promotion of chemical safety, and to provide
    technical assistance in strengthening national capacities for the
    sound management of chemicals.

         The Inter-Organization Programme for the Sound Management of
    Chemicals (IOMC) was established in 1995 by UNEP, ILO, the Food and
    Agriculture Organization of the United Nations, WHO, the United
    Nations Industrial Development Organization, the United Nations
    Institute for Training and Research, and the Organisation for Economic
    Co-operation and Development (Participating Organizations), following
    recommendations made by the 1992 UN Conference on Environment and
    Development to strengthen cooperation and increase coordination in the
    field of chemical safety.  The purpose of the IOMC is to promote
    coordination of the policies and activities pursued by the
    Participating Organizations, jointly or separately, to achieve the
    sound management of chemicals in relation to human health and the
    environment.

    WHO Library Cataloguing-in-Publication Data

    Principles for the assessment of risks to human health from exposure
    to chemicals.

    (Environmental health criteria ; 210)

    1.Chemicals - toxicity
    2.Chemicals - adverse effects
    3.Risk assessment - methods
    4.Environmental exposure
    5.Toxicity tests
    6.Dose-response relationship, Drug
    7.No-observed-adverse effect level

    I.International Programme on Chemical Safety
    II.Series

    ISBN 92 4 157210 8  (NLM Classification: QV 602)
    ISSN 0250-863X

    The World Health Organization welcomes requests for permission to
    reproduce or translate its publications, in part or in full. 
    Applications and enquiries should be addressed to the Office of
    Publications, World Health Organization, Geneva, Switzerland, which

    will be glad to provide the latest information on any changes made to
    the text, plans for new editions, and reprints and translations
    already available.

    (c) World Health Organization 1999

    Publications of the World Health Organization enjoy copyright
    protection in accordance with the provisions of Protocol 2 of the
    Universal Copyright Convention.  All rights reserved.
    The designations employed and the presentation of the material in this
    publication do not imply the expression of any opinion whatsoever on
    the part of the Secretariat of the World Health Organization
    concerning the legal status of any country, territory, city, or area
    or of its authorities, or concerning the delimitation of its frontiers
    or boundaries.

    The mention of specific companies or of certain manufacturers'
    products does not imply that they are endorsed or recommended by the
    World Health Organization in preference to others of a similar nature
    that are not mentioned. Errors and omissions excepted, the names of
    proprietary products are distinguished by initial capital letters.

    CONTENTS


    PRINCIPLES FOR THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM EXPOSURE
    TO CHEMICALS


    PREAMBLE

    ABBREVIATIONS

    1. SUMMARY

    2. INTRODUCTION

    3. HEALTH HAZARD IDENTIFICATION
         3.1. Introduction
         3.2. Human data
              3.2.1. Criteria for establishing causality
         3.3. Animal studies
         3.4.  In vitro studies
         3.5. Structure-activity relationships

    4. DOSE-RESPONSE
         4.1. Introduction
         4.2. Considerations in dose-response assessment
              4.2.1. Introduction
              4.2.2. Inter- and intra-species considerations
                        4.2.2.1 Introduction
                        4.2.2.2 Species differences
                        4.2.2.3 Human variability
         4.3. Non-neoplastic (threshold) effects
              4.3.1. Characterization of threshold
                        4.3.1.1 No-observed-adverse-effect level (NOAEL)
                        4.3.1.2 Benchmark dose/concentration
                        4.3.1.3 Lowest-observed-adverse-effect level
              4.3.2. Uncertainty factors
         4.4. Quantitative risk assessment for neoplastic (non-threshold)
              effects
              4.4.1. Introduction
              4.4.2. Linear extrapolation
              4.4.3. Estimation of potency in the experimental range
              4.4.4. Two-stage clonal expansion model
              4.4.5. Proportional analyses - carcinogenic and 
                        non-neoplastic effects

    5. EXPOSURE ASSESSMENT
         5.1. Definition of exposure and related terms
         5.2. Exposure and dose
         5.3. Approaches to quantification of exposure
              5.3.1. Measurement at point of contact (personal
                        monitoring)

              5.3.2. Scenario evaluation method (time activity and
                        monitoring/modelling)
              5.3.3. Biomarkers of exposure/estimation of internal dose
         5.4. Variability and uncertainty
              5.4.1. Assessing uncertainty
         5.5. Exposure settings
              5.5.1. Exposure in the general environment
              5.5.2. Occupational settings
              5.5.3. Consumer products

    6. RISK CHARACTERIZATION AND IMPLICATIONS FOR RISK MANAGEMENT
         6.1. General considerations
         6.2. Considerations in risk characterization
         6.3. Considerations in risk management
              6.3.1. Societal factors
              6.3.2. Individual and population risks
              6.3.3. Comparative risk
              6.3.4. Risk perception
              6.3.5. Risk and hazard communication
              6.3.6. Economic factors
                        6.3.6.1Cost-benefit analyses
              6.3.7. Political factors
              6.3.8. Regulatory limits
         6.4. Risk management options
              6.4.1. Risk reduction
                        6.4.1.1   Technology-based criteria

         REFERENCES

         APPENDIX

         RÉSUMÉ

         RESUMEN
    

    NOTE TO READERS OF THE CRITERIA MONOGRAPHS

         Every effort has been made to present information in the criteria
    monographs as accurately as possible without unduly delaying their
    publication.  In the interest of all users of the Environmental Health
    Criteria monographs, readers are requested to communicate any errors
    that may have occurred to the Director of the International Programme
    on Chemical Safety, World Health Organization, Geneva, Switzerland, in
    order that they may be included in corrigenda.

                             *     *     *

         A detailed data profile and a legal file can be obtained from the
    International Register of Potentially Toxic Chemicals, Case postale
    356, 1219 Châtelaine, Geneva, Switzerland (telephone no. + 41
    22 - 9799111, fax no. + 41 22 - 7973460, E-mail irptc@unep.ch).

                             *     *     *

         This publication was made possible by grant number
    5 U01 ES02617-15 from the National Institute of Environmental Health
    Sciences, National Institutes of Health, USA, and by financial support
    from the European Commission.

    Environmental Health Criteria

    PREAMBLE

    Objectives

         In 1973 the WHO Environmental Health Criteria Programme was
    initiated with the following objectives:

    (i)       to assess information on the relationship between exposure
              to environmental pollutants and human health, and to provide
              guidelines for setting exposure limits;
    (ii)      to identify new or potential pollutants;
    (iii)     to identify gaps in knowledge concerning the health effects
              of pollutants;
    (iv)      to promote the harmonization of toxicological and
              epidemiological methods in order to have internationally
              comparable results.

         The first Environmental Health Criteria (EHC) monograph, on
    mercury, was published in 1976 and since that time an ever-increasing
    number of assessments of chemicals and of physical effects have been
    produced.  In addition, many EHC monographs have been devoted to
    evaluating toxicological methodology, e.g., for genetic, neurotoxic,
    teratogenic and nephrotoxic effects.  Other publications have been
    concerned with epidemiological guidelines, evaluation of short-term
    tests for carcinogens, biomarkers, effects on the elderly and so
    forth.

         Since its inauguration the EHC Programme has widened its scope,
    and the importance of environmental effects, in addition to health
    effects, has been increasingly emphasized in the total evaluation of
    chemicals.

         The original impetus for the Programme came from World Health
    Assembly resolutions and the recommendations of the 1972 UN Conference
    on the Human Environment.  Subsequently the work became an integral
    part of the International Programme on Chemical Safety (IPCS), a
    cooperative programme of UNEP, ILO and WHO.  In this manner, with the
    strong support of the new partners, the importance of occupational
    health and environmental effects was fully recognized. The EHC
    monographs have become widely established, used and recognized
    throughout the world.

         The recommendations of the 1992 UN Conference on Environment and
    Development and the subsequent establishment of the Intergovernmental
    Forum on Chemical Safety with the priorities for action in the six
    programme areas of Chapter 19, Agenda 21, all lend further weight to
    the need for EHC assessments of the risks of chemicals.

    Scope

         The criteria monographs are intended to provide critical reviews
    on the effect on human health and the environment of chemicals and of
    combinations of chemicals and physical and biological agents.  As
    such, they include and review studies that are of direct relevance for
    the evaluation.  However, they do not describe  every study carried
    out.  Worldwide data are used and are quoted from original studies,
    not from abstracts or reviews.  Both published and unpublished reports
    are considered and it is incumbent on the authors to assess all the
    articles cited in the references.  Preference is always given to
    published data.  Unpublished data are only used when relevant
    published data are absent or when they are pivotal to the risk
    assessment.  A detailed policy statement is available that describes
    the procedures used for unpublished proprietary data so that this
    information can be used in the evaluation without  compromising its
    confidential nature (WHO (1990) Revised Guidelines for the Preparation
    of Environmental Health Criteria Monographs. PCS/90.69, Geneva, World
    Health Organization).

         In the evaluation of human health risks, sound human data,
    whenever available, are preferred to animal data.  Animal and
     in vitro studies provide support and are used mainly to supply
    evidence missing from human studies.  It is mandatory that research on
    human subjects is conducted in full accord with ethical principles,
    including the provisions of the Helsinki Declaration.

         The EHC monographs are intended to assist national and
    international authorities in making risk assessments and subsequent
    risk management decisions.  They represent a thorough evaluation of
    risks and are not, in any sense, recommendations for regulation or
    standard setting.  These latter are the exclusive purview of national
    and regional governments.

    Content

         The layout of EHC monographs for chemicals is outlined below.

    *    Summary -- a review of the salient facts and the risk evaluation
         of the chemical
    *    Identity -- physical and chemical properties, analytical methods
    *    Sources of exposure
    *    Environmental transport, distribution and transformation
    *    Environmental levels and human exposure
    *    Kinetics and metabolism in laboratory animals and humans
    *    Effects on laboratory mammals and  in vitro test systems
    *    Effects on humans
    *    Effects on other organisms in the laboratory and field
    *    Evaluation of human health risks and effects on the environment
    *    Conclusions and recommendations for protection of human health
         and the environment

    *    Further research
    *    Previous evaluations by international bodies, e.g., IARC, JECFA,
         JMPR

    Selection of chemicals

    Since the inception of the EHC Programme, the IPCS has organized
    meetings of scientists to establish lists of priority chemicals for
    subsequent evaluation.  Such meetings have been held in: Ispra, Italy,
    1980; Oxford, United Kingdom, 1984; Berlin, Germany, 1987; and North
    Carolina, USA, 1995. The selection of chemicals has been based on the
    following criteria: the existence of scientific evidence that the
    substance presents a hazard to human health and/or the environment;
    the possible use, persistence, accumulation or degradation of the
    substance shows that there may be significant human or environmental
    exposure; the size and nature of populations at risk (both human and
    other species) and risks for environment; international concern, i.e.
    the substance is of major interest to several countries; adequate data
    on the hazards are available.

         If an EHC monograph is proposed for a chemical not on the
    priority list, the IPCS Secretariat consults with the Cooperating
    Organizations and all the Participating Institutions before embarking
    on the preparation of the monograph.

    Procedures

         The order of procedures that result in the publication of an EHC
    monograph is shown in the flow chart.  A designated staff member of
    IPCS, responsible for the scientific quality of the document, serves
    as Responsible Officer (RO).  The IPCS Editor is responsible for
    layout and language.  The first draft, prepared by consultants or,
    more usually, staff from an IPCS Participating Institution, is based
    initially on data provided from the International Register of
    Potentially Toxic Chemicals, and reference data bases such as Medline
    and Toxline.

         The draft document, when received by the RO, may require an
    initial review by a small panel of experts to determine its scientific
    quality and objectivity.  Once the RO finds the document acceptable as
    a first draft, it is distributed, in its unedited form, to well over
    150 EHC contact points throughout the world who are asked to comment
    on its completeness and accuracy and, where necessary, provide
    additional material.  The contact points, usually designated by
    governments, may be Participating Institutions, IPCS Focal Points, or
    individual scientists known for their particular expertise.  Generally
    some four months are allowed before the comments are considered by the
    RO and author(s).  A second draft incorporating comments received and
    approved by the  Director,  IPCS, is then  distributed to Task Group
    members, who carry out the peer review, at least six weeks before
    their meeting.

    FIGURE 1

         The Task Group members serve as individual scientists, not as
    representatives of any organization, government or industry.  Their
    function is to evaluate the accuracy, significance and relevance of
    the information in the document and to assess the health and
    environmental risks from exposure to the chemical.  A summary and
    recommendations for further research and improved safety aspects are
    also required.  The composition of the Task Group is dictated by the
    range of expertise required for the subject of the meeting and by the
    need for a balanced geographical distribution.

         The three cooperating organizations of the IPCS recognize the
    important role played by nongovernmental organizations.
    Representatives from relevant national and international associations
    may be invited to join the Task Group as observers.  While observers
    may provide a valuable contribution to the process, they can only
    speak at the invitation of the Chairperson. Observers do not
    participate in the final evaluation of the chemical; this is the sole
    responsibility of the Task Group members.  When the Task Group
    considers it to be appropriate, it may meet  in camera.

         All individuals who as authors, consultants or advisers
    participate in the preparation of the EHC monograph must, in addition
    to serving in their personal capacity as scientists, inform the RO if
    at any time a conflict of interest, whether actual or potential, could
    be perceived in their work.  They are required to sign a conflict of
    interest statement. Such a procedure ensures the transparency and
    probity of the process.

         When the Task Group has completed its review and the RO is
    satisfied as to the scientific correctness and completeness of the
    document, it then goes for language editing, reference checking, and
    preparation of camera-ready copy.  After approval by the Director,
    IPCS, the monograph is submitted to the WHO Office of Publications for
    printing.  At this time a copy of the final draft is sent to the
    Chairperson and Rapporteur of the Task Group to check for any errors.

         It is accepted that the following criteria should initiate the
    updating of an EHC monograph: new data are available that would
    substantially change the evaluation; there is public concern for
    health or environmental effects of the agent because of greater
    exposure; an appreciable time period has elapsed since the last
    evaluation.

         All Participating Institutions are informed, through the EHC
    progress report, of the authors and institutions proposed for the
    drafting of the documents.  A comprehensive file of all comments
    received on drafts of each EHC monograph is maintained and is
    available on request.  The Chairpersons of Task Groups are briefed
    before each meeting on their role and responsibility in ensuring that
    these rules are followed.

    PARTICIPANTS IN THE PLANNING AND TASK GROUP MEETINGS ON PRINCIPLES FOR
    THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM EXPOSURE TO CHEMICALS

     Members

    Dr A. Aitio, Institute of Occupational Health, Laboratory of
    Biochemistry, Helsinki, Finland a,b

    Dr N. Aldrige, The Robens Institute of Industrial and Environmental
    Health and Safety, University of Guildford, Guildford, Surrey, United
    Kingdom (deceased)a,b

    Dr D. Anderson, British Industry Biological Research Association
    (BIBRA), Carshalton, Surrey, United Kingdoma,b

    Professor C.L. Berry, Department of Morbid Anatomy, London Hospital
    Medical College, London, United Kingdoma

    Dr R. Burnett, Biostatistics and Computer Division,  Environmental
    Health Directorate, Health and Welfare Canada, Ottawa, Ontario,
    Canadaa

    Dr J.R.P. Cabral, Unit of Mechanisms of Carcinogenesis, International
    Agency for Research on Cancer, Lyon, Francea

    Dr E. Cardis, Unit of Biostatistics Research and Informatics,
    International Agency for Research on Cancer, Lyon, Francea

    Dr M. Cikrt, Institute of Hygiene and Epidemiology, Prague, Czech
    Republica

    Dr D.B. Clayson, Carp, Ontario, Canada

    Mr D.J. Clegg, Pesticide Section, Toxicological Evaluation Division,
    Food Directorate, Health Protection Branch, Tunney's Pasture, Ottawa,
    Ontario, Canadaa

    Professor E. Dybing, Department of Environmental Medicine, National
    Institute of Public Health, Oslo, Norwayc

    Dr R. Fielder, Department of Health, Elephant and Castle, London
    United Kingdomb

    Dr L. Fishbein, Fairfax, Virginia, USAc

    Dr H. Gibb, US Environmental Protection Agency, Washington, DC,
    USAa,b,d

    Dr M. Goddard, Biostatistics and Computer Division, Environmental
    Health Centre, Health and Welfare Canada, Tunney's Pasture, Ottawa,
    Ontario, Canadab

    Professor B. Goldstein, Rutgers Medical College, Busch Campus,
    Pescataway, New Jersey, USAa

    Dr R.F. Hertel, Federal Institute for Consumers, Health Protection and
    Veterinary Medicine, FE-821 Bundesgesundheitsamt, BGVV, Berlin,
    Germanyc,d

    Dr J. Huff, Environmental Carcinogenesis Programme, National Institute
    of Environmental Health Sciences, Research Triangle Park, North
    Carolina, USAb

    Professor M. Ikeda, Department of Environmental Health, Tohoku
    University School of Medicine, Sendai, Japana

    Dr D. Krewski, Biostatistics and Computer Division, Environmental
    Health Directorate, Health and Welfare Canada, Ottawa, Ontario,
    Canadaa

    Professor R. Kroes,  initially National Institute of Public Health
    and Environmental Hygiene, Bilthoven,  subsequently Research
    Institute for Toxicology, University of Utrecht, Utrecht, the
    Netherlandsa,c

    Professor M. Lotti, University of Padua Medical School, Institute of
    Occupational Medicine, Padua, Italya

    Dr G.W. Lucier, Division of Biometry and Risk Assessment, National
    Institute of Environmental Health Sciences, Research Triangle Park,
    North Carolina, USAa

    Dr L. Magos, Toxicology Unit, Medical Research Council Laboratories,
    Carshalton, Surrey, United Kingdoma

    Dr E. McConnell, Raleigh, North Carolina, USAa

    Ms M.E. Meek, Environmental Health Directorate, Health Canada, Ottawa,
    Ontario, Canadac

    Dr R.L. Melnick, National Institute of Environmental Health Sciences,
    Division of Biometry and Risk Assessment, Research Triangle Park,
    North Carolina, USAa

    Professor D.V. Parke, Department of Biochemistry, University of
    Surrey, Guildford, Surrey, United Kingdoma

    Dr J. Parker, Office of Health and Environmental Assessment, US
    Environmental Protection Agency, Washington, DC, USAa

    Dr O.E. Paynter, Hazard Evaluation Division, US Environmental
    Protection Agency, Washington, DC, USAa

    Dr P.K. Ray, Industrial Toxicology Research Centre, Lucknow, Indiaa

    Dr A.G. Renwick, Clinical Pharmacology Group, University of
    Southampton, Southhampton, Hampshire, United Kingdomc

    Dr J. Sekizawa, Division of Information on Chemical Safety, National
    Institute of Hygienic Sciences, Tokyo, Japanb

    Dr J. Shaum, US Environmental Protection Agency, National Center for
    Environmental Assessment, Washington, DC, USAd

    Professor J.A. Sokal, Institute of Occupational Medicine and
    Environmental Health, Sosnowiec, Polandc

    Dr J. Steadman, Department of Health and Social Security, Elephant and
    Castle, London, United Kingdoma

    Dr L. Strayner, Division of Standards Development and Technology
    Transfer, National Institute for Occupational Safety and Health,
    Cincinnati, Ohio, USAb

    Dr G.M.H. Swaen, Department of Occupational Medicine, University of
    Limburg, Maastricht, the Netherlandsa,b

    Dr A. Walker, Organisation for Economic Co-operation and Development,
    Paris, Francea

    Professor R. Walker, Food Safety Group, Division of Toxicology, School
    of Biological Sciences, University of Surrey, Guildford, Surrey,
    United Kingdomc

    Dr J.E. Zejda, Department of Epidemiology, Institute of Occupational
    Medicine and Environmental Health, Sosnowiec, Polandc

     Observers

    Professor G. Di Renzo, International Union of Toxicology, Department
    of Neuroscience, Faculty of Medicine and Surgery, University of Naples
    "Federico II", Naples, Italyc

    Dr M. Jaroszewski, Health and Safety Directorate, Occupational
    Medicine and Hygiene Unit, Commission of the European Community,
    Luxembourgb

    Dr C. Lally, European Council of Chemical Industry Federation (CEFIC),
    Procter and Gamble, Strombbek Bever, Belgiumc

    Professor A. Mutti, Institute of Clinical Medicine and Nephrology,
    Parma, Italyc

    Dr J. O'Donoghue (Representing AIHC) Corporate Health and Environment
    Laboratories, Eastman Kodak Company, Rochester, New York, USAb

    Dr M. Penman, ICI C & P Limited, Occupational Health Division, Wilton,
    Middlesborough, Cleveland, United Kingdomc

    Mrs M. Richold, European Centre for Ecotoxicology and Toxicology of
    Chemicals (ECETOC), Unilever Research Laboratory, Environmental Safety
    Laboratory, Sharnbrook, Bedford, United Kingdomc

    Mr P. Verschuren, International Life Sciences Institute, Brussels
    Belgiumc,b

     Secretariat

    Dr G.C. Becking, Inter-regional and Research Unit, International
    Programme on Chemical Safety, World Health Organization, Research
    Triangle Park, North Carolina, USAb

    Dr K. Gutschmidt, International Programme on Chemical Safety, World
    Health Organization, Geneva, Switzerlandd

    Dr E. Smith, International Programme on Chemical Safety, World Health
    Organization, Geneva, Switzerlandc

    Dr M. Younes, International Programme on Chemical Safety, World Health
    Organization, Geneva, Switzerlandd



                  

    a    Participated in Planning and Working Groups on Scientific
         Principles for the Assessment of Risks to Human Health from
         Exposure to Chemicals.

    b    Participated in the WHO Task Group Meeting on the initial draft
         of Principles for the Assessment of Risk from Exposure to
         Chemicals (British Industry Biological Research Association
         (BIBRA), Carshalton, Surrey, United Kingdom, March 1993).

    c    Participated in the WHO Task Group Meeting on the initial draft
         of General Principles and Methods for Chemical Safety (Human
         Health Protection (National Institute of Public Health and
         Environmental Protection) (RIVM), Bilthoven, the Netherlands, 22-
         25 March 1994).

    d    Participated in the WHO Finalizing Group Meetings on Principles
         for the Assessment of Risks to Human Health from Exposure to
         Chemicals (World Health Organization, Geneva, Switzerland, 2-5
         September 1996 and 18-20 September 1997).

    PRINCIPLES FOR THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM EXPOSURE
    TO CHEMICALS

         This monograph is an amalgamation of two draft documents
    "Principles for the Assessment of Risk from Exposure to Chemicals" and
    "General Principles and Methods for Chemical Safety (Human Health
    Protection)".

         Both documents were planned to cover different aspects of
    chemical safety and risk assessment; one dealing with the basic
    science for general readers, and the other providing more practical
    approaches to risk assessment of chemicals for risk assessors.
    However, they turned out to have a substantial amount of overlapping
    information and it was therefore decided to use both drafts as a basis
    for this new, comprehensive document. The more detailed draft on
    "General Principles and Methods for Chemical Safety (Human Health
    Protection)" will be published as a separate document for training
    purposes.

         This Environmental Health Criteria monograph is aimed at
    furnishing a practical overview of chemical safety and at providing
    the framework of risk assessment for regulatory and research
    scientists, as well as risk managers. It is intended to complement
    existing Environmental Health Criteria that address methodologies for
    the assessment of risks from exposure to chemicals with a view towards
    different end-points or to susceptible population groups. It is not
    intended as a textbook on toxicology.

         This monograph should not be considered as being of a
    prescriptive nature. The chapters on exposure assessment and risk
    characterization, in particular, provide rather some practical
    guidance.

         Several planning, working and Task Group meetings took place to
    discuss and agree upon the structures and contents of both
    Environmental Health Criteria documents.

         A WHO Task Group on "Principles for the Assessment of Risk from
    Exposure to Chemicals" met at the British Industrial Biological
    Research Association (BIBRA), Carshalton, Surrey, United Kingdom, in
    March 1993. Dr G.C. Becking, IPCS, welcomed the participants on behalf
    of the Director, IPCS, and the three IPCS cooperating organizations
    (UNEP/ILO/WHO), and the Task Group reviewed the draft document.

         The main contributors to the first draft on Principles for the
    Assessment of Risk from Exposure to Chemicals were Dr N. Aldridge,
    Robens Institute of Industrial and Environmental Health and Safety,
    United Kingdom, Dr H. Gibb, US Environmental Protection Agency, Dr J.
    Huff, National Institute of Environmental Health Sciences, USA, Dr L
    Stayner, National Institute for Occupational Safety and Health, USA.

         A second WHO Task Group met to review the draft monograph on
    General Principles and Methods for Chemical Safety (Human Health
    Protection). This group met in at the National Institute of Public
    Health and Environmental Protection (RIVM), Bilthoven, the
    Netherlands, from 22 to 25 November 1995. Dr E. Smith, IPCS, welcomed
    the participants on behalf of the Director, IPCS, and the three IPCS
    cooperating organizations (UNEP/ILO/WHO), and the Task Group reviewed
    the draft document.

         The main contributors to the draft on Principles for the
    Assessment of Risk from Exposure to Chemicals were Dr D.B. Clayson,
    Carp, Canada, Professor E. Dybing, National Institute of Public
    Health, Norway, Dr L. Fishbein, Fairfax, Virginia, USA, Dr A.G.
    Renwick, University of Southampton, United Kingdom, Professor R.
    Walker, University of Surrey, United Kingdom, and Professor J.A Sokal,
    Institute of Occupational Health and Environmental Medicine,
    Sosnowiec, Poland.

         In addition to the Task Group meetings, meetings were held during
    1996 and 1997 in Geneva to combine the two documents.

         Dr E. Smith and Dr G. Becking, both members of the IPCS, were
    responsible for the preparation of the initial draft documents. Dr M.
    Younes (IPCS) was responsible for the overall scientific content of
    the final monograph and Dr P.G. Jenkins (IPCS) for the technical
    editing.

         The efforts of all who helped in the preparation and finalization
    of the document are gratefully acknowledged.

    ABBREVIATIONS

    ADD      average daily dose
    ADI      acceptable daily intake
    EPI      exposure/potency index
    GLP      good laboratory practice
    IARC     International Agency for Research on Cancer
    LOAEL    lowest-observed-adverse-effect level
    NOAEL    no-observed-adverse-effect level
    OECD     Organisation for Economic Co-operation and Development
    PBPK     physiologically based pharmacokinetic
    SAR      structure-activity relationship
    US EPA   US Environmental Protection Agency

    1.  SUMMARY

         Control of risks from exposure to chemicals (chemical safety)
    requires first of all a scientific, ideally quantitative, assessment
    of potential effects at given exposure levels (risk assessment). Based
    upon the results of risk assessment, and taking into consideration
    other factors, a decision-making process aimed at eliminating or, if
    this is not possible, reducing to a minimum the risk to the
    chemical(s) under consideration (risk management), can be started.

         Risk assessment is a conceptual framework that provides the
    mechanism for a structured review of information relevant to
    estimating health or environmental outcomes. In conducting risk
    assessments, the National Academy of Sciences risk assessment paradigm
    has proven to be a useful tool (US NAS, 1983). This paradigm divides
    the risk assessment process into four distinct steps: hazard
    identification, dose-response assessment, exposure assessment and risk
    characterization.

         The purpose of hazard identification is to evaluate the weight of
    evidence for adverse effects in humans based on assessment of all
    available data on toxicity and mode of action. It is designed to
    address primarily two questions: (1) whether an agent may pose a
    health hazard to human beings, and (2) under what circumstances an
    identified hazard may be expressed. Hazard identification is based on
    analyses of a variety of data that may range from observations in
    humans to analysis of structure-activity relationships. The result of
    the hazard identification exercise is a scientific judgement as to
    whether the chemical evaluated can, under given exposure conditions,
    cause an adverse health effect in humans. Generally, toxicity is
    observed in one or more target organ(s). Often, multiple end-points
    are observed following exposure to a given chemical. The critical
    effect, which is usually the first significant adverse effect that
    occurs with increasing dose, is determined.

         Dose-response assessment is the process of characterizing the
    relationship between the dose of an agent administered or received and
    the incidence of an adverse health effect. For most types of toxic
    effects (i.e. organ-specific, neurological/behavioural, immunological,
    non-genotoxic carcinogenesis, reproductive or developmental), it is
    generally considered that there is a dose or concentration below which
    adverse effects will not occur (i.e. a threshold). For other types of
    toxic effects, it is assumed that there is some probability of harm at
    any level of exposure (i.e. that no threshold exists). At the present
    time, the latter assumption is generally applied primarily for
    mutagenesis and genotoxic carcinogenesis.

         If a threshold has been assumed (e.g., for non-neoplastic effects
    and non-genotoxic carcinogens), traditionally, a level of exposure
    below which it is believed that there are no adverse effects, based on
    a no-observed-adverse-effect level (NOAEL) (approximation of the
    threshold) and uncertainty factors, has been estimated. Alternatively,

    the magnitude by which the no (lowest)-observed-adverse-effect level
    (N(L)OAEL) exceeds the estimated exposure (i.e. the "margin of
    safety") is considered in light of various sources of uncertainty. In
    the past, this approach has often been described as a "safety
    evaluation". Therefore, the dose that can be considered as a first
    approximation of the threshold, i.e. the NOAEL, is critical.
    Increasingly, however, the "benchmark dose", a model-derived estimate
    (or its lower confidence limit) of a particular incidence level (e.g.,
    5%) for the critical effect, is being proposed for use in quantitative
    assessment of the dose-response for such effects.

         There is no clear consensus on appropriate methodology for the
    risk assessment of chemicals for which the critical effect may not
    have a threshold (i.e. genotoxic carcinogens and germ cell mutagens).
    Indeed, a number of approaches based largely on characterization of
    dose-response have been adopted for assessment in such cases.
    Therefore, the critical data points are those that define the slope of
    the dose-response relationship (rather than the NOAEL, which is the
    first approximation of a threshold).

         The third step in the process of risk assessment is the exposure
    assessment, which has the aim of determining the nature and extent of
    contact with chemical substances experienced or anticipated under
    different conditions. Multiple approaches can be used to conduct
    exposure assessments. Generally, approaches include indirect and
    direct techniques, covering measurement of environmental
    concentrations and personal exposures, as well as biomarkers.
    Questionnaires and models are also often used. Exposure assessment
    requires the determination of the emissions, pathways and rates of
    movement of a substance and its transformation or degradation, in
    order to estimate the concentrations to which human populations or
    environmental spheres (water, soil and air) may be exposed.

         Depending on the purpose of an exposure assessment, the numerical
    output may be an estimate of either the intensity, rate, duration or
    frequency of contact exposure or dose (resulting amount that actually
    crosses the boundary). For risk assessments based on dose-response
    relationships, the output usually includes an estimate of dose. It is
    important to note that the internal dose, not the external exposure
    level, determines the toxicological outcome of a given exposure.

         Risk characterization is the final step in risk assessment. It is
    designed to support risk managers by providing, in plain language, the
    essential scientific evidence and rationale about risk that they need
    for decision-making. In risk characterization, estimates of the risk
    to human health under relevant exposure scenarios are provided. Thus,
    a risk characterization is an evaluation and integration of the
    available scientific evidence used to estimate the nature, importance,
    and often the magnitude of human and/or environmental risk, including
    attendant uncertainty, that can reasonably be estimated to result from
    exposure to a particular environmental agent under specific
    circumstances.

         The term "risk management" encompasses all of those activities
    required to reach decisions on whether an associated risk requires
    elimination or necessary reduction. Risk management strategies/or
    options can be broadly classified as regulatory, non-regulatory,
    economic, advisory or technological, which are not mutually exclusive.
    Thus legislative mandates (statutory guidance), political
    considerations, socioeconomic values, cost, technical feasibility,
    populations at risk, duration and magnitude of risk, risk comparison,
    and possible impact on trade between countries can generally be
    considered as a broad panoply of elements that can be factored into
    final policy or rule making. Key decision factors such as the size of
    the population, the resources, costs of meeting targets and the
    scientific quality of risk assessment and subsequent managerial
    decisions vary enormously from one decision context to another. It is
    also recognized that risk management is a complex multidisciplinary
    procedure which is seldom codified or uniform, is frequently
    unstructured, but which can respond to evolving input from a wide
    variety of sources. Increasingly, risk perception and risk
    communication are recognized as important elements, which must also be
    considered for the broadest possible public acceptance of risk
    management decisions.

         Chemicals have become an indispensable part of human life,
    sustaining activities and development, preventing and controlling many
    diseases, and increasing agricultural productivity. Despite their
    benefits, chemicals may, especially when misused, cause adverse
    effects on human health and environmental integrity. The widespread
    application of chemicals throughout the world increases the potential
    of adverse effects. The growth of chemical industries, both in
    developing as well as in developed countries, is predicted to continue
    to increase. In this context, it is recognized that the assessment and
    management of risks from exposure to chemicals are among the highest
    priorities in pursuing the principles of sustainable development.

    2.  INTRODUCTION

         Despite the societal benefits that accrue from the use of
    chemicals, substantial potential hazards to health may be associated
    with exposure during the production, use or disposal of the
    approximately 100 000 unique chemicals or 4 million mixtures,
    formulations and blends already in commercial use or the several
    hundred new synthetic chemicals introduced each year (EC, 1990). This
    monograph outlines the nature of the data available and their use in
    the assessment of risk in a risk assessment/risk management framework.
    It is hoped that scientists, risk assessors and health risk managers
    will find this monograph helpful to decision-making in this area.

         A number of national and international organizations and agencies
    have developed guidance on assessment of exposure and various health
    end-points (e.g., carcinogenicity, developmental toxicity, etc.). It
    is not the purpose of this monograph to endorse particular approaches
    but rather to acquaint the reader with relevant methodology and issues
    for consideration.

         It is also hoped that the reader will find this monograph useful
    in the interpretation of risk assessments on specific chemicals. The
    reader is referred to such sources for chemical-specific hazard
    identification and, depending on the monograph, dose-response
    information. A list of assessments produced by various national and
    international agencies is included in ECETOC/UNEP (1996). These
    sources do not, of course, provide the exposure information necessary
    to characterize risk at the local level. Since exposure will vary
    considerably under different circumstances, responsible authorities
    are strongly encouraged to characterize risk on the basis of local
    measured or predicted exposure scenarios. It is hoped that the general
    approaches to exposure assessment described in this monograph will
    assist the reader in characterizing risk in specific situations.

         In the chapters of this monograph, the following four distinct
    and essential components of the risk assessment paradigm are
    addressed:

    (1)   hazard identification - identification of the inherent
         capability of a substance to cause adverse effects;

    (2)   assessment of dose-response relationships involves
         characterization of the relationship between the dose of an agent
         administered or received and the incidence of an adverse effect;

    (3)   exposure assessment is the qualitative and/or quantitative
         assessment of the chemical nature, form and concentration of a
         chemical to which an identified population is exposed from all
         sources (air, water, soil and diet);

    (4)   risk characterization is the synthesis of critically evaluated
         information and data from exposure assessment, hazard
         identification and dose-response considerations into a summary
         that identifies clearly the strengths and weaknesses of the
         database, the criteria applied to evaluation and validation of
         all aspects of methodology, and the conclusions reached from the
         review of scientific information. 

         The logical consequence of the process of assessment of potential
    risk is the application of the information to the development of
    practical measures (risk management) for the protection of human
    health. Although not the principal focus of this monograph, the
    importance of clear understanding and communication of the nature and
    limitations of the scientific basis for risk assessment in risk
    management is addressed in the final chapter.

         In Appendix 1 to this monograph, an example of a hazard
    identification scheme for carcinogenicity, developed by the
    International Agency for Research on Cancer (IARC), is presented. In
    Appendix 2, the currently available and draft guidelines of the
    Organisation for Economic Cooperation and Development (OECD) for
    testing of chemicals are presented. For sample exposure and risk
    characterizations, readers are referred to IPCS (1994).

    3.  HEALTH HAZARD IDENTIFICATION

    3.1  Introduction

         The purpose of hazard identification is to evaluate the weight of
    evidence for adverse effects in humans based on assessment of all
    available data on toxicity and mode of action. It is designed to
    address primarily two questions: (a) whether an agent may pose a
    health hazard to humans, and (b) under what circumstances an
    identified hazard may be expressed. Hazard identification is based on
    analyses of a variety of data that may range from observations in
    humans to analysis of structure-activity relationships.

         In hazard identification, the weight of evidence is assessed on
    the basis of combined strength and coherence of inferences
    appropriately drawn from all of the available data. This entails
    rigorous examination of the quantity, quality and nature of the
    results of available toxicological and epidemiological studies and
    structure-activity analyses and information on mechanisms of toxicity.
    The latter is particularly important with respect to assessment of
    relevance to humans.

         Several classification schemes provide a framework for assessment
    of the weight of evidence for various toxicological end-points (DFG,
    1972; IPCS, 1986 (neurotoxicity); US EPA, 1986a, 1996a; IARC, 1987;
    EC, 1992; Health Canada, 1994; IPCS, 1996 (immunotoxicity); IPCS, 1997
    (delayed hypersensitivity)). An example (the IARC scheme) is presented
    in Appendix 1 to illustrate the nature of criteria on which
    classification of weight of evidence is based. Such classification
    schemes have been helpful in standardizing and communicating the
    assessment of hazard identification for particular end-points. In
    addition to the classifications themselves, narrative statements to
    summarize the nature of and confidence in the evidence based on
    limitations and strengths of the database are helpful. Issues that are
    often addressed include: the nature, reliability, validity and
    consistency of data on response in humans and in laboratory animals,
    current knowledge of the mechanistic basis for the response, and, in
    the absence of human data, the relevance of responses in experimental
    animals to humans.

         The result of the hazard identification exercise is a scientific
    judgement as to whether the chemical can cause an adverse effect in
    humans.

         The following is intended to provide the reader with an
    appreciation of the complexity of considerations made in assessing
    different types of data as a basis for hazard identification in risk
    assessment. Fundamentals of epidemiology and toxicity testing are not
    addressed here since they are considered in several other sources. An
    Environmental Health Criteria monograph on the principles of exposure
    assessment is currently in preparation (IPCS, in preparation).

         Each source of information (e.g., human data, animal data,
    structure-activity relationships) has its advantages and limitations
    in contributing to an assessment of weight of evidence, but,
    collectively, they permit characterization of potential adverse health
    effects.

    3.2  Human data

         Well-documented observational and clinical epidemiological
    studies have the clear advantage over studies in animals in providing
    the most relevant information on health effects in the species of
    interest, thus avoiding extrapolation from animals to humans. In
    addition, epidemiological studies can address hazards to which humans
    are exposed in their natural environment, in the presence of
    concomitant risk factors such as diet and smoking.

         Human populations are heterogeneous in their composition, and
    studies of exposed populations are likely to include individuals of
    differing susceptibility to the chemical of interest. This may be
    viewed as an advantage relative to toxicological studies, which
    involve genetically homogeneous populations of test animals.

         The database for direct hazard identification in human
    populations consists primarily of observational (epidemiological)
    studies and case reports. Some information is also available from
    ethically conducted human volunteer studies.

         In observational studies, the investigator does not control
    assignment of study subjects to either exposed or non-exposed groups.
    Rather, such studies involve investigation of various individuals or
    groups of subjects as they happen to have been exposed, and at no
    stage of the study is the exposure of subjects influenced by the
    research protocol. Although exposure scenarios are more realistic than
    those in the experimental setting, owing to their observational nature
    it is often difficult to control for "confounding factors", which may
    be contributing to the etiology of the disease being investigated. For
    example, variations in smoking between groups may confound
    interpretation of observations concerning lung cancer.

         Ethical experimental studies in human volunteers offer the
    advantage of being better able to control for confounding factors. The
    assignment of study subjects to exposure groups is made by the
    investigator, who also controls the quality and quantity. Although
    such investigations are generally reliable for the establishment of
    both causality and exposure-response relationships, they are most
    often restricted for ethical reasons to the examination of mild,
    temporary effects (e.g., neurobehavioural or biochemical changes) of
    short-term exposures in a limited number of subjects. They have
    contributed considerably, particularly to our understanding of
    kinetics and to the development of air quality guidelines and
    standards for traditional pollutants.

         Case reports describe a particular effect in an individual or
    group of individuals who were exposed to a substance and often
    observed by a single physician or group of physicians. These reports
    are often anecdotal or highly selected in nature. Owing primarily to
    their lack of statistical stability, they are of limited use for
    hazard assessment, though helpful in generating hypotheses for further
    study. However, reports of cases of the disease or effect of interest
    can identify associations, particularly when there are unique features
    such as an association with a rare disease or effect of interest
    (e.g., vinyl chloride and angiosarcoma or methylmercury and Minamata
    disease).

         The major types of epidemiological (observational) studies are
    analytical and descriptive or correlational studies. Each study type
    has well-known strengths and weaknesses that affect interpretation of
    study results (Lilienfeld & Lilienfeld, 1979; Mausner & Kramer, 1985;
    Kelsey et al., 1986; Rothman, 1986). Analytical epidemiological
    studies (that is, cohort and case-control studies), in which exposure
    and outcome are examined in individuals rather than in populations,
    are generally most reliable in hazard identification as a basis for
    risk assessment since it is possible to adjust more rigorously for
    confounding factors. The assessment of results of such studies is
    based on several features of study design including estimation of
    exposure, the role of confounding variables and the measurement of
    outcome. Potential limitations, depending upon the nature of the
    design, include lack of information on exposure, insufficient sample
    size, short length of follow-up and potential bias and confounding.
    These factors may limit the usefulness of particular studies for the
    purposes of risk assessment.

         Epidemiological data demonstrating dose-response, if available,
    provide an advantageous basis for analysis, since concerns about
    inter-species extrapolation do not arise. Adequacy of human exposure
    data for quantification is an important consideration in deciding
    whether epidemiological data are the best basis for analysis in a
    particular case. If adequate exposure data exist in a well-designed
    and well-conducted epidemiological study that detects no effects, it
    may be possible to obtain an upper estimate of the potential human
    risk to provide a check on plausibility of available estimates based
    on animal tumour or other responses (e.g., do confidence limits on one
    overlap the point estimate of the other?) (Stayner & Bailer, 1993; US
    EPA 1996a).

    3.2.1  Criteria for establishing causality

         The first step in the evaluation of results of studies in humans
    as a basis for hazard identification is the assessment of the
    individual results of each separate report. The strengths and
    weaknesses of each study must be considered along with potential for
    the existence of bias (Gehlbach, 1982), with particular attention to
    exposure data, criteria for definition of health outcome under study,
    the size of the study population and the statistical power of the
    analysis to detect adverse health effects. A set of standardized

    criteria for assessing the weight of evidence of causality based on
    assessment of the database has been developed (Hill, 1965; Susser,
    1977).

         Studies in which there is an apparent absence of evidence for a
    hypothesized causal relationship between exposure and effect
    ("negative studies") need to be interpreted carefully (Hernberg,
    1980). Such studies should be evaluated for dilution (the inclusion of
    unexposed people in an allegedly exposed group of persons),
    misclassification (Copeland et al., 1977), omissions, or premature
    examination of subjects for diseases that may have long induction
    (latency) periods. In addition, the statistical power of the study,
    i.e. the probability that the study will be able to demonstrate the
    presence of an effect, such as excessive disease or mortality, in a
    population if the effect is actually present (Beaumont & Breslow,
    1981), must be assessed.

         There is no clear-cut criterion to distinguish positive from
    negative studies. Although statistical significance has often been
    used as the criteria, most epidemiologists believe that it is overly
    simplistic to base decisions on arbitrary probability values (Rothman,
    1986). For example, when a study fails to detect a statistically
    significant effect, this may simply reflect inadequate sample size or
    other aspects of study design. Conversely, when the results of a study
    are statistically significant, the seemingly positive results may
    still be due to confounding or even chance.

         A positive association between an agent and an effect may be
    interpreted as implying causality, to a greater or lesser extent, if
    the following criteria are met: (a) there is not identifiable positive
    bias; (b) the possibility of positive confounding has been considered;
    (c) the association is unlikely to be due to chance alone; (d) the
    association is strong; and (e) there is a dose-response relationship
    (IARC, 1990). The following criteria for inferring causality from the
    results of epidemiological studies have been developed by Hill (1965):

     (a) The strength of the association as measured by the relative risk

         In general, epidemiologists have more confidence in their results
    when the magnitude of the relative risk is large. However, relative
    risks of small magnitude do not necessarily imply lack of causality
    and may be important if the disease under study is common (IARC,
    1990). In evaluating relative risks, it is important to note the
    actual numbers of observed and expected cases.

     (b) The consistency of the association

         The case for causal inference is strengthened by repetition of
    findings "by different investigators, in different places,
    circumstances and times" (Hill, 1965). The reproducibility of findings
    constitutes one of the strongest arguments for the existence of
    causality. If there are discordant results among investigations,
    possible reasons such as differences in exposure should be considered

    in assessing the results, and data from studies judged to be of high
    quality given greater weight than data from studies judged to be
    methodologically less sound (IARC, 1990).

     (c) The temporal relationship between cause and effect

         This principle may be simply restated as exposure must precede
    illness. When latency is a factor, exposures must have occurred
    sufficiently early to have produced an effect by the time of the
    study.

     (d) The biological gradient of the association

         The evidence for causality is strengthened when the risk of
    disease is shown to increase with levels of exposure. Because there
    are many possible reasons that an epidemiological study may fail to
    detect an exposure-response relationship (e.g., poor exposure data,
    lack of adequate exposure gradient), the absence of a dose-response
    relationship does not necessarily imply that the relationship is not
    causal (IARC, 1990). Strong evidence for causality is provided when a
    change in exposure brings about a change in disease frequency
    (Hernberg, 1980), e.g., the decrease in risk of lung cancer that
    follows cessation of smoking (Doll & Hill, 1956).

     (e) the specificity of the association

         A highly specific association is one in which the disease under
    study is only induced by a particular agent. Specificity of cause is
    common in infectious diseases but less common in chronic diseases that
    often have a multi-factorial etiology. However, a specific association
    may be observed for certain chronic diseases such as between exposure
    to crocidolite asbestos and mesothelioma or vinyl chloride and
    angiosarcoma. Although the presence of specificity seems to imply
    causality, its absence does not exclude it (Fralick, 1983).

     (f) biological plausibility of the association

         Hill (1965) stated strongly that a proposed causal relationship
    should not seriously conflict with knowledge of the biology and
    pathophysiology of a disease under study. An epidemiological inference
    of causality may be strengthened by data from experimental studies
    showing consistency with biological mechanisms. For example, exposure
    to ionizing radiation causes cancer in many animal species. However,
    the lack of mechanistic or positive animal bioassay data to support an
    association observed in an epidemiological study is not, in itself,
    sufficient reason to reject causality.

    3.3  Animal studies

         Owing to the lack of adequate epidemiological data for most
    substances, toxicological studies in animal species play an important
    role in hazard identification for risk assessment. Toxicity studies

    vary widely in purpose, design and conduct, and range from relatively
    well-standardized and widely accepted test methods for assaying
    various types of toxicity to large numbers of basically
    research-oriented investigations employing specialized study designs.

         The design, conduct and completeness of reporting of experimental
    findings in toxicological studies on mammalian species are of critical
    importance in determining the validity and relevance of results.
    Toxicological results from adequate animal systems signal anticipated
    effects in humans. Thus, negative results cannot be assessed from an
    inadequate study, and full evaluation of a positive effect is
    confounded by incomplete reporting from poorly designed or poorly
    conducted studies. However, positive findings cannot be ignored.
    Studies should be of good scientific quality and follow standard
    guidelines and recognized good laboratory practices (GLPs) wherever
    possible.

         Information on the design of specific bioassays, including those
    that address acute, short-term, sub-chronic, chronic and developmental
    and reproductive toxicity, immunotoxicity and carcinogenicity, are not
    presented here but are available in test guidelines, for which
    principles of GLP are also specified (IARC, 1986; OECD, 1987, 1998;
    Chhabra et al., 1990). A list of currently available OECD Guidelines
    is included in Appendix 2. In this section, examples of factors to be
    taken into account in assessing these various aspects of study design
    for hazard identification are described.

         Major end-points in toxicity studies can be grouped into the
    following categories (IPCS, 1987a):

    *    Functional manifestations (weight loss, laxative effects, etc.);
    *    non-neoplastic lesions with morphological
         manifestations/organ-directed toxic effects;
    *    neoplastic/carcinogenic manifestations.

         In addition, a number of specific end-points may require targeted
    testing strategies. Such end-points include skin and eye irritation,
    reproductive/developmental manifestations, immunotoxicity and
    neurotoxicity (including neurodevelopmental effects).

         It is important to recognize that there are two types of data
    generated in such studies; those in which response is graded, such as
    enzyme inhibition (i.e. continuous data), and those in which the
    response occurs or does not occur in a single animal, such as a
    particular tumour (i.e. quantal data).

         In assessing the relevance of various toxicological studies to
    hazard identification and risk assessment, several features of study
    design are considered, including the purity of the compound
    administered, physico-chemical properties (volatility, stability,
    solubility), homogeneity of distribution in inhalation experiments,
    the size of the study (i.e. the number of exposed and control

    animals), whether the study adhered to the principles of GLP, the
    relevance of the route of exposure to that of humans, duration of
    exposure, the number and suitability of the dose levels administered,
    the extent of examination of various toxicological end-points and the
    statistical analysis of the data. The types, site, incidence and
    severity of effects and the nature of the exposure- or dose-response
    relationship are also taken into account. Where data indicate that
    there are significant differences in absorption, distribution,
    metabolism and elimination of the compound in different animal
    species, wherever possible, studies in which the species and strain of
    animal are most similar to  Homo sapiens in this regard are used
    (where relevant human data are available). The consistency of the
    results of the principal studies are also considered in the assessment
    of the weight of evidence for an effect (e.g., whether similar effects
    have been observed in studies in other species or whether such effects
    would have been expected based on the structure or properties of the
    chemical).

         For example, the size of each exposure and concurrent control
    group should be large enough for thorough toxicological and
    statistical evaluation. The number of animals considered sufficient
    depends on the variability, sensitivity and nature (e.g., quantal or
    continuous) of the end-point being evaluated. For example, it is
    commonly 50 per group in carcinogenicity bioassays where the responses
    of interest are quantal in nature and 10 per group in subchronic
    studies, where many of the examined end-points are continuous.

         Studies in which the route of exposure is similar to that of
    humans are most relevant to hazard identification for risk assessment.
    For substances of low toxicity, it is important to ensure that when
    administered in the diet, the quantities of the substance do not
    interfere with normal nutritional needs.

         Studies designed and conducted with 3-5 dosed groups plus a
    vehicle control group of animals will yield reasonable dose-response
    data relevant to hazard identification. The highest concentration of
    the chemical should be one that induces a recognizable effect in the
    animals such as changes in body or organ weights, enzyme changes or
    minor histological changes. Changes such as mortality, gross
    pathological changes, and painful or stressful conditions should be
    avoided as they may confound the results of the study and may not be
    in compliance with national and local animal welfare regulations.
    Intermediate dose(s) should be targeted to produce minimally
    observable toxic effects. Dose levels should be selected to produce
    graded responses; too large intervals may complicate accurate
    estimations of the lowest-observed-effect level (LOEL). Ideally, the
    lowest dose should not demonstrate any toxicity (e.g., a NOAEL).

         To assess fully the toxicological potential of a chemical for
    local and systemic effects, all major organ systems should be examined
    for dose-related effects and adverse effects in various organs should
    be evaluated and described.

    3.4   In vitro studies

         Isolated cells, tissues and organs can be prepared and maintained
    in culture by methods that preserve their  in vivo properties and
    characteristics. Increasing concern about the ethics of animal
    experimentation has served to catalyse efforts leading to the possible
    replacement or reduction in the use of animals, and the refinement of
    test methods to minimize the stress and suffering to animals (ECETOC,
    1989; Gelbke, 1993).  In vitro testing contributes particularly to
    the assessment of genotoxicity, permitting a decision concerning the
    need for further testing.

         Over the last decade,  in vitro tests have been proposed as a
    pre-screen or as an alternative method for other end-points, such as
    prenatal toxicity, eye irritation, dermal irritation, tumour promotion
    and target organ toxicity (Purchase, 1986; Tennant et al., 1987;
    Anderson, 1990; Frazier, 1993; Atterwill, 1995). There has been
    particular emphasis on validation programmes for skin and eye
    irritation, but most of the tests mentioned above have not yet been
    sufficiently validated and the results of validation studies,
    especially in the past, have been lacking in consistency. The results
    have failed to meet the need for reproducibility and high correlation,
    ideally with sound human data but usually, for practical reasons, with
    existing animal tests, which they are intended to replace.

         Aspects that are important in assessing the adequacy of
     in vitro studies include:

    *    the range of exposure levels, taking into account the toxicity of
         the substance in the bacteria/cells, its solubility and, where
         appropriate, its effects on the pH and osmolality of the culture
         medium;

    *    whether, in the case of volatile substances, precautions were
         taken to ensure the maintenance of effective concentrations of
         the substance in the test medium;

    *    whether (when necessary) an appropriate exogenous metabolism mix
         (e.g., S9 from induced rat or hamster liver) was used;

    *    whether appropriate negative and positive controls were included;
         and

    *    whether there was an adequate number of replicates (within the
         tests and of the tests).

         Clearly, greater mechanistic understanding would facilitate
    moving from purely empirical/correlative approaches to more
    mechanistic-based tests. This is likely to facilitate greatly the
    chances of adequate validation and acceptance of alternatives for
    regulatory purposes.

    3.5  Structure-activity relationships

         Where epidemiological and toxicological data are not available,
    the use of structure-activity relationships (SARs) may be considered.
    SARs are based on the assumption that chemical substances that reach
    and interact with target sites by the same mechanism do so as a result
    of their similar chemical properties.

         At present, SAR techniques, particularly those of a quantitative
    nature, are not well developed in relation to mammalian toxicity. They
    are primarily of value in predicting toxicokinetic properties and in
    priority setting for research and evaluation.

    4.  DOSE-RESPONSE

    4.1  Introduction

         Approaches to quantification of dose-response vary according to
    the scope and purpose of assessments. However, for most types of toxic
    effects (i.e. organ-specific, neurological/behavioural, immunological,
    non-genotoxic carcinogenesis, reproductive or developmental), it is
    generally considered that there is a dose or concentration below which
    adverse effects will not occur (i.e. a threshold). For other types of
    toxic effects, it is assumed that there is some probability of harm at
    any level of exposure (i.e. that no threshold exists); this currently
    applies primarily for mutagenesis and carcinogenesis. Some have
    restricted the non-threshold assumption to genotoxic carcinogens.

         The distinction in approaches for genotoxic carcinogens and other
    types of toxic effects is based primarily on the premise that simple
    events such as  in vitro activation and covalent binding may be
    linear over many orders of magnitude. Though it is not possible to
    demonstrate experimentally the presence or absence of a threshold,
    differences in approach to the dose-response assessment of genotoxic
    versus non-genotoxic carcinogens have been adopted in some countries.
    However, simple pragmatic distinction on this basis is increasingly
    problematic. For example, it is likely that there are thresholds for
    aneugenic genotoxic effects.

         If a threshold has been assumed (e.g., for non-neoplastic effects
    and non-genotoxic carcinogens), traditionally, a level of exposure
    below which it is believed that there are no adverse effects, based on
    a no-observed-adverse-effect level or NOAEL (approximation of the
    threshold) and uncertainty factors, has been estimated (section 4.3).
    Alternatively, the magnitude by which the N(L)OAEL exceeds the
    estimated exposure (i.e. the "margin of safety"), is considered in
    light of various sources of uncertainty (Commission Regulation (EC)
    No. 1488/94; Council Regulation (EEC) 793/93) (EC, 1993, 1994). In the
    past, this approach has often been described as "safety evaluation".
    Therefore, the dose that can be considered as a first approximation of
    the threshold, i.e. the NOAEL, is critical. Increasingly, however, the
    "benchmark dose", a model-derived estimate (or its lower confidence
    limit) of a particular incidence level (e.g., 5%) for the critical
    effect, is being proposed for use in quantitative assessment of the
    dose-response for such effects.

         At present, there is no clear consensus on appropriate
    methodology for the risk assessment of chemicals for which the
    critical effect may not have a threshold (i.e. genotoxic carcinogens
    and germ cell mutagens). Indeed, a number of approaches based largely
    on characterization of dose-response have been adopted for assessment
    in such cases (section 4.4). Therefore, the critical data points are
    those that define the slope of the dose-response relationship (rather
    than the NOAEL, which is the first approximation of a threshold).

         In North America and some European countries, cancer risks have
    traditionally been assessed by mathematical modelling of the
    dose-response data in the observable range to estimate the risk at
    much lower human intakes or exposures (low dose risk extrapolation).
    It should be noted, however, that quantitative estimation of such
    risks, particularly those orders of magnitude below the experimental
    range (i.e. low dose risk estimation), is uncertain. Owing to this
    uncertainty, some countries have chosen not to adopt this approach as
    the basis for their regulatory actions for genotoxic carcinogens, and
    other countries are increasingly adopting alternative measures of
    dose-response. In Canada and the USA, for example, there is,
    currently, increasing reliance on specification of the margin between
    potency in the experimental range and exposure as the measure of risk
    for carcinogens (Health Canada, 1994; US EPA, 1996b). In the United
    Kingdom, dose-response for genotoxic carcinogens is not quantified;
    instead the goal in risk management is to eliminate exposure or to
    reduce levels to as low as is reasonably practical (UK DOH, 1991).

         Owing to the increasing reliance on modelling in the experimental
    range to characterize dose-response for tumours, which is essentially
    similar to the benchmark dose being used increasingly to characterize
    dose-response for non-neoplastic effects, approaches to quantitative
    risk estimation for carcinogenic and non-neoplastic effects are
    converging.

    4.2  Considerations in dose-response assessment

    4.2.1  Introduction

    In considering toxic effects at various dose levels, the dose range of
    interest is generally the low-dose range, since it usually reflects
    the human exposure situation. Often, however, data on dose-response
    are available for higher doses only, and are often derived from animal
    experiments only. Therefore, the uncertainty in the dose-response
    assessment is larger than the uncertainty in hazard identification, as
    it requires extrapolation both from animal to human and from high-dose
    to low-dose levels. In certain instances, a distinction is made
    between response and effect, with a response being quantal and counted
    (e.g., the incidence of a tumour) and an effect being graded and
    measured (e.g., relative liver weight).

    4.2.2  Inter- and intra-species considerations

     4.2.2.1  Introduction

         The strains and species of laboratory animals exposed in toxicity
    studies have been selected to show minimum inter-individual
    variability. In contrast to laboratory animals, humans represent a
    very heterogeneous population with both genetic and acquired
    diversity.

         Therefore, two principal areas are considered when interpreting
    data on toxicity acquired in animal species in relation to human risk:

     a)   Inter-species consideration: comparison of the data for animals
         with a representative healthy human. Species differences result
         from metabolic, functional and structural variations.

     b)   Intra-species or inter-individual consideration: comparison of
         the representative healthy human with the range of variability
         present within the human population in relation to the relevant
         parameter(s).

         For each of these areas, there are two aspects to be considered
    in assessing risk, i.e. toxicokinetics (the delivery of the compound
    to the site of action) and toxicodynamics (the inherent sensitivity of
    the site of action to the chemical). Any approach that allows for the
    incorporation of adequate data on toxicokinetic or toxicodynamic
    differences between test animal and humans, or between different
    humans, will increase the scientific validity of risk assessment.

         Sources of inter-species and inter-individual variations in
    toxicokinetics include differences in anatomy (e.g., gastrointestinal
    structure and function), physiological function (e.g., cardiac output,
    renal and hepatic blood, glomerular filtration rate and gastric pH),
    and biochemical differences in, for example, enzymes involved in
    xenobiotic metabolism. Sources of inter-species and inter-individual
    differences in toxicodynamics (or inherent sensitivity) also include
    anatomy. For example, the effect may occur in an organ of questionable
    relevance to humans, such as the rodent forestomach. Physiological
    differences, such as the hormonal control of the target organ, and
    biochemical differences, e.g., species differences in key biochemical
    components such as alpha2u-globulin, may also play a role (Flamm &
    Lehman-McKeeman, 1991).

         In some cases, it may be possible to conclude that effects
    detected in animals are unlikely to be relevant to humans. In other
    cases, there may be data to indicate that humans are likely to be more
    or less sensitive than animal species; this information is important
    for consideration in selection of critical effects.

         If compound-specific toxicokinetic data are introduced into risk
    assessment, then it is essential that these are related to the
    species, protocol and active chemical entity (e.g., parent compound or
    metabolite) involved in the toxicity that is the basis for the hazard
    identification (Monro, 1990, 1993; Renwick, 1993a).

     4.2.2.2  Species differences

         Metabolism and structural/functional variations are both
    important determinants of species differences. Common areas of
    metabolic variation between species are digestive tract enzymes,
    levels of circulating enzymes, liver enzymes and detoxification
    processes.

         In extrapolating between species, three aspects need to be
    considered: the first relates to differences in body size, which
    requires dose normalization or scaling (often done by expressing the
    dose per kg body weight). The second relates to differences in
    toxicokinetics, particularly bioactivation and/or detoxification
    processes. The third aspect concerns the nature and severity of the
    target for toxicity. Inter-species normalization (or scaling) is
    generally based on physical characteristics (e.g., body weight, body
    surface area), although occasionally it is based on caloric demand or,
    where there are data in four species, multiple species regression.

         When clearance of the parent substance is limited by enzyme
    activity rather than blood flow or when metabolites are the toxic
    agents, more sophisticated physiologically based pharmacokinetic
    models are more appropriate, provided that adequate data are
    available. Currently, such data are available for only a small number
    of substances.

     4.2.2.3  Human variability

         Although data from animal studies may provide limited information
    on inter-individual variability within the test species, it is the
    greater potential variability in the human population that must be
    addressed in risk assessment. Sources of inter-individual variability
    in human populations include, for example, variations in genetic
    composition, nutrition, disease state and lifestyle.

         Inter-individual variability may occur in both the toxicokinetics
    of the chemical and the sensitivity of the target for toxicity.

    4.3  Non-neoplastic (threshold) effects

         Although specific aspects vary, comparable schemes have been
    developed by various national and international agencies and
    organizations to derive levels of exposure considered to present
    minimal or no risk for non-neoplastic effects to the general
    population. These include: Reference Dose/Concentrations (US
    Environmental Protection Agency), Tolerable Daily
    Intakes/Concentrations (Health Canada), Minimal Risk Levels (US
    ATSDR), Tolerable/Acceptable Daily Intakes (IPCS, 1987a,b, 1990a,b,
    1994). In evaluating dose-response for non-neoplastic effects, the
    European Union does not derive tolerable intakes; instead effect
    levels are compared to estimated exposures ("margin of safety").

         In the case of substances for which the critical effect is not
    carcinogenicity, it is generally assumed that there is a level of
    exposure below which the probability for an adverse effect to occur is
    minimal, if not zero (i.e. a threshold). The mechanism underlying this
    assumption is that multiple cells (or cell components) must be
    irreversibly injured before an adverse effect becomes evident, and
    that cellular defence and repair mechanisms are overwhelmed by the
    rate at which injury occurs.

    4.3.1  Characterization of threshold

         For toxic effects, other than heritable mutations and genotoxic
    carcinogenicity, considered to have a threshold, i.e. a dose below
    which there would be no detectable effect, a number of different
    estimates may be used as an approximation of the biological threshold.

     4.3.1.1  No-observed-adverse-effect level (NOAEL)

         This is a simple estimate of the highest dose in which the
    incidence of a toxic effect or change in target organ weight,
    histopathology etc., was not significantly different from the
    untreated group (from a statistical and biological assessment). It is
    based on toxic effects of functional importance or pathological
    significance rather than adaptive responses, and is defined as the
    highest observed dose or concentration of a substance at which there
    is no detectable adverse alteration of morphology, functional
    capacity, growth, development or life span of the target (IPCS, 1994).
    The NOAEL will depend on the sensitivity of the methods used, the
    sizes of the exposed groups and the differences between estimated
    exposures or doses. The NOAEL is an observed value which does not take
    into account the nature or steepness of the dose-response curve.

         In consequence, the NOAEL is not the same as the biological
    threshold and may either underestimate or overestimate the true
    no-effect level. Though such limitations are recognized and have been
    the basis for criticism of the use of the NOAEL (Leisenring & Ryan,
    1992; Calabrese & Baldwin, 1994), dose-response relationships are
    often so poorly characterized that the NOAEL or LOAEL is the only
    quantitative value available as the basis for characterization of
    dose-response.

     4.3.1.2  Benchmark dose/concentration

         This is an alternative method of defining the lower end of the
    dose-response curve in the area of the observed threshold
    (Crump, 1984). The benchmark dose is the effective dose (or its lower
    confidence limit) that produces a certain increase in incidence above
    control levels (e.g., 1% or 5% of the maximum toxic response). The
    benchmark dose is derived by modelling the data in the observed range
    and selecting the point on the curve (or its upper confidence limit)
    corresponding to a specified increase in the incidence of an effect.
    Any model that fits the empirical data well is likely to provide a
    reasonable estimate of the benchmark dose, and choice of the model may
    not be critical since estimation is within the observed dose range.
    The advantages of the benchmark dose are that it takes into account
    the slope of the dose-response curve, the size of the study groups and
    the variability in the data. It should be recognized that unless there
    are a sufficient number of dose levels at which effects have been
    observed, the benchmark dose/concentration offers little advantage
    over effect levels as an approximation of the biological threshold.
    Statistical modelling of continuous data as a basis for developing
    benchmark doses/concentrations is also currently problematic.

     4.3.1.3  Lowest-observed-adverse-effect level (LOAEL)

         In some studies, there is a significant effect compared to
    controls in the lowest dose group. In such cases, there is no NOAEL
    and an alternative approach must be adopted. These include estimation
    of a benchmark dose or threshold estimate (if the dose-response data
    approach zero response) or application of an additional uncertainty
    factor.

    4.3.2  Uncertainty factors

         In deriving tolerable intakes (or RFDs or ADIs), the N(L)OAEL or
    benchmark dose/concentrations are divided by uncertainty factors to
    account for variabilities and uncertainties. Principal factors applied
    relate to extrapolation from animal studies to the human situation and
    to inter-individual variability within the response for the human
    population. Traditionally, default factors of 10 have been applied to
    account for each of these variations. Additional uncertainty factors
    have been applied to account for the inadequacy of the database, for
    extrapolation from subchronic to chronic exposure and from LOAEL to
    NOAEL, and for the severity of a given effect.

         Knowledge of actual inter-species differences and
    inter-individual variability in the biokinetic behaviour of a given
    compound (toxicokinetics) and its target organ (toxicodynamics) would
    enable the development of full biologically based dose-response models
    or physiologically based pharmacokinetic models. In the absence of
    full biological understanding, several approaches have been developed
    to incorporate as much scientific information as possible in the
    development and application of uncertainty factors. Indeed, a formal
    approach to the development of data-derived uncertainty factors has
    been developed by Renwick (1993a,b) and proposed by IPCS (IPCS, 1994).
    It is presented here as an example of a flexible but structured
    approach to the selection of uncertainty factors which reflects the
    nature and extent of the database (Lewis, et al., 1990; Renwick,
    1993b).

         The scheme retains the two 10-fold default uncertainty factors
    (for inter-species and inter-individual variation) as the cornerstone
    of the structure, in the absence of specific and relevant data on
    toxicokinetics or mechanism of action (Renwick, 1993a). However, it
    allows for the division of the two default uncertainty factors (for
    inter- and intra-species variation) to account for toxicokinetics and
    toxicodynamics. The default components of these two factors can then
    be replaced by actual quantitative data, when available. This reduces
    the extent of uncertainty by allowing the incorporation of appropriate
    data on the compound of interest in one or both of these aspects,
    where they exist (Fig. 1). There would be very few databases in which
    adequate information was available to account quantitatively for both
    aspects of either inter-species or of inter-individual differences.
    Incorporation of data on one aspect only (e.g., inter-species

    toxicokinetics) requires the use of a default factor for the
    uncertainty associated with the remaining undefined aspect (e.g.,
    inter-species toxicodynamics).

    Uncertainty factors often address:

     a) Nature of toxicity

         Some bodies, e.g., the FAO/WHO Joint Meeting on Pesticide
    Residues (JMPR), have used an additional "safety factor" in cases
    where the NOAEL is derived for a critical effect that is a severe and
    irreversible phenomenon, such as teratogenicity or non-genotoxic
    carcinogenicity, especially if the dose-response relationship is
    shallow (IPCS, 1987a,b, 1990a,b). This additional factor (of up to 10)
    has been applied in such cases to provide a greater margin between the
    intake/exposure of any particularly susceptible humans and the
    dose-response curve for such toxicity demonstrable in animals.
    However, for other types of toxic effect, for example, changes in
    organ weight or histopathology, a value of 1 (no further correction)
    would be appropriate.

     b) Adequacy of the database

         A minimum dataset that is considered adequate for risk assessment
    is generally established. This will vary according to the purpose of
    the assessment (e.g., screening level or full). Additional
    deficiencies in a toxicity database that increase the uncertainty of
    the extrapolation process have also been recognized by the use of an
    additional uncertainty factor. A value of 1 would be applied to an
    appropriate and complete database, but a higher factor would be
    considered necessary for barely adequate databases.

     c) LOAEL to NOAEL extrapolation

         In situations where a NOAEL has not been achieved but data are of
    sufficient quality to be the basis of the risk assessment, then an
    extra uncertainty factor may be applied (Dourson & Stara, 1983). The
    magnitude of this factor (e.g., 3 or 10) should be based on the
    dose-response data.

     d) Inter-species extrapolation

    The inter-species uncertainty factor is not necessary if the NOAEL or
    risk assessment is based on human data. Where an assessment is based
    on data in animals, however, and in situations where there are
    appropriate compound-specific toxicokinetic and/or toxicodynamic data,
    the relevant default uncertainty factor for inter-species variation
    would be replaced by the data-derived factor (Renwick, 1993b). Data on
    physiologically based pharmacokinetic (PBPK) modelling should be
    included wherever possible; however, such information is available
    currently for only a small number of substances. If a data-derived

    FIGURE 2

    factor is introduced, then the commonly used 10-fold factor would be
    replaced by the product of that factor and the remaining default
    factor.

         The composite default value of 10 has been criticized as
    inadequate, for example, to allow for metabolic processes in mice
    which can be related to body surface area (Calabrese et al., 1992);
    the introduction of data-derived uncertainty factors would allow the
    logical future development of more appropriate species specific
    defaults.

     e) Inter-individual variability in humans

         In situations where appropriate toxicokinetic and toxicodynamic
    data exist for a particular compound in humans, then the relevant
    uncertainty factor should be replaced by the data-derived factor
    (Renwick, 1993b). Data on PBPK modelling may also be able to
    contribute to this assessment. If a data-derived factor is introduced,
    then the commonly used 10-fold factor would be replaced by the product
    of the data-derived factor and the remaining default factor.

         Although the 10-fold default uncertainty factor is reasonable for
    most cases (Dourson & Stara, 1983), it has been criticised as
    inadequate for human variability especially when genetically
    determined differences in a bioactivation process may be involved
    (Calabrese, 1985; Goldstein, 1990). This concern reinforces the
    importance of using an approach that allows the incorporation of data
    on human variability in either toxicokinetics of the compound or the
    sensitivity to its mechanism of action.

         In addition to approaches aimed at incorporating as much
    biological data as possible in the derivation of uncertainty factors,
    probabilistic approaches have been investigated for the
    characterization of uncertainty (Baird et al., 1996; Price et al.,
    1997). Distributions can be developed on the basis of empirical
    relationships observed for, for example, variations between LOAELs and
    NOAELs and effect levels in subchronic versus chronic studies. Monte
    Carlo techniques can be used to integrate probabilities for the
    various areas of uncertainty.

    4.4  Quantitative risk assessment for neoplastic (non-threshold)
         effects

    4.4.1  Introduction

         A number of approaches have been adopted for characterization of
    dose-response in the assessment of genotoxic neoplastic effects,
    including quantitative extrapolation by mathematical modelling of the
    dose-response curve to estimate the risk at likely human intakes or
    exposures (low-dose risk extrapolation). Traditionally, where
    dose-response has been extrapolated into the low-dose range, this has
    been accomplished by the use of the linearized Armitage-Doll

    multi-stage model. Dose-response may also be estimated in a two-step
    process by straight linear extrapolation into the low-dose range from
    a modelled point on the dose-response curve. Other measures of
    dose-response include estimation of carcinogenic potency in the
    experimental range and division of effect levels by a margin of
    protection. In more recently developed biological models, different
    stages in the process of carcinogenesis have been incorporated and
    time to tumour has been taken into account (Moolgavkar et al., 1988),
    although currently data are sufficient for application in only a
    limited number of cases. In some cases where data permit, the dose
    delivered to the target tissue has been incorporated into the
    dose-response analysis (PBPK modelling) (IPCS, 1993).

         In the same way as approaches adopted for non-neoplastic
    (threshold) effects, there are increasingly attempts to incorporate
    more of the scientific data in adopted approaches. For example, the
    proposed cancer guidelines issued by the US EPA (1996b), updating the
    previous guidelines (US EPA, 1986a), put emphasis on the full
    integration of mechanistic information and dose-response data.
    Depending on the mode of action, linear extrapolation into the
    low-dose range or, alternatively, a margin of exposure would be
    presented. The adequacy of the latter approach must be judged by
    criteria similar to those used in developing tolerable
    intakes/exposures for non-cancer effects.

    4.4.2  Linear extrapolation

         Where data on the mechanism of tumour induction are not
    available, as a default, risks are often linearly extrapolated into
    the low-dose range. Previously (e.g., US EPA, 1986a) the linearized
    multistage model was widely adopted for such extrapolations for data
    from studies in animal species, whereas data from epidemiological
    studies were generally modelled using a multistage model with a linear
    term. More recently, curve fitting within the range of observation
    with extrapolation from the lower 95% confidence limits on a dose
    associated with a 10% extra risk (the LED10) has been recommended (US
    EPA, 1996a). Linear extrapolation is considered to be appropriate if
    available evidence supports a mode of action that is anticipated to be
    linear or, as a science policy default, there is no evidence of either
    linearity or non-linearity.

         Other approaches to linear extrapolation have been described in
    the literature. Gross et al. (1970) suggested a method based on
    discarding data at the upper end of the dose range until a linear
    model provides an adequate description of the remaining data. Van
    Ryzin (1980) suggested the use of any model that fits the data
    reasonably well to estimate the dose producing an excess risk of 1%,
    and then using simple linear extrapolation to lower doses. Gaylor &
    Kodell (1980) proposed fitting a model to the available data and then
    using linear extrapolation below the lowest dose at which observations
    were taken. Since the estimates at the lower doses might be unduly
    influenced by the choice of the model used in the experimental dose

    range, Farmer et al. (1982) suggested linear extrapolation below the
    lowest dose or the dose corresponding to an estimated risk of 1%,
    whichever was larger.

         A model-free procedure based on linear extrapolation below the
    lowest dose showing an increased (not necessarily statistically
    significant) risk has been proposed by Krewski et al. (1984, 1986)
    using linear extrapolation from all doses for which there were no
    statistically significant increases in tumour incidence above the
    baseline level, and selecting the smallest slope for low-dose risk
    estimation. Similarly, Gaylor (1987) considered the smallest slope
    obtained from all the possible combinations of data from the doses
    where the lowest dose was in the convex portion of the dose-response
    curve. In both cases, upper confidence limits on the slopes were used.

         A number of arguments have been advanced in support of the
    hypothesis of low-dose linearity (Krewski et al., 1986; Murdoch et
    al., 1987). For example, the class of additive background models
    considered by Crump et al. (1976) predicts low-dose linearity provided
    only that the response increases smoothly with dose. However, it is
    difficult to prove or disprove low-dose linearity experimentally even
    in bioassays involving extremely large numbers of animals (Gaylor et
    al., 1985). Indeed, dose-response curves for different types of
    tumours in mice following exposure to 2-acetylaminofluorene (2-AAF) in
    an ED01 study varied considerably.

         Often, linear extrapolation is criticized as being too
    conservative. For example, Bailar et al. (1988) demonstrated that a
    significant fraction of bioassays conducted for the National
    Toxicology Program indicate that, at high experimental doses, observed
    response rates are higher than those predicted by a linear model. They
    argue that, at low doses, the one-hit model may thus not be
    conservative in some cases. However, these observations are not
    necessarily inconsistent since, at low doses, the linear term
    predominates. Crump et al. (1976), Peto (1978) and Hoel (1980) argue
    that low-dose linearity occurs when substances augment existing
    carcinogenic processes. The formation of DNA adducts, which may be
    predictive of certain tumours induced by genotoxic carcinogens, has
    often been observed to be linear at very low doses (Poirier & Beland,
    1987). Based on these considerations, it is unclear whether an
    estimate based on a linear approximation over- or under-estimates the
    true risk.

         The outcome of low-dose extrapolation is the resulting lifetime
    cancer risk associated with estimated exposure for a particular
    population. In view of the considerable uncertainties in extrapolating
    results over several orders of magnitude, in the absence of
    information on mechanisms of tumour induction, specification of risks
    in terms of predicted incidence or numbers of excess deaths per unit
    of the population implies a degree of precision that is considered
    misleading by some (e.g., Health Canada, 1994).

    4.4.3  Estimation of potency in the experimental range

         For assessment of Priority Substances under the Canadian
    Environmental Protection Act (CEPA), e.g., for genotoxic carcinogens,
    a Tumorigenic Dose or Concentration05 (TD5) has been adopted as the
    measure of dose-response (Health Canada, 1994; Meek et al., 1994). It
    is the intake or concentration associated with a 5% incidence of
    tumours in experimental studies on animals or epidemiological studies
    on human populations. It serves as the basis for development of an
    Exposure/Potency Index (EPI) which is the estimated daily human intake
    or exposure divided by the TD5. A calculated EPI of 10-6 represents
    a one million fold difference between human exposure and that at the
    lower end of the dose-response curve, on which the estimate of potency
    is based.

         Any model that fits the empirical data well is likely to provide
    a reasonable estimate of the TD5. Choice of the model may not be
    critical since estimation is within the observed dose range, thereby
    avoiding the numerous uncertainties associated with low-dose
    extrapolation. Wherever possible, and if considered appropriate,
    information on pharmacokinetics, metabolism and mechanisms of
    carcinogenicity and mutagenicity is incorporated into the quantitative
    estimates of potency derived particularly from studies in animals (to
    provide relevant scaling of potency for human populations). The value
    of 5% is arbitrary; selection of another value would not affect the
    relative potencies for each of a range of compounds. Indeed, in the
    literature, others have proposed the TD50 (Peto et al., 1984) and the
    TD25 (Allen et al., 1988; Dybing & Huitfeldt, 1992; Dybing et al.,
    1997). The Committee on Carcinogenicity of Chemicals in Food, Consumer
    Products and the Environment in the United Kingdom has concluded that
    the TD50 is the most practical quantitative estimate of carcinogenic
    potency for the ranking of genotoxic carcinogens (UK DOH, 1995).

         If there is no evidence for linearity, and there is sufficient
    evidence to support an assumption of non-linearity for the
    carcinogenic response, US EPA (1996a) recommends estimation of a
    margin of exposure, which is the LED10 or other point of departure
    divided by the environmental exposure of interest. It should be noted,
    however, that this contrasts with the approach in Canada and Europe,
    where characterization of potency within the experimental range is
    considered appropriate for carcinogens, whereas the default in the USA
    is linear. Indeed the Committee on Carcinogenicity of Chemicals in
    Food, Consumer Products and the Environment in the United Kingdom
    concluded that potency indices are not appropriate for the ranking of
    non-genotoxic carcinogens. Rather for non-genotoxic compounds, the
    emphasis should be on understanding mechanisms and their relevance to
    humans.

    4.4.4  Two-stage clonal expansion model

         This approach is based on the two-stage model of carcinogenesis,
    in which it is hypothesized that chemical carcinogenesis occurs in two
    steps. Cells are initiated following the occurrence of genetic damage

    in one or more cells in the target tissue. Such initiated cells may
    then undergo malignant transformation to give rise to a cancerous
    lesion. The rate of occurrence of such lesions may be increased by
    subsequent exposure to a promoter, which serves to increase the pool
    of initiated cells through mechanisms that result in clonal expansion.

         Mathematical formulations of this process have been presented by
    Moolgavkar et al. (1988) and Chen & Farland (1991). This stochastic
    birth-death-mutation model assumes that two mutations, each occurring
    at the time of cell division, are necessary for a normal cell to
    become malignant. Initiating activity may be quantified in terms of
    the rate of occurrence of the first mutation. The overall rate of
    occurrence of the second mutation describes progression to a fully
    differentiated cancerous lesion. Promotional activity is measured by
    the difference in the birth and death rates of initiated cells. In the
    absence of promotional effects and variability in the pool of normal
    cells, the two-stage birth-death-mutation model reduces to the
    classical two-stage model.

         It should be noted, however, that there are currently few cases
    where data are sufficient to permit application of such a model.

    4.4.5  Proportional analyses - carcinogenic and non-neoplastic effects

         There have been several investigations of the possibility of
    predicting potency for particular types of toxicity from data on other
    types of toxicity, including work by Tennant et al. (1987), Portier
    (1988), Travis et al. (1990a,b, 1991), Zeiger et al. (1990) and
    Haseman & Clark (1990). Such approaches have been necessary due, for
    example, to the high cost and degree of difficulty of long-term or
    carcinogenic bioassays. However, it is important to note that
    correlations between potencies for different types of effects may be
    artificially strengthened by dose selection (e.g., the top dose in
    carcinogenic bioassays is often the maximum tolerated dose, selected
    to elicit small reductions in body weight).

    5.  EXPOSURE ASSESSMENT

         The objective of exposure assessment is to determine the nature
    and extent of contact with chemical substances experienced or
    anticipated under different conditions. Approaches for assessing
    exposure and characterizing uncertainties/variability in resulting
    estimates presented here are derived primarily from the Exposure
    Assessment Guidelines (US EPA, 1986b, 1992).

    5.1  Definition of exposure and related terms

         Although there is reasonable agreement that human exposure means
    contact with the chemical or agent (Allaby, 1983; Environ, 1988;
    Hodgson et al., 1988), there has not yet been widespread agreement as
    to whether this means contact with (a) the visible exterior of the
    person (skin and openings into the body such as mouth and nostrils),
    or (b) the so-called exchange boundaries where absorption takes place
    (skin, lung, gastrointestinal tract). These different definitions have
    led to some ambiguity in the use of terms and units for quantifying
    exposure. In 1992, The US EPA published Guidelines (US EPA, 1992)
    defining exposure as taking place at the visible external boundary, as
    in (a) above.

         Under this definition, it is helpful to think of the human body
    as having a hypothetical outer boundary separating inside the body
    from outside the body. This outer boundary of the body is the skin and
    the openings into the body such as the mouth, the nostrils, and
    punctures and lesions in the skin. Exposure to a chemical is the
    contact of that chemical with the outer boundary. An exposure
    assessment is the quantitative or qualitative evaluation of that
    contact, which includes consideration of the intensity, frequency and
    duration of contact, the route of exposure (e.g., dermal, oral or
    respiratory), rates (chemical intake or uptake rates), the resulting
    amount that actually crosses the boundary (a dose), and the amount
    absorbed (internal dose). The Commission of the European Communities
    (EC, 1996) presented a similar definition for exposure assessment: the
    determination of the emissions, pathways and rates of movement of a
    substance and its transformation or degradation, in order to estimate
    the concentrations/ doses to which human populations or environmental
    spheres (water, soil and air) are or may be exposed.

         Depending on the purpose of an exposure assessment, the numerical
    output may be an estimate of the intensity, rate, duration and
    frequency of contact exposure or dose (the resulting amount that
    actually crosses the boundary). For risk assessments based on
    dose-response relationships, the output usually includes an estimate
    of dose.


    FIGURE 3

    5.2  Exposure and dose

         Most of the time, the chemical coming into contact with the outer
    boundary of the body is contained in air, water, soil, a product or a
    transport or carrier medium; the chemical concentration in these media
    at the point of contact is the concentration, on which exposure
    estimates are based. Exposure over a period of time can be represented
    by a time-dependent profile of the exposure concentration. The area
    under the curve of this profile is the magnitude of the exposure, in
    concentration-time units (Lioy, 1990; US NRC, 1990):

    CHEMICAL STRUCTURE 1

    where E is the magnitude of exposure, C(t) is the exposure
    concentration as a function of time, and t is time, t2-t1 being the
    exposure duration (ED). If ED is a continuous period of time (e.g., a
    day, week, year, etc.), then C(t) may be zero during part of this
    time. Integrated exposures are done typically for a single individual,
    a specific chemical, and a particular pathway or exposure route over a
    given time period.

         The integrated exposures for a number of different individuals (a
    population or population segment, for example), may then be displayed
    in a histogram or curve (usually, with integrated exposure increasing
    along the abscissa or x-axis, and the number of individuals at that
    integrated exposure increasing along the ordinate or y-axis). This
    histogram or curve is a presentation of an exposure distribution for
    that population or population segment.

         Applied dose is the amount of a chemical at the absorption
    barrier (skin, lung, gastrointestinal tract) available for absorption.
    Usually, it is very difficult to measure the applied dose directly, as
    many of the absorption barriers are internal to the human and are not
    localized in such a way as to make measurement easy. An approximation
    of applied dose can be made, however, using the concept of potential
    dose (Lioy, 1990; US NRC, 1990). Potential dose is simply the amount
    of the chemical ingested, inhaled or in material applied to the skin.

         For the dermal route, potential dose is the amount of chemical
    applied or the amount of chemical in the medium applied, e.g., as a
    small amount of particulate deposited on the skin. It should be noted
    that as not all of the chemical in the particulate is in contact with
    the skin, this differs from exposure (the concentration in the
    particulate multiplied by the time of contact) and applied dose (the
    amount in the layer actually touching the skin).

         The applied dose, or the amount that reaches the exchange
    boundaries of the skin, lung or gastrointestinal tract, may often be
    less than the potential dose if the material is only partly
    bioavailable. This will depend, for example, on the form in which the
    compound is administered (e.g., neat or in vehicle on skin). Where
    data on bioavailability are known, adjustments to the potential dose
    to convert it to applied dose and internal dose may be made. For
    example, chemicals reaching their target through the gastrointestinal
    tract can be metabolized in the anaerobic conditions of the lower
    colon prior to absorption. Bioavailability via various routes of
    exposure may also vary. For example, intestinal absorption results in
    a first pass effect that may lead to metabolic detoxication or
    activation by the liver.

         The amount of a chemical that has been absorbed and is available
    for interaction with biologically significant receptors is called the
    internal dose. Once absorbed, the chemical can undergo metabolism,
    storage, excretion or transport within the body. The amount
    transported to an individual organ, tissue or fluid of interest is
    termed the delivered dose. The delivered dose may be only a small part
    of the total internal dose. The biologically effective dose, or the
    amount that actually reaches cells, sites or membranes where adverse
    effects occur (US NRC, 1990), may only be a part of the delivered
    dose. Currently, most risk assessments dealing with environmental
    chemicals (as opposed to pharmaceutical assessments) use dose-response
    relationships based on potential (administered) dose or internal dose,
    since the pharmacokinetics necessary to base relationships on the
    delivered dose or biologically effective doses are not available. This
    may change in the future, as more becomes known about the
    pharmacokinetics of environmental chemicals.

         Doses are often presented as dose rates, or the amount of a
    chemical dose (applied or internal) per unit time (e.g., mg/day), for
    instance, as dose rates on a per-unit-body-weight basis (e.g., mg/kg
    per day).

         The general equation for potential dose for intake processes,
    e.g., inhalation and ingestion, is simply the integration of the
    chemical intake rate (concentration of the chemical in the medium
    multiplied by the intake rate of the medium, C x IR) over time: 

    CHEMICAL STRUCTURE 2

    where Dpot is potential dose and IR(t) is the ingestion or inhalation
    rate.

         The quantity t2-t1, as before, represents the period of time
    over which exposure is being examined, or the exposure duration (ED).
    The exposure duration may contain times where the chemical is in
    contact with the person, and also times when C(t) is zero. Contact
    time represents the actual time period where the chemical is in
    contact with the person. For cases such as ingestion, where actual
    contact with food or water is intermittent, and consequently the
    actual contact time may be small, the intake rate is usually expressed
    in terms of a frequency of events (e.g., 8 glasses of water consumed
    per day) multiplied by the intake per event (e.g., 250 ml of water per
    glass of water consumed). Intermittent air exposures (e.g., 8 h
    exposed/day multiplied by one cubic metre of air inhaled/hour) can
    also be expressed easily using exposure duration rather than contact
    time. Hereafter, the term exposure duration will be used in the
    examples below to refer to the term t2-t1, since it occurs
    frequently in exposure assessments and it is often easier to use.

         Equation 2 can also be expressed in discrete form as a summation
    of the doses received during various events i:

    CHEMICAL STRUCTURE 3

    where EDi is the exposure duration for event i. If C and IR are
    nearly constant (which is a good approximation if the contact time is
    very short), equation 4-3 becomes:

    CHEMICAL STRUCTURE 4
                                                                      _
    where ED is the sum of the exposure durations for all events, and C
        __
    and IR are the average values for these parameters. Equation 4 will
    not necessarily hold in cases where C and IR vary considerably. In
    those cases, equation 3 can be used if the exposure can be broken out
    into segments where C and IR are approximately constant. If even this
    condition cannot be met, equation 2 may be used.

         For risk assessments, estimates of dose should be expressed in a
    manner that can be compared with available dose-response data.
    Frequently, dose-response relationships are based on potential dose
    (called administered dose in animal studies), although dose-response
    relationships are sometimes based on internal dose.

         Doses may be expressed in several different ways. Solving
    equations 2, 3 or 4 for example, gives a total dose accumulated over
    the time in question. The dose per unit time is the dose rate, which
    has units of mass/time (e.g., mg/day). Because intake and uptake can
    vary, dose rate is not necessarily constant. An average dose rate over
    a period of time is a useful number for many risk assessments.

         Exposure assessments take into account the time scale related to
    the biological response studied, unless the assessment is intended to
    provide data on the range of biological responses (US NRC, 1990). For
    developmental toxicity effects, a single short-term exposure can cause
    the adverse health effects. For many non-cancer effects, risk
    assessments consider the period of time over which the exposure
    occurred, and often, if there are no excursions in exposure that would
    lead to acute effects, average exposures or doses over the period of
    exposure are sufficient for the assessment. These averages are often
    in the form of average daily doses (ADDs) expressed, for example, in
    mg/kg body weight per day.

         An ADD can be calculated from equation 2 by averaging Dpot over
    body weight and an averaging time, provided the dosing pattern is
    known so that the integral can be solved. It is unusual to have such
    data for human exposure and intake over extended periods of time, so
    some simplifying assumptions are commonly used. Using equation 4
    instead of 2 or 3 involves making steady-state assumptions about C and
    IR, but this makes the equation for ADD easier to solve. For intake
    processes, then, using equation 4, this becomes:

    CHEMICAL STRUCTURE 5

    where ADDpot is the average daily potential dose, BW is body weight,
    and AT is the time period over which the dose is averaged (converted
                                                             _
    to days). As with equation 4, the exposure concentration C is best
    expressed as an estimate of the arithmetic mean regardless of the
    distribution of the data. Again, using average values for C and IR in
    equation 5 assumes that C and IR are approximately constant.

         For effects such as cancer, where the biological response is
    usually described in terms of lifetime probabilities, even though
    exposure does not occur over the entire lifetime, doses are often
    presented as lifetime average daily doses (LADDs). The LADD takes the
    form of equation 6, with lifetime (LT) replacing the averaging time
    (AT):

    CHEMICAL STRUCTURE 6

    5.3  Approaches to quantification of exposure

         Exposure (or dose) is assessed generally by one of the following
    approaches:

    a)   The exposure can be measured at the point of contact (the outer
         boundary of the body) while it is taking place, measuring both
         exposure concentration and time of contact and integrating them
         (point-of-contact or personal measurement);

    b)   The exposure can be estimated by separately evaluating the
         exposure concentration and the time of contact, then combining
         this information (scenario evaluation);

    c)   The exposure can be estimated from dose, which in turn can be
         reconstructed through internal indicators (biomarkers, body
         burden, excretion levels, etc.) after the exposure has taken
         place (reconstruction).

         These three approaches to quantification of exposure (or dose)
    are independent, as each is based on different data. This offers the
    opportunity of checking the accuracy of exposure estimated by one
    approach through use of an independent approach, where data permit.
    The independence of the three methods is a useful concept in verifying
    or validating results. Each of the three has strengths and weaknesses;
    using them in combination can considerably strengthen the credibility
    of an exposure or risk assessment.

    5.3.1  Measurement at point of contact (personal monitoring)

         Point-of-contact exposure measurement evaluates the exposure as
    it occurs, by measuring the chemical concentrations at the interface
    between the person and the environment as a function of time,
    resulting in an exposure profile. The best known example of the
    point-of-contact measurement is the radiation dosimeter. This small
    badge-like device measures exposure to radiation as it occurs and
    provides an integrated estimate of exposure for the period of time
    over which the measurement has been taken. Another example is the
    Total Exposure Assessment Methodology (TEAM) studies (US EPA, 1987a)
    conducted by the EPA and similar multimedia exposure studies in Canada
    (Otson et al., 1996). In the TEAM studies, a small pump with a
    collector and absorbent was attached to a person's clothing to measure
    his or her exposure to airborne solvents or other pollutants as it
    occurred. A third example is the carbon monoxide (CO) point-of-contact
    measurement studies where subjects carried a small CO measuring device
    for several days (US EPA, 1984). Dermal patch studies and duplicate
    meal studies are also point-of-contact measurement studies. In all of
    these examples, the measurements are taken at the interface between
    the person and the environment while exposure is occurring. Use of
    these data for estimating exposures or doses for periods that differ
    from those for which the data are collected (e.g., for estimates of
    lifetime exposures) will require some assumptions.

         The strength of this method is that it measures exposure
    directly, and providing that the measurement devices are accurate, is
    likely to give the most accurate exposure value for the period of time
    over which the measurement was taken. It is often expensive, however,
    and measurement devices and techniques do not currently exist for all
    chemicals. This method may also require assumptions to be made
    concerning the relationship between short-term sampling and long-term
    exposures, if appropriate. This method is also not source-specific, a
    limitation when particular sources will need to be addressed by risk
    managers.

    5.3.2  Scenario evaluation method (time activity and
           monitoring/modelling)

         In exposure scenario evaluation, the assessor attempts to
    determine the concentrations of chemicals in a medium or location and
    link this information with the time and ways that individuals or
    populations come into contact with the chemical. The set of
    assumptions about how this contact takes place is an exposure
    scenario.

         The first step in a scenario evaluation is usually to
    characterize the contaminant concentration in the media of concern at
    the point where contact occurs. This is typically accomplished
    indirectly by measuring, modelling or using existing data on
    concentrations in the bulk media, rather than at the true point of
    contact. An example of a scenario evaluation is presented in Table 1.
    Since the concentration in the bulk medium is not the same as the
    exposure concentration, this is a clear source of potential error in
    the exposure estimate. Generally, the closer the medium can be
    measured to the point of contact (in both space and time), the less
    uncertainty there is in the characterization of exposure
    concentration. Where monitoring data are inadequate, fate models are
    typically used to estimate chemical concentrations. These models can
    span a wide range of complexity in terms of spatial dimensions and
    temporal assumptions (i.e. steady-state versus non-steady-state).
    Types of fate models include:

    *    simple dilution models where a measured concentration in an
         effluent is divided by a dilution factor or the chemical release
         rate is divided by the bulk flow rate of the medium;

    *    equilibrium models which predict the distribution of a chemical
         in the environment based on partitioning ratios or fugacity (the
         escaping tendency of a chemical from one environmental phase to
         another);

    *    dispersion models which predict reductions in concentrations from
         point sources based on assumed mathematical functions or
         dispersion properties of the chemical;

    *    transport models which predict concentration changes over
         distance and can represent dispersion, biochemical degradation
         and absorption.

         Compilations of existing environmental fate models have been
    published (OECD, 1989, 1991a; Braat et al., 1991; ECETOC, 1992, 1993;
    RIVM, 1994). The US EPA has produced a software system called the
    Integrated Model Evaluation System (IMES) to help assessors select the
    fate model best suited to their needs (US EPA, 1992). The software
    prompts users to answer a variety of questions about their needs and
    then lists the models that have matching features. The system has
    information on over 150 models representing all media (air, surface
    water and groundwater). Model information includes descriptions of the
    model type, computer requirements, validation testing and contact for
    obtaining a copy. The Netherlands National Environmental Policy Plan
    Uniform System for the Evaluation of Substances (USES) is a
    decision-support system for the rapid quantitative assessment of the
    hazards and risks of chemicals, including new substances, agricultural
    pesticides and biocides (RIVM, 1994). USES has been the basis for the
    development of the European Union System for the Evaluation of
    Substances (EUSES).

         The reliability of modelled estimates of chemical concentration
    in the general environment depends on how well the model assumptions
    match reality (i.e. how realistic are the assumptions such as
    steady-state conditions and homogenous media properties), whether the
    model performance has been demonstrated under conditions similar to
    those of concern; and the quantity and quality of input data.
    Modelling efforts which use input values derived primarily on the
    basis of default assumptions are generally most useful for screening
    purposes to highlight areas in which specific additional data are
    required to estimate exposure more accurately. Further discussion
    about model uncertainty can be found below.

         The next steps involve identifying who is exposed and developing
    estimates of the frequency and duration of exposure. Like chemical
    concentration characterization, this is usually done indirectly by use
    of demographic data, survey statistics, behaviour observation,
    activity diaries, activity models or, in the absence of more
    substantive information, assumptions about behaviour. When estimating
    potential dose, this step also involves estimating how much contact
    occurs. Table 2 shows examples of standardized reference values for
    body weights, fluid intake and respiratory volumes. This type of data
    is also summarized in the Exposure Factors Handbook (US EPA, 1997).
    This Handbook includes information on consumption rates for various
    food types, fish ingestion, soil ingestion, dermal contact with soils,
    body surface area, lifetime, body weight, inhalation rate, breast milk
    ingestion rate, and activity patterns (time spent swimming, bathing
    time, time indoors/outdoors, time in vehicles, etc.). For each factor,
    descriptions are provided of the average values and the variability in
    the general population. Values are recommended for each factor, with a
    qualitative indication of the supporting weight of evidence.


        Table 1. Estimated daily intake of inorganic fluoride (mg/kg body weight per day), according to age group, by the general
    population of Canada (from Liteplo et al., 1994)

                                                                                                                                       
    Route of exposure                           0-6 monthsa     7 months-4 yearsb      5-11 yearsc     12-19 yearsd       20 + yearse
                                                                                                                                       

    Ambient airf                                0.01            0.01                   0.01            0.01               0.01
    Foodg                                       14-92           22                     16              13                 30
    Breast milkh                                0.5-1.1         -                      -               -                  -
    Soili                                       0.03-1.6        0.02-1.2               0.01-0.4        0.002-0.1          0.002-0.1
    "Fluoridated" drinking-waterj               -               45-77                  24-42           17-29              16-27
    "Non-fluoridated" drinking-waterk           -               3.1-12.9               1.7-7.0         1.1-4.8            1.1-4.5
    Household productsl                         -               20-60                  8.2-20          2.5                1.1
    Total intake of breast-fed infants          0.5-2.6         -                      -               -                  -
    Total intake of formula-fed infants         14-94           -                      -               -                  -
    Total intake ("Fluoridated" water)m         -               87-160                 49-79           33-45              47-58
    Total intake ("Non-fluoridated" water)n     -               45-96                  26-44           17-21              32-36
                                                                                                                                       

    a     Assumed to weigh 7 kg, breathe 2 m3 air, drink 750 ml of breast milk or infant formula (as food),
          and consume 35 mg soil per day.

    b     Assumed to weigh 13 kg, breathe 5 m3 air, drink 0.8 litres of water, and consume 50 mg soil per day.

    c     Assumed to weigh 27 kg, breathe 12 m3 air, drink 0.9 litres of water, and consume 35 mg soil per day.

    d     Assumed to weigh 57 kg, breathe 21 m3 air, drink 1.3 litres of water, and consume 20 mg soil per day.

    e     Assumed to weigh 70 kg, breathe 23 m3 air, drink 1.5 litres of water, and consume 20 mg soil per day.

    f     Based on the mean concentration of inorganic (gaseous and particulate) fluoride in ambient air of
          0.03 µg/m3, reported for Toronto, Ontario, and assuming the concentration in indoor air is identical
          to (outdoor) ambient air.

    Table 1 (Continued)

    g     Formula-fed infants (0-6 months): based on the mean concentrations of inorganic fluoride in infant
          formulas purchased in the USA of 0.127 and 0.854 mg/litre reported for ready-to-use, milk-based formula
          and soy-based powdered formula (prepared with drinking-water containing 1 ppm fluoride), respectively,
          and assuming infants are exclusively formula-fed and consume 750 ml formula per day. General population
          (7 months and older): based on levels of inorganic fluoride detected in 109 individual foods from Canada
          (and the USA), in the following food groups: 0.01-0.80 µg/g in dairy products, 0.12-1.02 µg/g in cereal
          products, 0.01-0.58 µg/g in fruit, 0.01-0.68 µg/g in vegetables, 0.04-4.57 µg/g in meat/fish/eggs;
          0.05-0.13 µg/g in fats, 0.11-0.35 µg/g in nuts/legumes, 0.02-0.86 µg/g in foods containing primarily sugar,
          0.41-0.84 µg/g in soup, 4.97 µg/g in tea; and the daily intake of each food item by the various age groups
          of the general population of Canada.

    h     Based on the mean concentrations of inorganic fluoride of 4.4 and 9.8 ng/g reported for samples of
          breast milk from mothers living in communities served by "non-fluoridated" and "fluoridated" drinking-water,
          respectively, assuming the density of breast milk is equal to 1.0 g/ml.

    i     Based on a range of concentrations of total inorganic fluoride of 6 µg/g reported by Sidhu (1982) for
          soil collected in Newfoundland, to 309 µg/g [mean concentration in Canadian surface soil (0-130 cm depth)].

    j     Based on a range of mean concentrations of inorganic fluoride in "fluoridated" drinking-water of 0.73 mg/litre,
          determined from fluoride levels in 3 communities in Newfoundland and Labrador, to 1.25 mg/litre, determined
          from 2 communities in the Yukon. "Fluoridated" refers to drinking-water to which inorganic fluoride has been
          intentionally added for the prevention of dental caries.

    k     Based on a range of mean concentrations of inorganic fluoride in "non-fluoridated" drinking-water of (at least)
          0.05 mg/litre (reported for 3 communities in British Columbia), to 0.21 mg/litre (reported for an unspecified
          number of communities in the Yukon). "Non-fluoridated" refers to drinking-water to which inorganic fluoride
          has not been intentionally added for the prevention of dental caries.

    l     Based on a mean concentration of inorganic fluoride in most dentifrice products of 1000 µg/g and an estimated
          intake of dentifrice of 0.26-0.78 g/day for children 7 months to 4 years of age, 0.22-0.54 g/day for children
          5 to 11 years of age, 0.14 g/day for adolescents 12 to 19 years of age, and 0.08 g/day for adults 20 + years
          of age, assuming an average of 2 brushings per day.

    m     Estimated total daily intake of inorganic fluoride by individuals consuming "fluoridated" drinking-water in Canada.

    n     Estimated total daily intake of inorganic fluoride by individuals in Canada consuming drinking-water
          that is not "fluoridated".

    
        Table 2.  Human contact parameters (from ICRP, 1974)
                                                                                             
    Body weight, kg
                                                                                             
          Adult male        =     70
          Adult female      =     58
          Average           =     64a

    Daily fluid intake (milk, tap water, other beverages), ml/day

    Normal conditions:
          Adults               =    1000-2400, representative figure = 1900b
                Adult male     =    1950
                Adult female   =    1400
          Child (10 years)     =    1400

    High average temperature (32 °C):
                Adults         =    2840-3410
    moderate activity:
                Adults         =    3700

    Respiratory volumes

    8-h respiratory volumes, litres per 8 h resting:
                                        Adult man         =     3600
                                        Adult woman       =     2900
                                        Child (10 years)  =     2300
     light/non-occupational activity:   Adult man         =     9600
                                        Adult woman       =     9100
                                        Child (10 years)  =     6240

    Daily inhalation volume, m3 (8 h resting, 16 h light/non-occupational activity)
          Adult male          =      23
          Adult female        =      21
          Average adult       =      22
          Child (10 years)    =      15
                                                                                             
    a     WHO uses 60 kg for calculation of acceptable daily intakes
          and water quality guidelines (IPCS, 1987b; WHO, 1993).
    b     WHO uses a daily per capita drinking-water consumption
          of 2 litres in calculating water quality guidelines (WHO, 1993).
             The chemical concentration and population characterizations are
    ultimately combined in an exposure scenario, and there are various
    ways to accomplish this. One of the major problems with this approach
    is that the limiting assumptions or boundary conditions (e.g.,
    steady-state assumptions) do not always hold true. Two ways to address
    to this aspect are: (a) to evaluate the exposure or dose equation
    under conditions where the limiting assumptions do hold true; or (b)
    to deal with the uncertainty caused by the divergence from the
    boundary conditions. As an example of the first option, in the
    microenvironment method, utilized primarily for evaluating airborne
    exposures in the general environment but including contact with the
    skin in the occupational environment, segments of time and location
    are evaluated where the assumption of constant concentration is
    approximately true and then summed over all such time segments for a
    total exposure for the respiratory route, effectively removing some of
    the boundary conditions. While estimates of exposure concentration and
    time-of-contact are still derived indirectly by this method, the
    concentration and time-of-contact estimates can be measured for each
    microenvironment. This avoids much of the error due to using average
    values in cases where concentration varies widely along with
    time-of-contact.

         As examples of the second approach, there are various tools used
    to describe uncertainty caused by parameter variation, such as Monte
    Carlo analysis (see below).

         One strength of the scenario evaluation approach is that it is
    usually the least expensive method of the three. In addition, it is
    particularly suited to analysis of the risk consequences of proposed
    actions. It is both a strength and a weakness of scenario development
    that the evaluation can be performed with little or no data; it is a
    technique that is best used when some knowledge exists about the
    soundness, validity and uncertainty of the underlying assumptions.

    5.3.3  Biomarkers of exposure/estimation of internal dose

         Exposure can also be estimated after it has taken place. If a
    total dose is known, or can be reconstructed, and information about
    intake and uptake rates is available, an average past exposure rate
    can be estimated. Reconstruction of dose relies on measuring internal
    body indicators after exposure, intake and uptake have already
    occurred, and using these measurements to back-calculate dose.
    However, the data on body burden levels or biomarkers cannot be used
    directly unless a relationship can be established between these levels
    or biomarker indications and internal dose, and interfering reactions
    (e.g., metabolism of unrelated chemicals) can be accounted for or
    ruled out. Biological tissue or fluid measurements that reveal the
    presence of a chemical may indicate directly that an exposure has
    occurred, provided the chemical is not a metabolite of other
    chemicals. These biomarkers of exposure are necessarily limited,
    however, to ethical relatively non-invasive techniques.

         Biological monitoring can be used to evaluate the amount of a
    chemical in the body by measuring one or more of the following items
    (not all of these can be measured for every chemical):

    *    the concentration of the chemical itself in biological tissues or
         sera (blood, urine, breath, hair, adipose tissue, etc.);

    *    the concentration of the chemical's metabolite(s);

    *    the biological effect that occurs as a result of human exposure
         to the chemical (e.g., alkylated haemoglobin or changes in enzyme
         induction);

    *    the amount of a chemical or its metabolites bound to target
         molecules.

         Biomarkers can be used to estimate chemical uptake during a
    specific interval if background levels do not mask the marker and the
    relationships between uptake and the marker selected are known. The
    time of sampling for biomarkers can be critical. Establishing a
    correlation between exposure and the measurement of the marker,
    including pharmacokinetics, can help optimize the sampling conditions.

         The strengths of this method are that it demonstrates that
    exposure to and absorption of the chemical has actually taken place,
    and it theoretically can give a good indication of past exposure.
    Biomarkers integrate exposure from all sources and take into account
    absorption, which may vary considerably due to a variety of factors
    including environmental characteristics, genetic predisposition, age,
    gender, ethnicity and/or lifestyle factors.

         For many environmental pollutants, the flow of events between
    exposure and health effects is not well understood. Biomarkers help
    address this problem by improving the sensitivity, specificity and
    predictive value of detection and quantification of adverse effects at
    low dose and early exposure (ECETOC, 1989; Fowle, 1989; Fowle &
    Sexton, 1992; US NRC, 1992). Sensitive subpopulations can be better
    pinpointed by biomarkers that measure increased absorption rate or a
    more severe biological response to a given environmental exposure
    (Lauwerys, 1984; ECETOC, 1989; Fowle & Sexton, 1992; Hemminki, 1992;
    US NRC, 1992).

         Over the last decade, biomarker methods have been developed for
    the detection of exposure to carcinogens and other DNA-damaging
    agents. These methods involve the detection of the parent compound or
    metabolites in body fluids or adducts bound to DNA or protein, such as
    haemoglobin and albumin (Shuker, 1989; Wogan, 1989, 1992; Beland &
    Poirier, 1993). Methods for detecting exposure to DNA-damaging agents
    are classifiable into two categories: a) measurements of levels of
    genotoxic chemicals, their metabolites and/or derivatives in cells,
    tissues, body fluids or excreta; and b) measurements of biological
    responses such as cytogenetic changes in exposed individuals.

         Biomarker methods have also been developed to detect exposure
    from tobacco use (polycyclic aromatic hydrocarbons (PAHs), aromatic
    amines and specific nitrosamines), dietary exposure (aflatoxins,
     N-nitrosamines, heterocyclic amines), medicinal exposure (cisplatin,
    alkylating agents, 8-methoxypsoralen, ultraviolet photoproducts),
    occupational exposure (benzene, ethylene oxide, styrene oxide, vinyl
    chloride, aromatic amines, PAHs) and oxidative damage
    (8-hydroxyguanine) (Perera, 1987, 1988; Groopman et al., 1988; Wogan,
    1989, 1992; Hemminki et al., 1990; Skipper & Tannenbaum, 1990; Beland
    & Poirier, 1993).

         The drawbacks of the reconstructive method are that it will not
    work for every chemical, due to interferences or the reactive nature
    of the chemical, it has not been methodologically established for very
    many chemicals, data relating internal dose to exposure are needed,
    and it may be expensive.

    5.4  Variability and uncertainty

         Characterization of variability and uncertainty is an integral
    component of all steps in risk assessment. However, quantitative
    characterization of these aspects is best developed for exposure
    estimation. Variability (the receipt of different levels of exposure
    by different individuals) is generally distinguished from uncertainty
    (the lack of knowledge about the correct value for a specific exposure
    measure or estimate). Most of the exposure and risk descriptors deal
    with variability directly, but, wherever possible, estimates of the
    uncertainty of these descriptors are included. This may be done
    qualitatively or quantitatively, and it is beyond the scope of this
    report to discuss the mechanics of uncertainty analysis in detail.

         Not all approaches historically used to construct measures or
    estimates of exposure attempted to distinguish variability and
    uncertainty. In particular, in many cases in which estimates were
    termed worst case, focusing on the high end of the exposed population
    and also selection of high-end values for uncertain physical
    quantities resulted in values that were seen to be quite conservative.
    By using both the high-end individuals (variability) and upper
    confidence bounds on data or physical parameters (uncertainty), these
    estimates might be interpreted as "not exceeding an upper bound on
    exposures received by certain high-end individuals".

         Variability in exposure occurs when some members of the
    population are exposed more than others. For example, exposures via
    one or more routes to some substances may be elevated for persons
    living in the vicinity of point sources (such as industrial
    emissions), depending on the form in which these substances are
    released and their subsequent environmental transport and
    transformation. The intake of some substances by subsistence hunters
    or fishermen may also be elevated due to accumulation in the game
    species that they consume. Owing to the variation in exposure patterns
    at various stages over a lifetime, exposure is often estimated for

    various age groups of the general population; for example, Health
    Canada (1994) estimates intake for several defined periods of life:
    for infants (0-6 months), pre-school children (7 months to 4 years),
    elementary school children (5-11 years), teenagers (12-19 years), and
    adults (20 years of age and older). Hence, the period up to 6 months
    of age is when many infants may be exposed to substances present in
    breast milk. In addition, pre-schoolers' exposure to contaminants in
    soil may be significantly higher than that for other age groups.
    Children of all ages have relatively high intakes of food per unit of
    body weight. Adulthood is a period of long-term lower-level exposure
    via most environmental media, with relatively high potential exposure
    to some substances through activities such as the use of consumer
    products. An example of age-stratified estimates of exposure is
    presented in Table 1, showing fluoride exposure for five age groups in
    the general population.

    5.4.1  Assessing uncertainty

         Assessing uncertainty may involve simple or very sophisticated
    techniques, depending on the requirements of the assessment.
    "Uncertainty characterization" generally involves a qualitative
    discussion of the thought processes that lead to the selection and
    rejection of specific data, estimates, scenarios, etc. For simple
    exposure assessments, where not much quantitative information is
    available, uncertainty characterization may be all that is necessary.

         "Uncertainty assessment" is more quantitative and can include
    simpler measures (i.e. ranges) and analytical techniques (i.e.
    sensitivity analysis) or, to the extent needed to support the decision
    for which the exposure assessment is conducted, more complex measures
    and techniques.

         Uncertainty in exposure assessment can be classified into three
    broad categories:

    1.   Uncertainty regarding missing or incomplete information needed to
         fully define the exposure and dose (scenario uncertainty).
    2.   Uncertainty regarding some parameter (parameter uncertainty).
    3.   Uncertainty regarding gaps in scientific theory required to make
         predictions on the basis of causal inferences (model
         uncertainty).

         Identification of the sources of uncertainty in an exposure
    assessment is the first step toward eventually determining the type of
    action necessary to reduce that uncertainty.

    5.5  Exposure settings

         Human exposure occurs in the general environment, at occupational
    settings or in households/businesses or other areas where consumer
    products are used. Each of these settings is discussed below.

    5.5.1  Exposure in the general environment

         Exposure to environmental substances may occur by inhalation,
    ingestion and/or dermal absorption from air, water, food and soil.
    Estimation of the total daily intake (often expressed as µg/kg body
    weight/day) from all sources is critical in assessing the true
    magnitude of risk associated with indirect exposure to substances in
    the general environment. This is often referred to as a "multimedia"
    approach (Table 1).

         The US EPA has sponsored the development of a computer software
    programme called Risk Assistant for conducting site-specific risk
    assessments for environmental chemicals. The programme prompts the
    user to identify the chemicals of concern, the contaminated media and
    concentrations in those media. The programme automatically lists the
    possible pathways of exposure associated with the contaminated media.
    The user can select which of these pathways is of interest. The user
    can choose to use default assumptions for exposure parameters or
    modify them as desired.

    5.5.2  Occupational settings

         Workers are exposed in the occupational environment by
    inhalation, through dermal contact or by ingestion, although the
    latter is not often quantified. Dermal and inhalation monitoring as
    well as biological monitoring (biomarkers) are often required to
    characterize adequately the exposure of special subgroups of workers
    such as mixers, loaders and applicators or pesticides (e.g., farm
    families) (WHO, 1986; US EPA, 1987b; Curry & Iyengar, 1992).

         Exposure by inhalation in the occupational environment is often
    expressed as the concentration of a substance in the breathing zone
    averaged over a reference period. This reference period is often 8 h
    to represent long-term exposure or 15 min for short-term exposure.
    Exposure to the skin is generally expressed as potential dose rate
    predominantly to the hands and forearms and is often available only as
    output of models.

         Measured data on concentrations of chemical substances in the
    occupational environment are often available from routine industrial
    hygiene or dedicated surveys. The suitability of the use of such
    information in estimation of exposure must be carefully assessed based
    on consideration of factors such as representation of levels, time
    periods and processes.

         Cumulative exposure (average intensity multiplied by time) is one
    of the most common summary measures for exposure in epidemiological
    studies of occupationally exposed populations. However, there may also
    be intermittent peak exposures that could be of importance but
    difficult to integrate properly in a single concentration-time
    exposure model (Ulfvarson, 1992). The elimination rate of a pollutant
    is of particular importance in considering the possible impact of peak
    versus continuous exposure (Axelson & Westberg, 1992).

         Where monitoring data are incomplete or not available,
    occupational exposures can also be modelled (EC, 1996), primarily to
    highlight areas in which specific additional data are required to
    estimate exposure more accurately. To date, these models are
    restricted primarily to prediction of mean concentrations over
    extended averaging periods (e.g., 8 h). For example, for workplace
    exposure modelling in the European Union, criteria to describe broadly
    the types of exposure possible address the physical properties of
    process chemicals, their use pattern and pattern of control.
    Descriptors for the physical properties of process chemicals include,
    for example, gas, liquid of high vapour pressure, liquid of medium
    vapour pressure, solid respirable dust, solid, granular or aerosol.
    Descriptors of use patterns include closed system, within a matrix or
    wide dispersive. Descriptors of control patterns include full
    containment, local exhaust ventilation, etc. Combinations of various
    subsets of these descriptors result in 160 complementary fields to
    which numerical ranges of concentrations have been assigned based on
    measured data in the United Kingdom National Exposure Database.

         Dermal exposure in occupational settings most commonly involves
    hands and forearms (approximately 2000 cm2) (EC, 1996). Dermal
    exposure to gases and vapours is typically assumed to be very low. The
    EU classifies the potential for dermal exposure as none, incidental
    (approximately one event per day), intermittent (2 to 10 events per
    day) or extensive (>10 events per day). Exposure ranges are estimated
    based on several databases and the published literature. Criteria for
    both inhalation and dermal exposure are incorporated within a
    knowledge-based electronic system (EC, 1996).

    5.5.3  Consumer products

         A consumer product is one which can be purchased from retail
    outlets by members of the general public. People of any age, either
    sex, and in any stage of health may be exposed to chemicals in these
    products. Much of the discussion below is based on an EU document
    providing guidance on assessing exposure to chemicals in consumer
    products (EC, 1996).

         Exposure to chemicals in consumer products is often considered as
    single events, a series of repeated events or as continuous exposure
    (e.g., concentrations in indoor air resulting from storage and use of
    such products). Routes of exposure are dermal (e.g., cleaning agents,
    cosmetics, shampoos), inhalation (e.g., hair spray, powdered
    detergents) or by ingestion (e.g., food, drinks or swallowing of tooth
    paste; see Table 1 for an example of the latter).

         The assessment of the exposure to consumer products can be
    conducted following an iterative procedure, which starts with an
    initial "screening". This screening would identify if a substance is
    used as or in consumer products where further consideration and
    possibly quantification of exposure is necessary.

         If a substance is used in more than one consumer product, or if
    more than one mode of use is employed (e.g., painting and spraying),
    or if the product could reasonably be expected to be used in other
    ways (e.g., use of a washing machine detergent for washing by hand),
    it may be necessary to assess exposure for each case. In addition, if
    the substance is used in different consumer products or has different
    modes of use, the exposure assessment could examine those uses for
    which the highest exposure is expected to occur on a regular basis.
    The cumulative exposure expected from the use of the same substance in
    different products may also be considered.

         To assess the exposure to substances present in consumer
    products, information is needed on two sets of parameters: contact
    parameters and concentration parameters. The contact parameters denote
    where, how long and how often contact with the consumer occurs. The
    concentration parameters are needed to estimate the concentration of a
    substance in a medium that might come into contact with the body. This
    is not necessarily equal to the concentration of the substance in the
    product, because a product might be diluted, mixed, undergo
    evaporation, etc., before the substance of interest actually reaches
    the human body.

         By combining the contact parameters with the concentration
    estimates, exposure or dose can be estimated. As discussed in section
    5.2, exposure and dose can be estimated in a variety of ways. Exposure
    to contaminants in air is commonly estimated in concentration-time
    units, as shown in equation 1. Exposure to ingested contaminants is
    commonly estimated as a potential dose, as shown in equation 2. Dermal
    exposures are commonly estimated as an internal dose.

         For example, exposure to a component of a hair spray used twice a
    day, could be based on assumptions that the weight of product used per
    event is 5000 mg, the weight fraction of the chemical substance is 1%,
    the inhaled fraction is 70%, the room volume is 2 m3, the volume
    inhaled is 0.8m3, and the exposure time is 6 min (EC, 1996). Dermal
    exposure to a component of a watch strap could be estimated taking
    into consideration the area of contact, the thickness and density of
    the material, the weight fraction of the chemical substance, period of
    contact per day and fraction likely to migrate from strap to skin, and
    fraction or rate that the chemical is absorbed into the body.

         For a realistic assessment, the following data would ideally be
    available:

     a) Contact data

         -    frequency of product use
         -    duration of product use per event
         -    site of product use, including size of room
         -    air exchange rate

     b) Concentration data

         -    weight fraction of substance in the product
         -    if available, concentration of substance in the products as
              used, e.g., after dilution or evaporation has occurred

     c) Product use

         -    physical form of product (aerosol, dry powder, large
              crystals, liquid, gas, etc)
         -    amount of product used per event
         -    contact surface (if appropriate)
         -    intended use of product

         The diversity of consumer products does not allow for a single
    set of information sources, handbooks or databases to be consulted.
    Rather, it is necessary to explore which information sources apply to
    the substance of interest. Below, an overview is provided of possible
    information sources that may be useful.

    i)   Product registers are available in some countries and may provide
         information on whether the substance under consideration is
         present in marketed consumer products.

    ii)  Specific information on use durations and contact frequencies for
         consumer products is often lacking. An estimate of these
         parameters can be derived from time budget data where available.
         Time budgets comprise information on the behaviour of a
         population during a day, week or year. Because time budgets may
         vary geographically, it is useful to check if the national
         statistical agencies have gathered such data on a regional basis.

    iii) Information on actual product use by the consumer is not widely
         available. The directions of the manufacturer provide information
         on the recommended use, not on the way products may be handled
         before or after actual use nor on reasonably foreseeable misuse.
         Although information can be gained from Poison Control Centres
         and case studies reported in the literature, such data generally
         represent the more extreme misuses of the product and might not
         be very informative about the normal range of uses.

    iv)  Information accompanying exposure assessment computer programmes
         (see below) may also be useful sources of data.

    v)   Some countries require manufacturers of certain products (e.g.,
         cosmetics, toys, pharmaceuticals, food contact materials,
         pesticides) to provide data useful for estimating exposure.
         Assessors should use these data, where available and appropriate,
         when conducting the exposure assessment.

         Measured data useful for exposure assessment may be available for
    a number of substances (e.g., concentrations of solvents in room air
    as a consequence of the application of consumer products containing a
    solvent or of their migration from articles; concentration of polymer
    softeners or other additives migrating from food contact materials,
    children's toys or other articles).

         The reliability and representativeness of the measured exposure
    data may be evaluated considering:

    *    if they represent the whole group of consumers or a certain
         subset;

    *    if they reflect all exposure scenarios of concern;

    *    if they describe the foreseeable use;

    *    if they reflect the complete range of reasonable exposure values
         or only an isolated value in any part of this range.

         The European Union (EC, 1996) has presented a variety of simple
    algorithms that can be used to assess consumer exposure for a number
    of common exposure scenarios. Many give an exposure value per event
    (single use), but are readily adaptable to different situations. In
    addition, the European Union (EC, 1996) has summarized a variety of
    more complex computer models for assessing consumer exposure
    (CONSEXPO, THERdbASE, US EPA household exposure models MCCEM and HOUSE
    EXP: SCIES, DERMAL, FLUSH and AMEM).

    6.  RISK CHARACTERIZATION AND IMPLICATIONS FOR RISK MANAGEMENT

    6.1  General considerations

         The traditional goal of regulating risks is to protect and
    improve public health and well-being. Since 1980, risk assessment has
    increasingly formed the methodological basis in many countries,
    particularly industrialized nations, for the regulation of chemicals
    in the occupational and general environments.

         Risk assessment, comprising the elements of hazard
    identification, dose-response assessment, exposure assessment and risk
    characterization, is now recognized as an essential tool by many
    national, regional and international bodies, and it is also recognized
    that it is a continuously evolving process which has changed
    considerably in the last two decades (US NAS, 1983; Somers, 1987,1993;
    UK HSE, 1989; Scala; 1991; Ballantyne et al., 1993; EC, 1996). It
    should be recognized as a vital mechanism for the delivery of salient
    information to decision-makers.

         Risk characterization aims to provide a synthesis of estimates of
    exposure levels and health risks; it also summarizes sources of
    uncertainty in scientific data and provides the primary basis for
    making risk management decisions. The results of a risk assessment (as
    summarized in the characterization) are the basis of identification of
    chemical exposures that pose no significant health threat and those
    that present significant risks. Additionally, to the extent permitted
    by available data, risk characterization indicates how risk varies
    with exposure, to help risk managers evaluate a range of options. It
    assists risk management officials and decision makers in allocating
    scarce resources and money to the most important resolvable
    uncertainties and reduction of risks. However, the results of risk
    assessment, as summarized in the risk characterization, are but one
    consideration in health and environmental decision-making.

         The term "risk management" encompasses all of those activities
    required to reach decisions on whether an associated risk requires
    elimination or necessary reduction. Risk management strategies/or
    options can be broadly classified as regulatory, non-regulatory,
    economic, advisory or technological, which are not mutually exclusive.
    Thus legislative mandates (statutory guidance), political
    considerations, socioeconomic values, cost, technical feasibility,
    populations at risk, duration and magnitude of risk, risk comparison,
    and possible impact on trade between countries can generally be
    considered as a broad panoply of elements that can be factored into
    final policy or rule-making. Key decision factors such as the size of
    the population, the resources, costs of meeting targets and the
    scientific quality of risk assessment and subsequent managerial
    decisions vary enormously from one decision context to another (Stern,
    1986; Ricci & Cox, 1987; Somers, 1987, 1993; Environ, 1988;
    Munro & Morrison, 1990; Merrill, 1991; Scala, 1991;
    Presidential/Congressional Commission on Risk Assessment and Risk
    Management, 1997a,b).

         It is also recognized that risk management is a complex
    multidisciplinary procedure that is seldom codified or uniform,
    frequently unstructured, but which can respond to evolving input from
    a wide variety of sources (Stern, 1986). Increasingly, risk perception
    and risk communication are recognized as important elements that must
    also be considered for the broadest possible public acceptance of
    risk-management decisions (Krewski et al., 1987; Slovic, 1987, 1993;
    Kraus & Slovic, 1988; Konheim, 1988; Cohrssen & Covello, 1989; US NRC,
    1989; Pariza, 1992; ILSI/National Safety Council, 1993; Morgan, 1993;
    Singer & Endreny, 1993; Sandman et al., 1993; Van Eijndhoven et al.,
    1994).

    6.2  Considerations in risk characterization

         Definitions and guidance for risk characterization have been
    published in US EPA (1996b), where it is defined as:

         "a summary, integration, and evaluation of the major scientific
         evidence, reasoning and conclusions of a risk assessment. It is a
         concise description of the estimates of potential risk and the
         strengths and weaknesses of those estimates."

    Similarly, the European Union defines risk characterization as: "the
    estimation of the incidence and severity of the adverse effects likely
    to occur in a human population or environmental sphere due to actual
    or predicted exposure to a substance, and may include risk estimation,
    i.e. the quantification of that likelihood (Hertel, 1996) .

         A risk characterization is the final step in risk assessment. It
    is designed to support risk managers by providing, in plain language,
    the essential scientific evidence and rationale about risk that they
    need for decision-making. In risk characterization, estimates of the
    risk to human health under relevant exposure scenarios are provided.
    Thus, a risk characterization is an evaluation and integration of the
    available scientific evidence used to estimate the nature, importance
    and, where possible, the magnitude of human and/or environmental risk,
    including attendant uncertainty, that can reasonably be estimated to
    result from exposure to a particular environmental agent under
    specific circumstances. It is important that risk characterizations be
    clear, transparent and reasonable.

         For the risk manager, a risk characterization answers the
    question: What is the impact (in terms of potential occurrence of
    adverse effects or increased risk) from exposure to the agent? Along
    with the concise description of risk, a characterization addresses the
    uncertainty in the underlying data and models. The characterization
    provides a sense of the degree of confidence in the risk estimates and
    a sense of where the supporting data lie on the continuum between
    evidence that is based on humans, or is highly relevant to humans, and
    evidence that is based on animals or  in vitro experiments.

         The following are sample questions of risk managers that are
    commonly addressed in risk characterization:

    1)   What is the bottom line of the risk assessment?

    2)   Does the risk assessment provide sufficient information to
         support a regulatory decision?

    3)   What is the range of uncertainty around the estimated exposure
         level and the projected number of people who may be exposed to
         the chemical? Do we know if people are actually being exposed to
         the levels identified in the risk assessment? Are these levels of
         public health concern?

    4)   What data gaps are likely to elicit criticism of the risk
         estimate and/or selected risk management options? There will
         always be data gaps, but which are the ones that may lead to
         criticism of the risk assessment or of the risk management
         options and decision(s)?

    5)   Are studies being conducted that will "soon" provide new
         information that could fill a critical data gap or gaps?

    6)   Has the risk assessment been peer reviewed? If so, by whom, and
         what was the outcome of the review?

    7)   Indicate how likely, or if, there is a chance of zero risk. Has
         zero risk actually been ruled out?

    8)   What is the key parameter that drives the analysis? Is there
         research on the horizon that will address this key parameter and
         reduce its uncertainty? How much interest is there in issues
         surrounding this parameter?

    9)   If studies were excluded, what would be the consequence for the
         risk assessment results? What was the rationale for excluding
         these studies? 

         Other questions primarily concern the issue of uncertainty. Data
    lie on a continuum from strong evidence in humans (based on extensive
    epidemiology and/or other clinical/field observations) to weak
    evidence in humans, animals or other test systems (based on incomplete
    data in one or a limited number of species, or structure-activity
    relationships). Confidence in the conclusions of the risk assessment
    and the estimate of risk also lie on a continuum from high to low.
    This degree of confidence is based, to a large extent, on the
    completeness, quality and consistency of the database (i.e. the weight
    of evidence). Where do the results of the risk assessment fit on the
    continuum from high to low confidence?

    *    What are the specific conditions of exposure believed to cause or
         contribute to the risk? Have exposures and/or dose been measured
         in the population of interest? If so, has it been possible to
         relate exposure to actual body burden? If exposures have been
         calculated through analogy, modelling, or other estimation
         techniques, what evidence is there that the estimates are
         realistic?

    *    What is the degree of confidence in the existence of the risk and
         the magnitude of the risk estimate? If the risk is based on
         animal models, is there an observable parallel between humans and
         the positively responding animal species in terms of the
         absorption, metabolism, distribution and excretion of the
         chemical of interest? If not, what is the basis for thinking such
         a parallel exists? Is there epidemiological evidence indicating
         that comparable effects seen in the animal model have been seen
         in human populations (e.g., heavily exposed occupational or
         environmental settings, accidents)?

    *    Can population subgroups be identified who are at increased risk
         of exposure and/or especially sensitive to such exposures? At a
         given exposure or dose level, are there observable differences in
         the range of response among different human subgroups (e.g.,
         infants, children, healthy adults, the elderly)? If so, have
         these differences been evaluated and employed in the models used
         to calculate specific risks? If not, what evidence provides the
         basis for conclusions drawn about differences in sensitivity
         among subpopulations and their (potential) risks?

    6.3  Considerations in risk management

         Decisions concerning management of risks are made on the basis of
    identified and quantified risk(s), and the potential for impact on
    individual humans, groups, populations and the environment. This
    involves consideration of socioeconomic, political, risk-benefit and
    cost-benefit factors.

         The analytical tools of risk assessment and management, as
    applied to chemicals with a potential for adverse effects on human
    health and environmental integrity, have assumed a more critical role
    in decision-making in many countries and are having an increasing
    impact on the political process. Potentially many jobs, new products
    and industrial facilities can be created, threatened or protected by
    the outcomes of risk assessment and management.

    6.3.1  Societal factors

         The actual level of risk considered "acceptable" must be a
    societal and political judgement taking into account such factors as
    benefit of the chemical or process, and the cost of its replacement or
    removal.

         There is increasing concern that a disproportionate share of
    human health risks, e.g., from environmental pollution, is being
    incurred by low-income deprived and minority populations in developed
    and developing countries, and that this has not been sufficiently
    addressed in requisite risk evaluations and managerial decisions
    (Mushak, 1993; Silbergeld, 1993; Zimmerman, 1993). It is important to
    recognize, however, that lifestyle factors are often more important in
    determining health status in this regard. The term "environmental
    equity" has been applied to the perceived unequal burdens borne by
    minorities and the poor in terms of where municipal landfills,
    incinerators, hazardous waste sites and industries producing toxic
    emissions are located. Race and socioeconomic status are also linked
    in some studies to chronic exposures to greater than acceptable levels
    of environmental pollution such as lead (Mushak, 1993; Silbergeld,
    1993). The term "environmental justice" refers to diverse
    environmental regulations, environmental law enforcement and
    environmental clean-up programmes, including those in the workplace.
    Hence a growing body of scientific evidence and political advocacy is
    focusing attention on what is increasingly considered in some quarters
    as the inequitable distribution of risk in society. The concept of
    environmental justice is being built into national and supranational
    regulatory policy considerations. Requirements to conduct risk
    management are increasingly being incorporated into national and
    supranational legislation e.g., European Commission Regulation CEC No.
    1488/94, (EC, 1994).

         In contrast, it needs to be recognized that regulations that are
    too stringent may impact unnecessarily adversely on the socioeconomic
    and, hence, health status of populations.

    6.3.2  Individual and population risks

         Individual risk can be defined as the probability of someone from
    a certain group (or sub-group) suffering health effects from exposure
    to a toxicant during an established period (e.g., a year or lifetime).
    The distinction made between individual risks for persons from a
    critical group and that for persons from the whole population is
    important because the acceptability of a certain individual risk
    varies according to the size of the group running the risk. An
    individual risk can be considered when effects are involved for which
    no threshold value exists (stochastic effects), e.g., carcinogens, or
    when exposures are involved that are higher than existing threshold
    values for non-stochastic effects.

         Frequently, individual risks are calculated for some or all of
    the persons in the population being studied and are then put into the
    context of where they fall in the distribution of risks for the entire
    population. Key questions often asked when considering strategies for
    dealing with individual risk include:

    *    to what risk levels are the persons at the highest risk
         subjected?

    *    can individuals with a high degree of susceptibility be
         identified?

    *    what is the average individual risk?

    *    what is the estimate of the probability that an individual will
         suffer an adverse effect given a specific set of exposure
         circumstances?

         It has also been suggested that sub-groups of the population
    could be considered in a meaningful risk management scenario. The
    different factors predisposing individuals to sensitive responses to
    pollutants include: developmental processes, existing disease, prior
    exposure to a particular chemical, chemical class or group of
    chemicals that can act mechanistically in a similar manner,
    nutritional deficiencies, and tobacco smoking and alcohol consumption
    (Seidman et al., 1991; US EPA, 1992).

         Group or population risk (which generally is calculated) is
    defined as the chance that a certain group of individuals in a certain
    environment will simultaneously experience the detrimental
    consequences of a significant exposure to a toxicant(s) during a
    period, e.g., a year or lifetime.

         A clear trend has not yet emerged concerning the question as to
    whether risks to individuals, risks to groups or populations, or both,
    are to be considered in significant risk decisions (Environ, 1988;
    Rodricks, 1992; US EPA, 1992). For example, is a large risk to a small
    number of individuals more important from a public health perspective
    than a small risk to a large number of people (general public
    ingesting a food or water contaminant for a considerable time period)?
    A suggested first step following any risk evaluation could be a
    determination of whether the risk is large enough to threaten the
    public health to a significant degree (Environ, 1988). Resources are
    limited and there will always be the possibility that some fraction of
    the population will respond adversely to a compound or mixture
    regardless of the exposure. The ultimate question could be (given the
    limited resources in every society) what percentage of individuals is
    society unable to protect in this way? Certain sub-groups, for example
    idiosyncratic responders, may be given protection by appropriate
    product labelling and information programmes.

    6.3.3  Comparative risk

         Risk implies uncertainty and subsequent risk evaluations and risk
    management decisions are concerned with the concept of probability.
    There is an apparent lack of consensus concerning the appropriate
    background risk with which to make comparisons (Environ, 1988; US NRC,
    1989). While many analysts would find it difficult to compare
    voluntary assumed risks to involuntarily assumed risks, proponents of
    risk comparisons strongly suggest that there should be consolidation
    and greater efforts by those engaged in risk evaluation to identify,
    assess and compare risks to public health and the environment posed by

    the highest risk hazards (Wilson & Crouch, 1987; Wiener, 1993).
    Comparisons should be seen as only one of a number of inputs to risk
    decisions, not as a primary determinant (US NRC, 1989).

         However, it is also suggested that many people do not perceive
    the various threats to health and well-being simply as matters of
    probability (Slovic, 1987; Kraus & Slovic, 1988; Pariza, 1992; Sandman
    et al., 1993). Indeed, estimated risks of death or disease associated
    with exposure to chemicals in the general environment are often
    similar to those considered rare, such as being struck by lightening
    or dying in an airplane crash, although they are not perceived as such
    (Wilson, 1990). Moreover, people tend not to be deeply concerned about
    risks that are a matter of choice such as smoking or motorcycle
    riding. However, they do expect that governments pay attention to
    risks that they cannot control, even though these might be
    considerably less.

    6.3.4  Risk perception

         Whereas analysts employ risk assessment, risk evaluation and risk
    management to evaluate hazards and formulate strategies and
    regulations for their reduction or elimination, the majority of
    individuals rely on intuitive judgements typically called "risk
    perception". For these people, the experience with hazards tends to
    come from the news media, which principally document mishaps and
    threats occurring globally (Slovic, 1987, 1993; Kraus & Slovic, 1988;
    Cohrssen & Covello, 1989; Sandman et al., 1993; Van Eijndhoven et al.,
    1994).

         Risk perception is being increasingly recognized as an important
    factor influencing both risk evaluation and risk management. A major
    factor that influences the complexity of the social debate over
    appropriate laws and regulations is the nature and extent of the
    perceived threat to health. The message that is frequently conveyed to
    the public is that government standards for risk assessment, risk
    evaluation and regulatory action are inconsistently applied, subject
    to bureaucratic manipulation, and subject to alteration depending on
    the degree of economic impact on the affected industry (Munro &
    Morrison, 1990).

         Different people perceive risks differently, depending on the
    likelihood of adverse effects, whom it affects, how familiar,
    widespread and dreaded the effects are, how a hazard affects
    individuals personally, and whether or not individuals have
    voluntarily agreed to bear the risks. Perceptions of risk are also
    influenced to a large degree by the supposed benefits derived from
    accepting the risk (Slovic, 1987; Krewski, et al., 1987; Kraus &
    Slovic, 1988; Cohrssen & Covello, 1989; Pariza, 1992; Morgan, 1993;
    Sandman et al., 1993).

         Risks perceived as potentially uncontrollable, capable of causing
    a catastrophe on a global scale or risking future generations cause
    public anxiety. Fig. 3 illustrates a mosaic of public perception of
    risks in terms of risk space quadrants; the upper right quadrant of
    this space captures uncontrollable risks that are most likely to
    provoke calls for government regulation (Morgan, 1993).

         Tables 3 and 4 further depict qualitative factors affecting risk
    perception (US NRC, 1989; Scala, 1991). While different people weigh
    these factors differently in reaching their overall perceptions of the
    riskiness of a hazard, the set of factors that are important in
    determining relative perceptions of risk go well beyond the
    statistical frequency, magnitude and uncertainty of effects. Public
    opinion on acceptable risk constantly changes, usually in the
    direction of further risk reduction, which provides further impetus
    for additional legislation and regulation in many quarters (Munro &
    Morrison, 1990).

    6.3.5  Risk and hazard communication

         Implicit in the process of risk evaluation and management is the
    increasingly recognized role of communication (Cohrssen & Covello,
    1989; US NRC, 1989; Morgan, 1993; Sandman et al., 1993; Slovic, 1993).
    Risk communication is an interactive process of exchange of
    information and opinion among individuals, groups and institutions
    involving multiple messages about the nature of risk and other
    messages, not strictly about risk, that express concerns, opinions or
    reactions to risk messages or to legal and institutional arrangements
    for risk management (US NRC, 1989).

         Until the mid-1980s, there was little research on communicating
    risk to the public. There is now a reasonable consensus on the optimum
    basic elements of risk communication. These efforts should be more
    systematically oriented to the intended audience, addressing the
    audience's perspectives and concerns. To the greatest extent possible,
    openness, not minimizing the existence of uncertainty, and discussion
    of data gaps and areas of significant disagreement among experts is
    recommended. The acceptance of any risk is more dependent on public
    confidence in risk management than on quantitative estimates of risk.

         Although there is as yet no widely agreed structured knowledge on
    communication about chemical hazards, analyses of risk communication
    efforts and case studies suggest that risk communication problems
    arise from message, source, channel and receiver problems (Cohrssen &
    Covello, 1989). Message problems relate primarily to deficiencies in
    scientific understanding leading to large uncertainties in risk
    estimates or highly technical risk analyses that are unintelligible to
    lay persons. Source problems include disagreements among scientific
    experts, failures to disclose limitations of risk assessments and
    resulting uncertainties, and limited understanding of the concerns and
    values of public groups and bureaucratic presentation. Channel
    problems include selective and biased media reporting that emphasizes

    FIGURE 4



        Table 3.  Qualitative factors affecting risk perception and evaluation (from: US NRC, 1989)
                                                                                                                                  
    Factor                             Conditions associated with increased                    Conditions associated with
                                       increased public concern                                decreased public concern
                                                                                                                                  
    Catastrophic potential             Fatalities and injuries grouped                         Fatalities and injuries
                                       in time and space                                       scattered and random

    Familiarity                        Unfamiliar                                              Familiar

    Understanding                      Mechanisms or process not understood                    Mechanisms or process understood

    Controllability (personal)         Uncontrollable                                          Controllable

    Voluntariness of exposure          Involuntary                                             Voluntary

    Effects on children                Children specifically at risk                           Children not specifically at risk

    Effects manifestation              Delayed effects                                         Immediate effects

    Effects on future generations      Risk to future generations                              No risk to future generations

    Victim identity                    Identifiable victims                                    Statistical victims

    Dread                              Effects dreaded                                         Effects not dreaded

    Trust in institutions              Lack of trust in responsible institutions               Trust in responsible institutions

    Media attention                    Much media attention                                    Little media attention

    Accident history                   Major and sometimes minor accidents                     No major or minor accidents

    Equity                             Inequitable distributions of risks and benefits         No major or minor accidents

    Benefits                           Unclear benefits                                        Clear benefits

    Reversibility                      Effects irreversible                                    Effects reversible

    Origin                             Caused by human actions or failures                     Caused by acts of nature or God
                                                                                                                                  

    Table 4.  Characteristics of risk (from: Scala, 1991)
                                                                                                                                      
    Characteristic              Description                                              Level                   Examples
                                                                                                                                      
    Knowledge                   Society's awareness of risk from activity                Little known            Food Additivies
                                                                                         Much known              Alcoholic drinks

    Newness                     Extent of societal experience                            Old                     Guns
                                                                                         New                     Space travel

    Voluntariness               Does individual have a choice about                      Not voluntary           Crime
                                exposure to risk                                         Voluntary               Rock climbing

    Control                     Can an individual control exposure,                      Risk not controlled     Natural Disasters
                                protect himself or control consequences                  by skill or diligence
                                                                                         Risk controlled         Smoking

    Dreadedness                 How much is risk or its consequences feared              People do not dread     Vaccination
                                                                                         People have much dread  Nerve gas

    Catastrophic potential      Chance of widespread disastrous outcome                  Not likely              Sunbathing
                                                                                         Likely                  War

    Equity                      Are the benefits and risk shared equally                 Distributed unequally   Hazardous Dump
                                                                                         Distributed equally     Skiing

                                                                                                                                      
    

    drama, wrongdoing, disagreement, conflict and oversimplification,
    distortion, and inaccuracy in interpreting technical risk information.
    Receiver problems include inaccurate perception of levels of risk,
    strong beliefs and opinions that are resistant to change, and demands
    for scientific certainty.

         There is a clear need to educate the public, including community
    leaders, workers and school children, to enhance awareness so that
    they can take voluntarily the action required to reduce or avoid risks
    associated with exposure to chemicals in the workplace and general
    environments (e.g., indoor air pollutants, pesticides and household
    chemicals).

    6.3.6  Economic factors

         Unlike regulation, which involves strict criteria to be enforced
    by regulatory agencies, economic approaches to risk management rely
    largely on economic incentives to reduce the levels of pollutants
    introduced into the environment (Krewski et al., 1989; Somers, 1993).

         The OECD since 1972 has espoused the "Polluter Pays Principle"
    (PPP) concept, with the goal of maintaining equitable trading
    practices by encouraging polluters to reduce emissions. However, it is
    recognized that the consumer ultimately pays the cost required to
    accomplish environmental improvements. The main types of economic
    instruments in use in OECD countries include charges, subsidies,
    deposit-refund schemes, market creation arrangements and financial
    enforcement incentives (OECD, 1991b). In 1989, the OECD adopted a
    Recommendation on the Application of the PPP to Accidental Pollution,
    which links the economic principle and the legal principle to damage
    compensation (OECD, 1991b).

     6.3.6.1  Cost-benefit analyses

         Traditionally, risk reduction has not included a thorough
    analysis of costs and benefits (Hammond & Coppock, 1990). Indeed,
    there is no widely adopted framework for cost-benefit.

         As an example, three major categories of costing relationships
    are typically employed in risk reduction by the US EPA, depending on
    the situation:

    a)   benefit/cost analysis weighs the cost of control against monetary
         benefits of control;

    b)   risk/benefit analysis weighs the economic benefits of a polluting
         activity against the risks to health and the environment;

    c)   cost-effectiveness analysis accepts the desirability of
         regulation and identifies the least-cost solution to achieve a
         given goal, such as a pollution discharge standard (Ris & Preuss,
         1988).

         The US EPA estimated that the annual compliance cost for USA
    federal environmental regulations in 1990 was about 2.1% of the gross
    national product (GNP of about 6 trillion dollars). This is expected
    to increase to approximately 2.8% of the GNP by the year 2000
    (ILSI/National Safety Council, 1993). The benefits of regulation such
    as improved quality of life and cleaner environment are often
    difficult to quantify in contrast to the enormous costs often cited
    for regulatory compliance.

         There is broad diversity of opinion as to how costs should be
    considered in risk management decisions. Key questions include: How
    much can society afford to spend to reduce risks? What is an
    acceptable cost per life saved? How should costs be factored into
    priority-setting processes? Future success in risk management may to a
    large degree depend on ways to weigh benefits and costs and to strike
    the appropriate balance in defining how fast to pursue risk
    regulations (ILSI/National Safety Council, 1993; Wiener, 1993).

    6.3.7  Political factors

         Political factors often have an impact on national and local
    priorities, drafting of regulatory statutes and introduction of
    resulting risk reduction measures. Trade barriers and global
    competition also have a considerable impact on risk reduction. For
    example, in Canada the decision in 1980 to ban the sale of
    urea-formaldehyde foam insulation (UFFI) led to unprecedented public
    anger (and anxiety and resentment), great government expense, the
    longest civil suit in Canadian history, and appreciable political
    consequences. After an 8-year legal trial, it was concluded that there
    was not sufficient scientific evidence to substantiate the reported
    health problems of UFFI home owners (Somers, 1993).

         In 1977, the US Food & Drug Administration (FDA), reacting to
    studies that reported the artificial sweetening agent saccharin to be
    a bladder carcinogen in rodent feeding studies, proposed to ban the
    agent under the Delaney Amendment ("zero-risk") requirement. The
    Congress of the USA in November 1977, reacting to the overwhelming
    public outcry in support of unrestricted use of saccharin, enacted the
    Saccharin Study and Labeling Act (SSLA), which prevented the FDA from
    banning saccharin based on the information that was then available.
    This made it clear that the public is willing to accept certain risks
    from food additives if it perceives that the benefits are high enough
    and, possibly, that the risks are low enough (Flamm & Lorentzen,
    1988).

    6.3.8  Regulatory limits

         Traditionally, one avenue of protection of human health has been
    through the establishment of exposure limits (variously referred to as
    standards, quality criteria, etc.). These are established in a
    two-step process, the first involving consideration of the

    health-based scientific data and the second involving establishment of
    regulatory limits, taking into account the health-based recommendation
    along with other factors.

         Examples of health-based exposure guidelines include the
    Acceptable Daily Intake (ADI), Tolerable Daily Intake (TDI),
    Provisional Tolerable Weekly Intake (PTWI), and health-based Maximum
    Allowable Concentrations (MAC). Acceptable/Tolerable Intakes are the
    amounts of a food additive, contaminant, pesticide or veterinary drug
    residue, expressed on a body weight basis, that can be ingested for a
    lifetime without appreciable risk to health. The term ADI is commonly
    used for additives to food since they impart some beneficial
    characteristic (and hence are considered "acceptable") while a TDI
    commonly refers to environmental contaminants which are undesirable.
    Maximum Allowable Concentrations are either a time-weighted average
    concentration of a substance in a medium of exposure that does not
    present appreciable hazard for continuing exposure or an upper limit
    (ceiling value) which, if exceeded, will have adverse consequences for
    health. Often, health-based guidelines are considered, along with
    other factors (i.e., technological, socioeconomic, feasibility,
    enforcement), to develop operational regulatory limits such as the
    Maximum Residue Level (MRL) for pesticides or veterinary drugs, MAC in
    exposure media and workplaces, occupational Threshold Limit Values
    (TLV), Maximum Workplace Concentrations (MAK), Occupational Exposure
    Limits (OEL), Air Quality Standards (AQS), Water Quality Standards
    (WQS) or Maximum Use Levels.

         Some media of (direct and indirect) exposure and associated
    limits are listed below:

     Food

    *    limits for food additives, contaminants, pesticide residues,
         veterinary drug residues
    *    limits for certain chemicals in food packaging materials
    *    limits for additives and contaminants in animal feed

     Cosmetics and other consumer products

    *    limits for additives and contaminants in cosmetic products (these
         include soap and toothpaste)
    *    limits for other consumer products such as children's toys,
         paints and solvents

     Water

    *    drinking-water quality standards
    *    water quality standards for surface water
    *    water quality standards for fresh water used for fishing
    *    water quality standards for estuarine and marine waters
    *    aqueous effluent standards for industrial effluents and sewage
         treatment outfall

    *    guideline limits for the use of waste water in agriculture and
         aquaculture

     Air

    *    air quality (ambient or indoor) limits for gases, vapours,
         fibres, particulates
    *    air quality standards for gaseous or smoke emissions from
         industries

     Occupational

    *    occupational exposure limits for gases, vapours, dusts, aerosols
         in workplace air and substances absorbed through the skin, mucous
         membranes or alimentary tract
    *    regulatory limits for exposure can be based on appropriate
         biomarkers

     Soil

    *    limits for certain chemicals in soil

     Agricultural chemicals

    *    limits for certain contaminants in agrochemicals (fertilizers)
    *    limits for application rates of pesticides

     Chemical waste

    *    limits for disposal of chemicals as waste products
    *    waste (including liquid and solid)
    *    chemical (including mixed industrial), dumps, surface water and
         deep well injection
    *    municipal surface and groundwater contamination, use of sludge in
         agriculture
    *    atmospheric effluents and residual ash from incineration

         The two stages and their outputs should not be confused. The
    outputs are frequently expressed in different units. For example,
    considering pesticide residues in food crops, the ADI is a daily dose
    expressed in mg/kg body weight (per day being implicit) whereas the
    MRL is a concentration on the crop expressed in mg/kg of the produce.
    The MRL may be derived on the basis of Good Agricultural Practice and,
    if adhered to, would not result in the ADI being exceeded even if all
    the designated crop contained the pesticide at the MRL (an unlikely
    postulate). Clearly, to arrive at this conclusion requires information
    on daily intakes of the commodities carrying the residue.

    6.4  Risk management options

    Risk managers can intervene at many points:

    a)   to prevent the process producing the risk

    b)   to reduce or eliminate exposures
    c)   to modify the effects
    d)   to alter perceptions or valuation, through education and public
         relations
    e)   to compensate for damage after the fact (Morgan, 1993).

    6.4.1  Risk reduction

         Risk reduction goals can vary considerably and can also be
    hampered by the fragmented regulatory structure enforcing
    environmental laws in many countries. For example, in the USA, the
    regulatory approach to risk reduction depends upon whether a chemical
    is a food additive, a food contaminant, a pesticide, a drinking-water
    contaminant, an air pollutant, or several of these (Rodricks, 1992).
    Increasingly, however, national legislation (such as the Canadian
    Environmental Protection Act) that allows for introduction of control
    measures for chemicals in a variety of media is being introduced.
    Essentially, such legislation enables the development of control
    measures in the medium that will contribute most significantly to
    reduction of risk. The existing substances regulation of the European
    Union also provides the opportunity for concerted action based on
    evaluation of risks for different scenarios and routes of exposure
    (EEC Council Regulation No.793/93) (EC, 1993).

         However, there is no clear consensus on what is considered a risk
    of concern. While target risk levels are embodied in some national
    legislation, other countries recommend that exposure be reduced as low
    as possible for effects for which it is assumed that there is no
    threshold.

         It is also well recognized that different countries, as well as
    different agencies within the same country, often come to different
    conclusions in the manner in which they judge and manage a health risk
    employing basically the same scientific data (Nilsson et al., 1993;
    Somers, 1993). Nilsson et al. (1993) found that 11 countries regulated
    the same pesticides to different degrees, which should not be too
    surprising recognizing the differing economic interests and statutes
    (Somers, 1993).

     6.4.1.1  Technology-based criteria

         Technology-based criteria for risk reduction are not based on
    costs, benefits or rights, but rather the level of technology to
    control certain risks. Regulations based on these criteria typically
    mandate "the best available technology" (BAT) or emissions that are
    "as low as reasonably achievable". Such rules can be difficult to
    apply because people seldom agree on the definition of "available" or
    "reasonably achievable" (Morgan, 1993). Similar difficulties can arise
    with the implementation of "good agricultural practice", "technically
    achievable" and "as far as may be reasonably practicable".

    REFERENCES

    Allaby M (1983) A dictionary of the environment. 2nd ed. New York,
    NY, New York University Press, p 195.

    Allen BC, Crump KS, & Shipp AM (1988) Correlation between carcinogenic
    potency of chemicals in animals and humans. Risk Analysis, 8: 531-544.

    Anderson D (1990)  In vitro models. Drug Saf; 5 Suppl 1:27-39.

    Atterwill CK (1995) Alternative method of assessing toxicity. Methods
    Mol Biol 43: 1-9.

    Axelson O & Westberg H (1992) Introductory note on the concept of
    exposure and dose in occupational epidemiology. Am J Ind Med, 21: 3-5.

    Bailar JC III, Crouch EAC, Shaikh R, & Spiegelman D (1988) One-hit
    models of carcinogenesis: conservative or not? Risk Analysis,
    8: 485-497.

    Baird SJS, Cohen JT, Graham JD, Shyakhter A & Evans JS (1996)
    Noncancer risk assessment: a probabilistic alternative to current
    practice. J Human Ecological Risk Assessment 2 (1): 79-102.

    Ballantyne B, Marrs T, & Turner P (1993) General and Applied
    Toxicology, Vol. 2, Stockton, Stockton Press, pp 1069-1158.

    Beaumont JJ & Breslow NJ (1981) Power consideration in epidemiologic
    studies of vinyl chloride workers. Am J Epidemiol, 114: 725-734.

    Beland FA & Poirier MC (1993) Significance of DNA adduct studies in
    animal models for cancer dosimetry and risk assessment. Environ Health
    Perspect, 99: 5-10.

    Braat L, Bakema AH, de Boer KF, Meijers RM, & Van Minnen JG (1991)
    EXPECT: Outline of an integrated model for environmental scenario
    analysis and impact asessment (Report No 259102001). Bilthoven,
    National Institute of Public Health and Environmental Protection.

    Calabrese EJ (1985) Uncertainty factors and interindividual variation.
    Regul Toxicol Pharmacol, 5: 190-196.

    Calabrese EJ, Beck BD, & Chappell WR (1992) Does the animal-to-human
    uncertainty factor incorporate differences in surface area? Regul
    Toxicol Pharmacol, 15: 172-179.

    Calabrese EJ & Baldwin LA (1994) Improved method for detection of the
    NOAEL. Regul Toxicol Pharmacol, 19: 48-50.

    Chhabra RS, Huff JE, Schwetz BS & Selkirk J (1990) An overview of
    prechronic and chronic toxicity / carcinogenicity experimental designs
    and criteria used by the National Toxicology Program. Environ Hlth
    Perspect 86: 313-321.

    Chen C & Farland W (1991) Incorporating cell proliferation in
    quantative cancer risk assessment: approaches, issues, and
    uncertainties. Prog Clin Biol Res, 369: 481-499.

    Cohrssen JJ & Covello VT (1989) Risk analysis: A guide to principles
    and methods for analyzing health and environmental risks. Washington,
    DC, Council on Environmental Quality.

    Copeland KT, Checkoway H, McMichael AJ, & Holbrook RH (1977) Bias due
    to mis-classification in the estimation of relative risk. Am J
    Epidemiol, 105: 488-494.

    Crump KS, Hoel DG, Langley CH, & Peto R (1976) Fundamental
    carcinogenic processes and their implications for low dose risk
    assessment. Cancer Research, 36: 2973-2979.

    Crump KS (1984) A new method for determining allowable daily intakes.
    Fundam Appl Toxicol, 4: 854-871.

    Curry P & Iyengar S (1992) Comparison of exposure assessment
    guidelines for pesticides. Revs Environ Contam Toxicol, 129: 80-93.

    DFG (German National Research Foundation) (1972) [Hazardous working
    compounds: Toxicological-occupational explanation of maximum-allowable
    concentrations (MAK-Werte)] in German. Senatskommission zur Prüfung
    gesundheitlicher Arbeitsstoffe. D Henschler/H Greim (Hrsg.), Wiley-VCH

    Doll R & Hill AB (1956) Lung cancer and other causes of death in
    relation to smoking - a second report on the mortality of British
    doctors. Br Med J, 2: 1071-1077.

    Dourson ML & Stara JF (1983) Regulatory history and experimental
    support of uncertainty (safety) factors. Regul Toxicol Pharmacol,
    3: 224-238.

    Dybing E, Sanner T, Roelfzema H, Kroese D & Tennant RW (1997) T25: a
    simplified potency index: description of the system and study of
    correlations between carcinogenic potency and species/site specificity
    and mutagenicity. Pharmacol-Toxicol, Jun, 80 (6): 272-279.

    Dybing E & Huitfeldt HS (1992) Species differences in carcinogen
    metabolism and interspecies extrapolation. In: Vainio H, Magee PN
    McGregor DB, & McMichael AJ ed. Mechanisms of Carcinogenicity in Risk
    Identification. Lyon, France, International Agency for Research on
    Cancer, pp 501-522.

    EC (1990) EEC Note for Guidance: Good Clinical Practice for trials on
    medical products in the European Community.  Pharmacology and
    Toxicology, 67:361-372.

    EC (1992) Council Directive 92/32/EEC of 30th April 1992.  Amending
    for the 7th time Directive 67/548/EEC on the approximation of the
    laws, regulations and administrative provision relating to the
    classification, packaging and labelling of dangerous substances. 
    Official Journal of the European Communities L 154.

    EC (1993) Council Regulation (EC) 793/93 of 23 March 1993 on the
    evaluation and control of the risks of existing substances. Official
    Journal of the European Communities L 84.

    EC (1994) Commission Regulation (EC) No 1488/94 of 28 June 1994 laying
    down the principles for the assessment of risks to man and the
    environment of existing substances in accordance with Council
    Regulation (EEC) No 793/93. Official Journal of the European
    Communities L 161.

    EC (1996) Technical Guidance Document in Support of the Commission
    Directive 93/67/EEC on Risk assessment for New Notified Substances and
    Commission Regulation 1488/94/EEC on Risk assessment for Existing
    Chemicals. Brussels, European Comission.

    ECETOC (1989) Alternative approaches for the assessment of
    reproductive toxicity. Brussels, Belgium, European Chemical Industry
    Ecology and Toxicology Centre (Monograph No 12).

    ECETOC (1992) Estimating environmental concentrations of chemicals
    using fate and exposure models. Brussels, Belgium, European Chemical
    Industry Ecology and Toxicology Centre (Technical Report No 50).

    ECETOC (1993) Environmental hazard assessment. Brussels, Belgium,
    European Chemical Industry Ecology and Toxicology Centre (Technical
    Report No 51).

    ECETOC/UNEP (1996) Inventory of Critical Reviews on Chemicals.
    Brussels, Belgium, European Chemical Industry Ecology and Toxicology
    Centre. United Nations Environment Programme. International Register
    of Potentially Toxic Chemicals, Geneva.

    Environ (1988) Elements of Toxicology and Chemical Risk Assessment.
    Revised Edition. Washington, DC, Environ Corporation, 74 pp.

    Farmer JH, Kodell RL, & Gaylor DW (1982) Estimation and extrapolation
    of tumor probabilities from a mouse bioassay with survival/sacrifice
    components. Risk Analysis, 2: 27-34.

    Flamm WG & Lehma-McKeeman LD (1991) The human relevance of the renal
    tumor-inducing potential of  d-limonene in male rats: implications
    for risk assessment. Regul Toxicol Pharmacol, 13: 70-86.

    Flamm WG & Lorentzen RJ (1988) Quantitative Risk Assessment (QRA): A
    special problem in the approval of new products. In: Cothern CR,
    Mehlman MA, & Marcus WL ed. Risk Assessment of Industrial and

    Environmental Chemicals. Advances in Modern Toxicology. Princeton, NJ,
    Princeton Scientific Publ Co, Vol XV, pp.91-108.

    Fowle JR (1989) Summary and perspectives: Panel discussion on
    toxicological exposure assessment: State of the art. J Am Coll
    Toxicol, 8: 865-870.

    Fowle JR & Sexton K (1992) EPA priorities for biological research in
    environmental health. Environ Hlth Perspec, 98: 235-241.

    Fralick RA (1983) The role of epidemiology in defining an occupational
    carcinogen. Occup Health Ontario, 4: 2-16.

    Frazier JM (1993)  In vitro models for toxicological research and
    testing.  Toxicol Lett, 68: 73-90.

    Gaylor DW & Kodell RL (1980) Linear interpolation algorithm for low
    dose risk assessment of toxic substances. J Environ Path Toxicol,
    4: 305-312.

    Gaylor DW, Greenman DL, & Frith CH (1985) Urinary bladder neoplasms
    induced in Balb/C female mice with low doses of 2-acetylaminofluorene.
    J Environ Pathol Toxicol Oncol, 6: 127-136.

    Gaylor DW (1987) Linear-nonparametric upper limits for low dose
    extrapolation. In: Proc Biopharm Sec Amer Statis Asso, pp. 63-66.

    Gehlbach SH (1982) Interpreting the medical literature a clinician's
    guide. Lexington, Mass. Collamore Press, ISBN: 0669045063.

    Gelbke HP (1993) New trends in toxicology and their impact on toxicity
    testing-scientific and practical aspects. Human Exp Toxicol,
    12: 511-515.

    Goldstein BD (1990) The problem with the margin of safety: toward the
    concept of protection. Risk Analysis, 10: 7-10.

    Groopman JD, Cain LG, & Kensler TW (1988) Aflatoxin exposure in human
    populations: measurements and relation to cancer. CRC Crit Revs
    Toxicol, 19: 113-145.

    Gross MA, Fitzhugh OG, & Mantel N (1970) Evaluation of safety for food
    additives: an illustration involving the influence of methyl
    salicylate on rat reproduction. Biometrics, 26: 181-194.

    Hammond PB & Coppock R (1990) Valuing Health Risks, Costs and Benefits
    for Environmental Decision Making. In: Report of a Conference. Hammond
    PB & Coppock R ed. Washington, DC, National Research Council, National
    Academy Press.

    Hasemann JK & Clark (1990) Carcinogenicity results for 114 laboratory
    animal studies used to asses the predictivity of four in vitro genetic
    toxicity assays for rodent carcinogenicity. Environ Mol Mutagen, 16
    Suppl 18: 15-31.

    Health Canada (1994) Human Health Risk Assessment for Priority
    Substances.  Environmental Health Directorate, Health Canada, Canada
    Communication Group - Publishing, Cat No En40-215/41E, Ottawa, 1994.

    Hemminki K, Grzybowska E, Chorazy M, Twardowska-Saucha K, Sroczynski
    JW, Putman KL, Randerath K, Phillips DH, Hewer A, & Santella RM (1990)
    DNA adducts in humans environmentally exposed to aromatic compounds in
    an industrial area of Poland. Carcinogenesis, 11(7): 1229-1231.

    Hemminki K (1992) Significance of DNA and protein adducts. In: Vainio
    H, Magee PN, McGregor DB, & McMichael AJ ed. Mechanisms of
    Carcinogenesis in Risk Identification. Lyon, France, International
    Agency for Research on Cancer, pp 525-534.

    Hernberg S (1980) Evaluation of epidemiologic studies in assessing the
    long-term effects of occupational noxious agents. Scand J Work Environ
    Health, 6: 163-169.

    Hertel RF (1996) Outline on risk assessment of existing substances in
    the European Union. Env Toxicol Pharmacol 2: 93-96.

    Hill AB (1965) The environment and disease. Association or causation?
    Proc R Soc Med, 58: 295-300.

    Hodgson E, Mailman RB, & Chambers JE (1988) Dictionary of Toxicology.
    New York, NY, Van Nostrand Reinhold Co, p 154.

    Hoel DG (1980) Incorporation of background in dose-response models.
    Fed Proc, 39: 73-75.

    IARC (1987) IARC Monographs on the Evaluation of Carcinogenic Risks to
    Humans, No. 42.  Lyon, International Agency for Research on Cancer.

    IARC (1990) IARC Scientific Publication on Cancer: Causes, Occurrence
    and Control, No. 100. Lyon, International Agency for Research on
    Cancer.

    ICRP (1974) International Commission on Radiological Protection:
    Report of the Task Group on Reference Man. ICRP Publication No. 23.
    Oxford, Pergamon Press.

    ILSI/National Safety Council (1993) Regulating Risk: The Science and
    Politics of Risk: A Conference Summary. Washington DC, ILSI Press,
    International Life Sciences Institute.

    IPCS (1978) Environmental Health Criteria 6: Principles and methods
    for evaluating the toxicity of chemicals. Part I. Geneva, Switzerland,
    World Health Organization, International Programme on Chemical Safety.

    IPCS (1983) Environmental Health Criteria 27: Guidelines on studies in
    environmental epidemiology. Geneva, Switzerland, World Health
    Organization,. International Programme on Chemical Safety.

    IPCS (1984) Environmental Health Criteria 30: Principles for
    evaluating health risks to progency associated with exposure to
    chemicals during pregnancy. Geneva, Switzerland, World Health
    Organization, International Programme on Chemical Safety.

    IPCS (1985a) Environmental Health Criteria 46: Guidelines for the
    study of genetic effects in human populations. Geneva, Switzerland,
    World Health Organization, International Programme on Chemical Safety.

    IPCS (1985b) , Environmental Health Criteria 47: Summary report on the
    evaluation of short-term  in vitro tests for carcinogens
    (collaborative study on  in vitro tests). Geneva, Switzerland, World
    Health Organization, International Programme on Chemical Safety.

    IPCS (1985c) Environmental Health Criteria 51: Guide to short-term
    tests for detecting mutagenic and carcinogenic chemicals. Geneva,
    Switzerland, World Health Organization, International Programme on
    Chemical Safety.

    IPCS (1986a) Environmental Health Criteria 57: Principles of
    toxicokinetic studies. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1986b) , Environmental Health Criteria 59: Principles for
    evaluating health risks from chemicals during infancy and early
    childhood: The need for a special approach. Geneva, Switzerland, World
    Health Organization, International Programme on Chemical Safety.

    IPCS (1986c) Environmental Health Criteria 60: Principles and methods
    for the assessment of neurotoxicity associated with exposure to
    chemicals. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1987a) Environmental Health Criteria 70: Principles for the
    safety assessment of food additives and contaminants in food. Geneva,
    Switzerland, World Health Organization, International Programme on
    Chemical Safety.

    IPCS (1987b) Environmental Health Criteria 72: Principles of studies
    on diseases of suspected chemical aetiology and their prevention.
    Geneva, Switzerland, World Health Organization, International
    Programme on Chemical Safety.

    IPCS (1990a) Environmental Health Criteria 104: Principles for the
    toxicological assessment of pesticide residues in food. Geneva,
    Switzerland, World Health Organization, International Programme on
    Chemical Safety.

    IPCS (1990b), Environmental Health Criteria 109: Summary report on the
    evaluation of short-term  in vivo tests for carcinogens
    (collaborative study on  in vivo tests). Geneva, Switzerland, World
    Health Organization, International Programme on Chemical Safety.

    IPCS (1991) Environmental Health Criteria 119: Principles and methods
    for the assessment of nephrotoxicity associated with exposure to
    chemicals. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1992a) Environmental Health Criteria 141: Quality management for
    chemical testing. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1992b) Environmental Health Criteria 144: Principles for
    evaluating the effects of chemicals on the aged population. Geneva,
    Switzerland, World Health Organization, International Programme on
    Chemical Safety.

    IPCS (1993) Environmental Health Criteria 155: Biomarkers and risk
    assessment: concepts and principles. Geneva, Switzerland, World Health
    Organization, International Programme on Chemical Safety.

    IPCS (1994) Environmental Health Criteria 170: Assessing human health
    risks to chemicals: derivation of guidance values for health-based
    exposure limits. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1996) Environmental Health Criteria 180: Principles and methods
    for assessing direct immunotoxicity associated with exposure to
    chemicals. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    IPCS (1997) Environmental chemicals and respiratory
    hypersensitization. Proceedings of an IPCS Workshop, Oslo, Norway, 29
    November December. Environ Toxicol Pharmacol, 2/3 (3-special issue),
    77-242.

    IPCS (1998) Draft Environmental Health Criteria: Principles of human
    exposure assessment. Geneva, Switzerland, World Health Organization,
    International Programme on Chemical Safety.

    Kelsey JL, Thompson WD & Evans AS (1986) Methods in observational
    epidemiology. Boston, MA, USA: Little, Brown and Company.

    Konheim CS (1988) Risk communication in the real world. Risk Anal,
    8: 367-373.

    Kraus NN & Slovic P (1988) Taxonomic analysis of perceived
    risk: Modeling individual and group perceptions within homogenous
    hazard domains. Risk Anal, 8: 435-455.

    Krewski D, Brown C, & Murdoch D (1984) Determining "safe" levels of
    exposure: safety factors or mathematical models? Fund Appl Toxicol,
    4: S383-S394.

    Krewski D, Murdoch D, & Dewanji A (1986) Statistical modeling and
    extrapolation of carcinogenesis data. In: Moolgavkar SH & Prentice RL,
    ed. Modern Statistical Methods in Chronic Disease Epidemiology. New
    York, NY, John Wiley and Sons, pp 259-282.

    Krewski D, Somers E, & Birkwood PL (1987) Risk perceptions in a
    decision making context. Environ Carcinogen Revs J Environ Sci Hlth,
    C5(2): 175-209.

    Krewski D, Thorslund T & Whithey J (1989) Carcinogenic risk assessment
    of complex mixtures. Toxicol Ind Health 5: 851-867.

    Lauwerys R (1984) Basic concepts of human exposure. In: Berlin A,
    Draper M, Hemminki K, & Vainio H ed. Monitoring Exposure to
    Carcinogenic and Mutagenic Agents. IARC Scientific Publications, Lyon,
    France, International Agency for Research on Cancer, No 59, pp. 31-36.

    Leisenring W & Ryan L (1992) Statistical properties of the NOAEL.
    Regul Toxicol Pharmacol, 15: 161-171.

    Lewis SC, Lynch JR, & Nikiforov AI (1990) New approach to deriving
    community exposure guidelines from "No-Observed-Adverse-Effect
    Levels". Regul Toxicol Pharmacol, 11: 314-330.

    Lilienfeld AM & Lilienfeld D (1979) Foundations of Epidemiology. 2nd
    ed. New York, NY: Oxford University Press.

    Lioy PJ (1990) Assessing total human exposure to contaminants. Environ
    Hlth Perspec, 24: 938-945.

    Liteplo RG, Meek ME, Gomes R, & Savard S (1994) Inorganic
    fluoride:  evaluation of risks to health from environmental exposure
    to fluoride in Canada.  Environ Carcinog & Ecotox Revs.
    c12(2): 327-344.

    Mausner JS & Kremer S (1985) Epidemiology, 2nd ed. Philadelphia: WB
    Saunders Company.

    Meek ME, Newhook R, Liteplo RG & Armstrong VC (1994) Approach to
    assessment of risk to human health for Priority Substance under the
    Canadian Environmental Protection. J Environ Sci Health
    C12(2): 105-134.

    Merrill RA (1991) Regulatory toxicology. In: Amdur MO, Doull J, &
    Klaasen CD ed. Casarett and Doull's Toxicology. 4th edition. New York,
    Oxford, Beijing, Singapore, Toronto, Pergamon Press, pp 970-983.

    Monro AM (1990) Interspecies comparisons in toxicology: the utility
    and futility of plasma concentrations of the test substance. Regul
    Toxicol Pharmacol, 12: 137-160.

    Monro A (1993) How useful are chronic (life-span) toxicology studies
    in rodents in identifying pharmaceuticals that pose a carcinogenic
    risk to humans? Adverse Drug React Toxicol Rev, 12: 5-34.

    Montesano R, Bartsch H, Vainio H, Wilbourn & Yamasaki H (eds) (1986)
    Long-term and short-term assays for carcinogens. A critical appraisal
    (IARC Scientific Publications No. 83), Lyon, France, International
    Agency for Research on Cancer (IARC).

    Moolgavkar SH, Dewanji A, & Venzon DJ (1988) A stochastic two-stage
    model for cancer risk assessment. I: The hazard function and the
    probability of tumor. Risk Anal, 8:383-392.

    Morgan MG (1993) Risk analysis and management. Sci Amer, 269: 32-41.

    Munro IC & Morrison AB (1990) Interaction of science and politics in
    toxicological regulation. In: Clayson DB, Munro IC, Shubik P, &
    Swenberg JA ed. Progress in Predictive Toxicology. Amsterdam, Elsevier
    Science Publ BV, pp 373-387.

    Murdoch DJ, Krewski D, & Crump KS (1987) Mathematical models of
    carcinogenesis. In: Thompson JR & Brown B ed. Cancer modeling, New
    York, NY, Marcel Dekker, pp 61-89.

    Mushak B (1993) Environmental equity: A new coalition for justice.
    Environ Hlth Persp, 101: 478-483.

    Nilsson R, Tasheva M, & Jaeger B (1993) Why different regulatory
    decisions when the scientific information base is similar?- Human risk
    asessment. Regul Toxicol Pharmacol, 17: 292-332.

    OECD (1987) Decision-recommendation of the Council on the systematic
    investigation of existing chemicals C (87) 90 (Final). Paris, France,
    Organization for Economic Cooperation and Development.

    OECD (1989) Compendium of Environmental Exposure Assessment Methods
    for Chemicals. Paris, France, Organization for Economic Cooperation
    and Development (Environmental Monograph No 27).

    OECD (1991a) The OECD Workshop on the Application of Simple Models for
    Environmental Assessment [Berlin, 11-13 December]. Paris, France,
    Organisation for Economic Co-operation and Development.

    OECD (1991b) The State of the Environment. Paris, France, Organisation
    for Economic Co-operation and Development, pp.253-265.

    OECD (1998) OECD Principles on Good Laboratory Practice (as revised in
    1997). OECD Series on Principles of Good Laboratory Practice and
    compliance monitoring. Number 1. Environment Directorate, Chemicals
    Group and Management Committee. Paris, France, Organisation for
    Economic Co-operation and Development, ENV/MC/CHEM (98)17.

    Otson R, Fellin P, Chan C (1996) Multi-media exposure study: rational
    and design. In: Measurement of Toxic and Related Air pollutants
    VIP-64. Air & Waste Management Association, One Gate Center, Third
    Floor, Pittsburgh, PA 15222, USA. pp 559-566.

    Pariza MW (1992) Risk-benefit perception. In: Food Safety Assessment.
    Finley JW, Robinson SF, & Armstrong DJ, eds. American Chemical Society
    (ACS) Symposium No 484. Washington, DC, American Chemical Society, pp
    36-40.

    Perera FP (1987) Molecular cancer epidemiology: A new tool in cancer
    prevention. J Natl Cancer Inst, 78: 887-898.

    Perera FP (1988) The significance of DNA and protein adducts in human
    biomonitoring studies. Mutat Res, 205: 255-269.

    Peto R (1978) Carcinogenic effects of chronic exposure to very low
    levels of toxic substances, Environ Health Perspect, 22: 155-161.

    Peto R, Pike MC, Bernstein L, Gold LS & Ames BN (1984) The TD50: a
    proposed general convention for the numerical description of the
    carcinogenic potency of chemicals in chronic-exposure animal
    experiments. Environ Health Perspective 58, 1-8.

    Poirier MC & Beland FA (1987) Determination of carcinogen-induced
    macromolecular adducts in animals and humans. Prog Exp Tumor Res,
    31: 1-10.

    Portier CJ (1988) Species correlation of chemical carcinogens. Risk
    Anal, Dec 8 (4): 551-553.

    Presidential/Congressional Commission on Risk Assessment and Risk
    Management (1997a) Framework for Environmental Health Risk Management.
    Final Report Vol. 1, Washington, DC, USA.

    Presidential/Congressional Commission on Risk Assessment and Risk
    Management (1997b) Risk Assessment and Risk Management in Regulatory
    Decision-Making. Final Report Vol. 2, Washington, DC, USA.

    Price PS, Keenan RE, Swartout JC, Gillis CA, Carlson-Lynch H, Dourson
    ML (1997) An approach for modeling noncancer dose responses with an
    emphasis on uncertainty. Risk Anal 17(4): 427-437.

    Purchase (1986) Unpredictability: an essay in toxicology. Food Chem
    Toxicol, Apr 24 (4): 343-349.

    Renwick AG (1993a) Toxicokinetics. In: Ballantyne B, Marrs T, & Turner
    P ed. General & Applied Toxicology. New York, Stockton Press, Vol 1,
    pp 121-151.

    Renwick AG (1993b) Data-derived safety factors for the evaluation of
    food additives and environmental contaminants. Fd Addit Contam,
    10: 275-305.

    Ricci PF & Cox LA (1987) Acceptability of chronic health risks. Toxic
    Law Rept, 1: 986-1001.

    Ris CH & Preuss PW (1988) Risk assessment and risk management : A
    process. In: Cothern CR, Mehlman MA, & Marcus WL ed.  Risk Assessment
    and Risk Management of Industrial and Environmental Chemicals.
    Princeton, NJ, Princeton Scientific Publ Co, Vol XV, pp 1-21.

    RIVM (1994) Uniform Systems for the Evaluation of Substances (USES),
    version 1.0. The Hague, The Netherlands, Ministry of Housing, Spatial
    Planning and Environment (Distribution no 11144/150).

    Rodricks JV (1992) Calculated Risks. Cambridge, MA, Cambridge
    University Press.

    Rothman KT (1986) Modern Epidemiology. Boston, MA, USA: Little, Brown
    and Company.

    Sandman PM, Muller PM, Johnson BB, & Weinstein NN (1993) Agency
    communication, community outrage and perception of risk.  Three
    simulation experiments. Risk Anal, 13: 585 592.

    Scala RA (1991) Risk assessment. In: Amdur MO, Doull J, & Klaasen CD,
    ed. Casarett and Doull's Toxicology. 4th edition, New York, Oxford,
    Beijing, Frankfurt, Sao Paulo, Sydney, Tokyo, Toronto, Pergamon Press,
    pp 985-996.

    Seidman BC, Brown SL, De Rosa CT, & Mumtaz MM (1991) Sensitive and
    Hyper-susceptible populations: Risk assessment considerations for
    exposure to single chemicals and chemical mixtures. In: Zervos C ed.
    Risk Analysis. New York, NY, Plenum Press, pp 305-313.

    Sexton K, Callahan MA, & Ryan EF (1995) Estimating exposure and dose
    to characterize health risks: the role of human tissue monitoring in
    exposure assessment. Env Health Health, Suppl 3: 13-30.

    Shuker DEG (1989) Nucleic acid-carcinogen adducts in human dosimetry.
    Arch Toxicol, (Suppl 13): 55-65.

    Silbergeld EK (1993) Risk assessment: The perspective experience of US
    environmentalists. Environ Hlth Persp, 101: 100-104.

    Singer E & Endreny PM (1993) Reporting on Risk. New York, Russel Sage
    Foundation.

    Skipper PI & Tannenbaum SR (1990) Protein adducts in the molecular
    dosimetry of chemical carcinogens. Carcinogenesis, 11: 507-518.

    Slovic P (1987) Perceptions of risk. Science, 236: 280-284.

    Slovic P (1993) Perceived risk, trust and democracy. Risk Anal,
    13: 675-682.

    Somers E (1987) Making decisions with numbers. Regul Toxicol
    Pharmacol, 8: 35-42.

    Somers E (1993) Perspectives on Risk Management. [Presented at
    Managing Risks to Life and Health Meeting, 18 October]. Ottawa, Royal
    Society of Canada.

    Stayner LT & Bailer AJ (1993) Comparing toxicologic and epidemiologic
    studies. Methylene chloride - a case study. Risk Anal, Dec 13
    (6): 667-673.

    Stern RM (1986) Analysis of the decision making process in chemical
    safety. Sci Total Environ, 51: 27-62.

    Susser M (1977) Judgement and causal inference: criteria in
    epidemiologic studies. Am J Epidemiol, 105: 1- 15.

    Tennant RW, Margolin BH, Shelby MD, Zeiger E, Haseman JK, Spalding J,
    Caspary W, Resnick M, Stasiewicz S, Anderson B, et al. (1987)
    Prediction of chemical carcinogenicity in rodents from  in vitro
    genetic toxicity assays. Science 236: 933-941.

    Travis CC, Pack SA, Saulsbury AW & Yambert MW (1990a) Prediction of
    carcinogenic potency from toxicological data. Mutal Res, May 241
    (1): 21-36.

    Travis CC, Saulsbury AW & Pack SA (1990b) Prediction of cancer potency
    using a battery of mutation and toxicity data. Mutagenesis, May 5
    (3): 213-219.

    Travis CC, Wang LA & Waehner MJ (1991) Quantitative correlation of
    carcinogenic potency with four different classes of short-term test
    data. Mutagenesis, Sep 6 (5): 353-360.

    UK DOH (1991) (Department of Health) Guidelines for the evaluation of
    chemicals for carcinogenicity. Committee on Carcinogenicity of
    Chemicals in Food, Consumer Products and the Environment. London, Her
    Majesty's Stationary Office (HMSO).

    UK DOH (1995) (Department of Health) Annual Report of the Committees
    on Toxicity, Mutagenicity, Carcinogenicity of Chemicals in Food,
    Consumer Products and the Environment. London, Her Majesty's
    Stationary Office (HMSO).

    UK HSE (1989) Health and Safety Executive.  Quantified risk
    assessment: Its input to decision making.  London, Her Majesty's
    Stationery Office (HMSO).

    Ulfvarson U (1992) Validation of exposure information in occupational
    epidemiology. Am J Ind Med, 21: 125-132.

    US EPA (1984) Study of carbon monoxide exposure on residents of
    Washington, DC, and Denver, CO. Environmental Monitoring Systems
    Laboratory, Office of Research and Development, Research Triangle
    Park, NC (EPA-600/S4-84/031, NTIS PB84-183516).

    US EPA (1986a) Guidelines for carcinogen risk assessment. Fed Reg,
    51: 33992-34003.

    US EPA (1986b) Guidelines for Estimating Exposures. Fed Reg, 51
    (185): 34042-34054.

    US EPA (1987a) The total exposure assessment methodology (TEAM) study.
    Vol I: Summary and analysis. Office of Acid Deposition, Environmental
    Monitoring and Quality Assurance, Office of Research and Development,
    Washington, DC, US Environmental Protection Agency
    (EPA-600/6-87/002a).

    US EPA (1987b) Pesticide Assessment Guidelines; Subdivision
    U-Applicator Exposure. Washington, DC, US Environmental Protection
    Agency (EPA PB 87-133286).

    US EPA (1992) Guidelines for exposure assessment. Washington, DC, US
    Environmental Protection Agency, Federal Register, 57:22888.

    US EPA (1996a) Risk Characterization: Practical Guidance for
    NCEA - Washington Based Risk Assessors, National Center for
    Environmental Assessment, Washington, DC, US Environmental Protection
    Agency (NCEAW-0105).

    US EPA (1996b) Proposed Guidelines for Carcinogen Risk Assessment.
    Washington, DC, US Environmental Protection Agency, Federal Register.
    6(79): 17960-18011.

    US EPA (1996c) Exposure Factors Handbook. Washington, DC, US
    Environmental Protection Agency EPA/600P-95/002Bc, Review Draft.
    Update to exposure Factors Handbook EPA/600/8-89/043 - May 1989.

    US FDA (1993) Food and Drug Administration: Toxicological Principles
    for the Safety Assessment of Direct Food Additives and Color Additives
    Used in Food. "Redbook II" Draft. Washington, DC, Center for Food
    Safety and Applied Nutrition, US Food and Drug Administration.

    US NAS (1983) National Academy of Science: Risk Assessment in the
    Federal Government: Managing the Process. National Research Council,
    Committee on the Institutional Means for Assessment of Risks to Public
    Health. Washington DC, National Academy Press, pp 1-50.

    US NRC (1989) National Research Council: Improving Risk Communication.
    Washington, DC, National Academy Press.

    US NRC (1990) National Research Council: Human exposure assessment for
    airborne pollutants: Advances and applications. Committee on Advances
    in Assessing Human Exposure to Airborne Pollutants, Committee on
    Geosciences, Environment, and Resources. Washington, DC, National
    Academy Press.

    US NRC (1992) National Research Council: Biological Markers in
    Immunotoxicology. Washington, DC, National Academy Press.

    Van Eijndhoven JCM, Wetering RAPM, Worrel CW, de Boer J, Van der Pligt
    J, & Stallen PJM (1994) Risk communication in the Netherlands: The
    monitored introduction of the EC "Post-Seveso" Directive. Risk Anal,
    14: 87-96.

    Van Ryzin J (1980) Quantitative risk assessment. J Occup Med,
    22: 321-326.

    WHO (1986) Field Surveys of Exposure to Pesticides. Standard Protocol.
    Toxicol Lett, 33: 2234-235.

    WHO (1993) Guidelines for drinking-water quality, Recommendations.
    Geneva, Switzerland, World Health Organization, Vol 1, 30 pp.

    Wiener JO (1993) Risk assessment and cost-benefit analyses: In the
    public interst? Environ Hlth Perspect, 101: 408-409.

    Wilson R (1990) Analyzing the daily risks of life. In: Readings in
    Risk. Glickman TS & Gough M ed. Washington, DC, Resources for the
    Future, pp 55-59.

    Wilson R & Crouch EAC (1987) Risk assessment and comparisons: An
    introduction. Science, 236: 267-270.

    Wogan GN (1989) Markers of Exposure to Carcinogens: Methods for Human
    Biomonitoring. J Am Coll Toxicol, 8: 871-881.

    Wogan GN (1992) Molecular epidemiology in cancer risk and prevention:
    Recent progress and avenues for future research. Environ Hlth
    Perspect, 98: 167-178.

    Zeiger E, Haseman JK, Shelby MD, Margolin BH & Tennant RW (1990)
    Evalution of four in vitro genetic toxicity tests for predicting
    rodent carcinogenecity: confirmation of earlier results with 41
    additional chemicals. Environ Mol Mutagen, 16 Suppl 18: 1-14.

    Zimmerman R (1993) Social equity and environmental risk. Risk Anal,
    13: 649-666.

    APPENDIX 1.  PREAMBLE TO THE IARC MONOGRAPHS

         The Preamble to the Monographs sets out the objective and scope
    of the evaluation programme, the procedures used when making
    assessments, and the types of evidence considered and criteria used in
    reaching the final evaluations. The list of contents is given here as
    is the full text referring to the Background and Evaluation sections.
    Full text of the Preamble should always be used when referring to the
    list of evaluations provided.

    Background

         In 1969, the International Agency for Research on Cancer (IARC)
    initiated a programme to evaluate the carcinogenic risk of chemicals
    to humans and to produce monographs on individual chemicals. The
     Monographs programme has since been expanded to include
    consideration of exposures to complex mixtures of chemicals (which
    occur, for example, in some occupations and as a result of human
    habits) and of exposures to other agents, such as radiation and
    viruses. With Supplement 6 (IARC, 1987a), the title of the series was
    modified from  IARC Monographs on the Evaluation of the Carcinogenic
     Risk of Chemicals to Humans to  IARC Monographs on the Evaluation
     of Carcinogenic Risks to Humans, in order to reflect the widened
    scope of the programme.

         The criteria established in 1971 to evaluate carcinogenic risk to
    humans were adopted by the working groups whose deliberations resulted
    in the first 16 volumes of the  IARC Monographs series. Those
    criteria were subsequently updated by further ad-hoc working groups
    (IARC, 1977, 1978, 1979, 1982, 1983, 1987b, 1988, 1991; Vainio et al.,
    1992).

    Evaluation

         Evaluations of the strength of the evidence for carcinogenicity
    arising from human and experimental animal data are made, using
    standard terms.

         It is recognized that the criteria for these evaluations,
    described below, cannot encompass all of the factors that may be
    relevant to an evaluation of carcinogenicity. In considering all of
    the relevant scientific data, the Working Group may assign the agent,
    mixture or exposure circumstance to a higher or lower category than a
    strict interpretation of these criteria would indicate.

     (a)  Degrees of evidence for carcinogenicity in humans and in
          experimental animals and supporting evidence

         These categories refer only to the strength of the evidence that
    an exposure is carcinogenic and not to the extent of its carcinogenic
    activity (potency) nor to the mechanisms involved. A classification
    may change as new information becomes available.

         An evaluation of degree of evidence, whether for a single agent
    or a mixture, is limited to the materials tested, as defined
    physically, chemically or biologically. When the agents evaluated are
    considered by the Working Group to be sufficiently closely related,
    they may be grouped together for the purpose of a single evaluation of
    degree of evidence.

     (i) Carcinogenicity in humans

         The applicability of an evaluation of the carcinogenicity of a
    mixture, process, occupation or industry on the basis of evidence from
    epidemiological studies depends on the variability over time and place
    of the mixtures, processes, occupations and industries. The Working
    Group seeks to identify the specific exposure, process or activity
    which is considered most likely to be responsible for any excess risk.
    The evaluation is focused as narrowly as the available data on
    exposure and other aspects permit.

         The evidence relevant to carcinogenicity from studies in humans
    is classified into one of the following categories:

     Sufficient evidence of carcinogenicity: The Working Group considers
    that a causal relationship has been established between exposure to
    the agent, mixture or exposure circumstance and human cancer. That is,
    a positive relationship has been observed between the exposure and
    cancer in studies in which chance, bias and confounding could be ruled
    out with reasonable confidence.

     Limited evidence of carcinogenicity: A positive association has been
    observed between exposure to the agent, mixture or exposure
    circumstance and cancer for which a causal interpretation is
    considered by the Working Group to be credible, but chance, bias or
    confounding could not be ruled out with reasonable confidence.

     Inadequate evidence of carcinogenicity: The available studies are of
    insufficient quality, consistency or statistical power to permit a
    conclusion regarding the presence or absence of a causal association,
    or no data on cancer in humans are available.

     Evidence suggesting lack of carcinogenicity: There are several
    adequate studies covering the full range of levels of exposure that
    human beings are known to encounter, which are mutually consistent in
    not showing a positive association between exposure to the agent,
    mixture or exposure circumstance and any studied cancer at any
    observed level of exposure. A conclusion of evidence suggesting lack
    of carcinogenicity is inevitably limited to the cancer sites,
    conditions and levels of exposure and length of observation covered by
    the available studies. In addition, the possibility of a very small
    risk at the levels of exposure studied can never be excluded.

         In some instances, the above categories may be used to classify
    the degree of evidence related to carcinogenicity in specific organs
    or tissues.

     (ii) Carcinogenicity in experimental animals

         The evidence relevant to carcinogenicity in experimental animals
    is classified into one of the following categories:

     Sufficient evidence of carcinogenicity: The Working Group considers
    that a causal relationship has been established between the agent or
    mixture and an increased incidence of malignant neoplasms or of an
    appropriate combination of benign and malignant neoplasms in (a) two
    or more species of animals or (b) in two or more independent studies
    in one species carried out at different times or in different
    laboratories or under different protocols.

         Exceptionally, a single study in one species might be considered
    to provide sufficient evidence of carcinogenicity when malignant
    neoplasms occur to an unusual degree with regard to incidence, site,
    type of tumour or age at onset.

     Limited evidence of carcinogenicity: The data suggest a carcinogenic
    effect but are limited for making a definitive evaluation because,
    e.g. (a) the evidence of carcinogenicity is restricted to a single
    experiment; or (b) there are unresolved questions regarding the
    adequacy of the design, conduct or interpretation of the study; or (c)
    the agent or mixture increases the incidence only of benign neoplasms
    or lesions of uncertain neoplastic potential, or of certain neoplasms
    which may occur spontaneously in high incidences in certain strains.

     Inadequate evidence of carcinogenicity: The studies cannot be
    interpreted as showing either the presence or absence of a
    carcinogenic effect because of major qualitative or quantitative
    limitations, or no data on cancer in experimental animals are
    available.

     Evidence suggesting lack of carcinogenicity: Adequate studies
    involving at least two species are available which show that, within
    the limits of the tests used, the agent or mixture is not
    carcinogenic. A conclusion of evidence suggesting lack of
    carcinogenicity is inevitably limited to the species, tumour sites and
    levels of exposure studied.

     (b)  Other data relevant to the evaluation of carcinogenicity and
          its mechanisms

         Other evidence judged to be relevant to an evaluation of
    carcinogenicity and of sufficient importance to affect the overall
    evaluation is then described. This may include data on preneoplastic
    lesions, tumour pathology, genetic and related effects,
    structure-activity relationships, metabolism and pharmacokinetics,
    physicochemical parameters and analogous biological agents.

         Data relevant to mechanisms of the carcinogenic action are also
    evaluated. The strength of the evidence that any carcinogenic effect
    observed is due to a particular mechanism is assessed, using terms
    such as weak, moderate or strong. Then, the Working Group assesses if
    that particular mechanism is likely to be operative in humans. The
    strongest indications that a particular mechanism operates in humans
    come from data on humans or biological specimens obtained from exposed
    humans. The data may be considered to be especially relevant if they
    show that the agent in question has caused changes in exposed humans
    that are on the causal pathway to carcinogenesis. Such data may,
    however, never become available, because it is at least conceivable
    that certain compounds may be kept from human use solely on the basis
    of evidence of their toxicity and/or carcinogenicity in experimental
    systems.

         For complex exposures, including occupational and industrial
    exposures, the chemical composition and the potential contribution of
    carcinogens known to be present are considered by the Working Group in
    its overall evaluation of human carcinogenicity. The Working Group
    also determines the extent to which the materials tested in
    experimental systems are related to those to which humans are exposed.

     (c)  Overall evaluation

         Finally, the body of evidence is considered as a whole, in order
    to reach an overall evaluation of the carcinogenicity to humans of an
    agent, mixture or circumstance of exposure.

         An evaluation may be made for a group of chemical compounds that
    have been evaluated by the Working Group. In addition, when supporting
    data indicate that other, related compounds for which there is no
    direct evidence of capacity to induce cancer in humans or in animals
    may also be carcinogenic, a statement describing the rationale for
    this conclusion is added to the evaluation narrative; an additional
    evaluation may be made for this broader group of compounds if the
    strength of the evidence warrants it.

         The agent, mixture or exposure circumstance is described
    according to the wording of one of the following categories, and the
    designated group is given. The categorization of an agent, mixture or
    exposure circumstance is a matter of scientific judgement, reflecting
    the strength of the evidence derived from studies in humans and in
    experimental animals and from other relevant data.

    *     Group 1: The agent (mixture) is carcinogenic to humans. The
          exposure circumstance entails exposures that are carcinogenic
          to humans.

         This category is used when there is  sufficient evidence of
    carcinogenicity in humans. Exceptionally, an agent (mixture) may be
    placed in this category when evidence in humans is less than
    sufficient but there is  sufficient evidence of carcinogenicity in

    experimental animals and strong evidence in exposed humans that the
    agent (mixture) acts through a relevant mechanism of carcinogenicity.

     *   Group 2

         This category includes agents, mixtures and exposure
    circumstances for which, at one extreme, the degree of evidence of
    carcinogenicity in humans is almost sufficient, as well as those for
    which, at the other extreme, there are no human data but for which
    there is evidence of carcinogenicity in experimental animals. Agents,
    mixtures and exposure circumstances are assigned to either group 2A
    (probably carcinogenic to humans) or group 2B (possibly carcinogenic
    to humans) on the basis of epidemiological and experimental evidence
    of carcinogenicity and other relevant data.

    *     Group 2A: The agent (mixture) is probably carcinogenic to
          humans.
          The exposure circumstance entails exposures that are probably
          carcinogenic to humans.

         This category is used when there is  limited evidence of
    carcinogenicity in humans and sufficient evidence of carcinogenicity
    in experimental animals. In some cases, an agent (mixture) may be
    classified in this category when there is inadequate evidence of
    carcinogenicity in humans and  sufficient evidence of carcinogenicity
    in experimental animals and strong evidence that the carcinogenesis is
    mediated by a mechanism that also operates in humans. Exceptionally,
    an agent, mixture or exposure circumstance may be classified in this
    category solely on the basis of limited evidence of carcinogenicity in
    humans.

    *     Group 2B: The agent (mixture) is possibly carcinogenic to
          humans.
          The exposure circumstance entails exposures that are possibly
          carcinogenic to humans.

    This category is used for agents, mixtures and exposure circumstances
    for which there is  limited evidence of carcinogenicity in humans and
    less than  sufficient evidence of carcinogenicity in experimental
    animals. It may also be used when there is  inadequate evidence of
    carcinogenicity in humans but there is  sufficient evidence of
    carcinogenicity in experimental animals. In some instances, an agent,
    mixture or exposure circumstance for which there is
     inadequate evidence of carcinogenicity in humans but
     limited evidence of carcinogenicity in experimental animals together
    with supporting evidence from other relevant data may be placed in
    this group.

    *     Group 3: The agent (mixture or exposure circumstance) is not
          classifiable as to its carcinogenicity to humans.

         This category is used most commonly for agents, mixtures and
    exposure circumstances for which the evidence of carcinogenicity is
    inadequate in humans and inadequate or limited in experimental
    animals.

         Exceptionally, agents (mixtures) for which the evidence of
    carcinogenicity is inadequate in humans but sufficient in experimental
    animals may be placed in this category when there is strong evidence
    that the mechanism of carcinogenicity in experimental animals does not
    operate in humans.

         Agents, mixtures and exposure circumstances that do not fall into
    any other group are also placed in this category.

    *     Group 4: The agent (mixture) is probably not carcinogenic to
          humans.

         This category is used for agents or mixtures for which there is
     evidence suggesting lack of carcinogenicity in humans and in
    experimental animals. In some instances, agents or mixtures for which
    there is  inadequate evidence of carcinogenicity in humans but
     evidence suggesting lack of carcinogenicity in experimental animals,
    consistently and strongly supported by a broad range of other relevant
    data, may be classified in this group.

    References:

    IARC (1977)  IARC Monographs Programme on the Evaluation of the
     Carcinogenic Risk of Chemicals to Humans. Preamble (IARC intern.
    tech. Rep. No. 77/002), Lyon 

    IARC (1978)  Chemicals with Sufficient Evidence
     of Carcinogenicity in Experimental Animals-IARC Monographs
     Volumes 1-17 (IARC intern. tech. Rep. No. 78/003), Lyon 

    IARC (1979)  Criteria to Select Chemicals for IARC Monographs (IARC
    intern. tech. Rep. No. 79/003), Lyon 

    IARC (1982)  IARC Monographs on the Evaluation of the Carcinogenic
     Risk of Chemicals to Humans, Supplement 4,
     Chemicals, Industrial Processes and Industries Associated with
     Cancer in Humans (IARC Monographs, Volumes 1 to 29), Lyon

    IARC (1983)  Approaches to Classifying Chemical Carcinogens According
     to Mechanism of Action (IARC intern. tech. Rep. No. 83/001), Lyon 

    IARC (1987a)  IARC Monographs on the Evaluation of Carcinogenic Risks
     to Humans, Supplement 6,  Genetic and Related Effects: An Updating
     of Selected IARC Monographs  from Volumes 1 to 42, Lyon

    IARC (1987b)  IARC Monographs on the Evaluation of Carcinogenic Risks
     to Humans, Supplement 7,  Overall Evaluations of Carcinogenicity:
     An Updating of IARC Monographs  Volumes 1 to 42, Lyon

    IARC (1988)  Report of an IARC Working Group to Review the Approaches
     and Processes Used to Evaluate the Carcinogenicity of Mixtures and
     Groups of Chemicals (IARC intern. tech. Rep.No. 88/002), Lyon 

    IARC (1991)  A Consensus Report of an IARC Monographs Working Group
     on the Use of Mechanisms of Carcinogenesis in Risk Identification
    (IARC intern. tech. Rep. No. 91/002), Lyon 

    Vainio, H., Magee, P., McGregor, D. & McMichael, A., eds (1992)
     Mechanisms of Carcinogenesis in Risk Identification (IARC Scientific
    Publications No. 116), Lyon, IARC 

    APPENDIX 2.  OECD'S GUIDELINES FOR THE TESTING OF CHEMICALS
    (from http://www.oecd.org/ehs/test/health.htm)

    1.  Adopted Test Guidelines

    TG 401    Acute Oral Toxicity (Updated Guideline, adopted 24th
              February 1987)
    TG 402    Acute Dermal Toxicity (Updated Guideline, adopted 24th
              February 1987)
    TG 403    Acute Inhalation Toxicity (Original Guideline, adopted 12th
              May 1981)
    TG 404    Acute Dermal Irritation/Corrosion (Updated Guideline,
              adopted 17th July 1992)
    TG 405    Acute Eye Irritation/Corrosion (Updated Guideline, adopted
              24th February 1987)
    TG 406    Skin Sensitisation (Updated Guideline, adopted 17th July
              1992)
    TG 407    Repeated Dose 28-day Oral Toxicity Study in Rodents (Updated
              Guideline, adopted 27th July 1995
    TG 408    Subchronic Oral Toxicity - Rodent: 90-day Study (Original
              Guideline, adopted 12th May 1981)
    TG 409    Subchronic Oral Toxicity - Non-Rodent: 90-day Study
              (Original Guideline, adopted 12th May 1981)
    TG 410    Repeated Dose Dermal Toxicity: 21/28-day Study (Original
              Guideline, adopted 12th May 1981)
    TG 411    Subchronic Dermal Toxicity: 90-day Study (Original
              Guideline, adopted 12th May 1981)
    TG 412    Repeated Dose Inhalation Toxicity: 28-day or 14-day Study
              (Original Guideline, adopted 12th may 1981)
    TG 413    Subchronic Inhalation Toxicity: 90-day Study (Original
              Guideline, adopted 12th May 1981
    TG 414    Teratogenicity (Original Guideline, adopted 12th May 1981
    TG 415    One-Generation Reproduction Toxicity Study (Original
              Guideline, adopted 26th May 1983)
    TG 416    Two-Generation Reproduction Toxicity Study (Original
              Guideline, adopted 26th May 1983
    TG 417    Toxicokinetics (Updated Guideline, adopted 4th April 1984)
    TG 418    Delayed Neurotoxicity of Organophosphorus Substances
              Following Acute Exposure (Updated Guideline, adopted 27th
              July 1995)
    TG 419    Delayed Neurotoxicity of Organophosphorus Substances: 28-day
              Repeated Dose Study (Updated Guideline, adopted 27th July
              1995
    TG 420    Acute Oral Toxicity - Fixed Dose Method (Original Guideline,
              adopted 17th July 1992
    TG 421    Reproduction/Developmental Toxicity Screening Test (Original
              Guideline, adopted 27th July 1995)
    TG 422    Combined Repeated Dose Toxicity Study with the
              Reproduction/Developmental Toxicity Screening Test (Original
              Guideline, adopted 22nd March 1996)
    TG 423    Acute Oral toxicity - Acute Toxic Class Method (Original
              Guideline, adopted 22nd March 1996)

     TG 424  Neurotoxicity Study in Rodents (Original Guideline, adopted
              21st July 1997
    TG 451    Carcinogenicity Studies (Original Guideline, adopted 12th
              May 1981)
    TG 452    Chronic Toxicity Studies (Original Guideline, adopted 12th
              May 1981)
    TG 453    Combined Chronic Toxicity/Carcinogenicity Studies (Original
              Guideline, adopted 12th May 1981
    TG 471    Bacterial Reverse Mutation Test (Updated Guideline, adopted
              21st July 1997
    TG 473     In vitro Mammalian Chromosomal Aberration Test (Updated
              Guideline, adopted 21st July 1997
    TG 474    Mammalian Erythrocyte Micronucleus Test (Updated Guideline,
              adopted 21st July 1997)
    TG 475    Mammalian Bone Marrow Chromosomal Aberration Test (Updated
              Guideline, adopted 21st July 1997)
    TG 476    In vitro Mammalian Cell Gene Mutation Test (Updated
              Guideline, adopted 21st July 1997)
    TG 477    Genetic Toxicology: Sex-Linked Recessive Lethal Test in
              Drosophila melanogaster (Updated Guideline, adopted 4th
              April 1984)
    TG 478    Genetic Toxicology: Rodent Dominant Lethal Test (Updated
              Guideline, adopted 4th April 1984)
    TG 479    Genetic Toxicology: In vitro Sister Chromatid Exchange Assay
              in Mammalian Cells (Original Guideline, adopted 23rd October
              1986)
    TG 480    Genetic Toxicology: Saccharomyces cerevisiae, Gene Mutation
              Assay (Original Guideline, adopted 23rd October 1986)
    TG 481    Genetic Toxicology: Saacharomyces cerevisiae, Miotic
              Recombination Assay (Original Guideline, adopted 23rd
              October 1986)
    TG 482    Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA
              Synthesis in Mammalian Cells in vitro (Original Guideline,
              adopted 23rd October 1986)
    TG 483    Mammalian Spermatogonial Chromosome Aberration Test
              (Original Guideline, adopted 21st July 1997) TG 484 Genetic
              Toxicology: Mouse Spot Test (Original Guideline, adopted
              23rd October 1986)
    TG 485    Genetic Toxicology: Mouse Heritable Translocation Assay
              (Original Guideline, adopted 23rd October 1986)
    TG 486    Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver
              Cells in vivo (Original Guideline, adopted 21st July 1997)

    2.  Draft Test Guidelines

    TG 403    Acute Inhalation Toxicity (Draft Updated Guideline, August
              1996)a
    TG 408    Repeated Dose 90-Day Oral Toxicity Study in Rodents (Draft
              Updated Guideline, May 1998, EPOC Document)a
    TG 409    Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents
               (Draft Updated Guideline, May 1998, EPOC Document)a

     TG 414  Prenatal Developmental Toxicity Study  (Draft Updated 
               Guideline, March 1998)a
    TG 416    Two-Generation Reproduction Toxicity Study (Draft Updated
              Guideline, April 1996)a
    TG 425    Acute Oral Toxicity: Up-and-Down Procedure (Draft New
              Guideline, May 1998, EPOC Document)a

    Somatic Mutation and Recombination Tests (SMART) in Drosophila
    melanogaster (Draft New Guideline, May 1994)a

    Percutaneous Absorption: in vitro Method (Draft New Guideline, May
    1996)a

    Percutaneous Absorption: in vivo Method (Draft New Guideline, June
    1996)a

    Acute Dermal Photoirritation Screening Test (Draft New Guideline,
    February 1995)a

    Acute Dermal Photoirritation Dose-Response Test (Draft New Guideline,
    February 1995)a

    In Vitro Syrian Hamster Embryo (SHE) Cell Transformation Assay (Draft
    New Guideline, March 1996)a

    Acute Dermal Irritation Study in Human Volunteers (Draft New
    Guideline, April 1997)a

    __________________________

    a Available in Portable Document Format or Word 6 Format.

    1.  RÉSUMÉ

         La maîtrise des risques résultant d'une exposition à des produits
    chimiques (la sécurité chimique) implique avant tout une évaluation
    scientifique - dans le meilleur des cas, quantitative - des effets
    potentiels en fonction de l'intensité de l'exposition (l'évaluation du
    risque). En s'appuyant sur les résultats de cette évaluation et compte
    tenu d'un certain nombre d'autres facteurs, il est possible d'entamer
    un processus décisionnel visant à éliminer ou, en cas d'impossibilité,
    à réduire au minimum, le ou les risques imputables à la ou aux
    substances chimiques en cause (la gestion du risque).

         L'évaluation du risque constitue le cadre conceptuel dans lequel
    peut s'exercer un processus ordonné d'examen des données permettant
    d'apprécier les conséquences sanitaires ou écologiques de l'exposition
    à telle ou telle substance. Aux Etats-Unis, l'Académie nationale des
    sciences suit, pour ses évaluations du risque, une démarche qui a fait
    la preuve de son utilité (US NAS, 1983). Elle distingue quatre phases
    distinctes dans le processus d'évaluation: la reconnaissance du
    danger, l'évaluation de la relation dose-réponse, l'évaluation de
    l'exposition et la caractérisation du risque.

         La reconnaissance du danger a pour objet d'apprécier les éléments
    qui tendent à prouver l'existence d'effets indésirables pour l'homme,
    en s'appuyant sur l'ensemble des données toxicologiques disponibles et
    sur tout ce que l'on peut savoir du mode d'action du produit en cause.
    Il s'agit essentiellement de répondre à deux questions, à savoir 1) si
    l'agent en cause représente un danger pour l'Homme et 2) dans quelles
    circonstances ce danger est susceptible de se manifester. La
    reconnaissance du danger repose sur l'analyse de diverses données qui
    peuvent aller d'observations sur l'Homme à l'étude des relations entre
    l'activité de la substance et sa structure. Il doit alors être
    possible de se prononcer scientifiquement sur la question de savoir si
    la substance à expertiser peut, dans des conditions d'exposition
    données, avoir des effets indésirables sur la santé humaine. En
    général, les effets toxiques s'observent au niveau d'un ou de
    plusieurs organes cibles. Souvent, on s'efforce d'observer les divers
    points d'aboutissement de l'action toxique de la substance. On
    détermine alors l'effet critique, qui représente habituellement le
    premier effet indésirable important à apparaître lorsque la dose
    augmente.

         L'évaluation de la relation dose-réponse consiste à établir la
    relation qui existe entre la dose de produit administrée ou reçue et
    la fréquence d'un effet nocif. Pour presque tous les types d'effets
    toxiques (c'est-à-dire organospécifiques, neurologiques ou
    comportementaux, immunologiques, cancérogènes non génotoxiques,
    génésiques ou développementaux), on estime généralement qu'il existe
    une dose ou une concentration au-dessous de laquelle aucun effet
    indésirable ne se produit (c'est-à-dire qu'il existe un seuil de
    toxicité). Pour d'autres types d'effets toxiques, on suppose qu'il
    existe une probabilité d'action toxique quelle que soit l'intensité de

    l'exposition (autrement dit qu'il n'y a pas de seuil de toxicité). A
    l'heure actuelle, cette dernière hypothèse s'applique en général
    essentiellement aux effets mutagènes et aux effets cancérogènes
    génotoxiques.

         Si l'on suppose l'existence d'un seuil (par exemple, dans le cas
    d'effets non cancérogènes ou d'effets cancérogènes non génotoxiques),
    on a l'habitude de déterminer le niveau d'exposition au-dessous duquel
    on estime nulle la probabilité d'effets toxiques et que l'on exprime
    par la dose sans effet nocif observable ou NOAEL, compte tenu d'un
    certain nombre de facteurs d'incertitude (il s'agit d'une valeur
    approchée du seuil de toxicité). On peut aussi déterminer de combien
    la dose (la plus faible) sans effet nocif observable dépasse le niveau
    d'exposition estimé (c'est-à-dire la "marge de sécurité") en fonction
    des diverses sources d'incertitude. C'est une méthode que l'on a pu
    souvent qualifier d'"évaluation du degré de sécurité". Par conséquent
    la dose que l'on peut considérer en première approximation comme le
    seuil de toxicité, c'est-à-dire la NOAEL, constitue la dose critique.
    On a toutefois de plus en plus tendance à utiliser la "dose de
    référence", une estimation (ou la limite inférieure de l'intervalle de
    confiance correspondant), obtenue par modélisation, de la dose
    produisant l'effet critique avec une fréquence particulière (par ex.
    5%) pour l'évaluation quantitative de la relation dose-réponse dans le
    cas de ce genre d'effets.

         Il n'y a pas de véritable consensus au sujet de la méthodologie à
    adopter pour évaluer le risque dans le cas de substances pour
    lesquelles il pourrait ne pas exister de seuil pour l'effet critique
    (par exemple les cancérogènes génotoxiques et les mutagènes agissant
    au niveau des cellules germinales). De fait, on utilise en pareil cas
    un certain nombre de méthodes qui reposent en grande partie sur la
    caractérisation de la relation dose-réponse. Dans ces conditions, ce
    qui compte, ce sont les points expérimentaux qui définissent la pente
    de la courbe dose-réponse (et non pas la NOAEL, qui constitue une
    première approximation de la valeur du seuil).

         La troisième phase du processus consiste dans l'évaluation de
    l'exposition. Elle a pour objet de déterminer la nature et le degré du
    contact qui a eu lieu ou qui pourrait avoir lieu avec telle ou telle
    substance chimique dans diverses conditions. Différentes méthodes
    peuvent être utilisées pour procéder à ce type d'évaluation. En
    général il s'agit de méthodes directes ou indirectes comportant la
    mesure des concentrations dans l'environnement et celle de
    l'exposition individuelle ou de marqueurs biologiques. On fait souvent
    appel aussi à des modèles et à des questionnaires. L'évaluation de
    l'exposition nécessite la détermination des émissions de produits
    chimiques, des voies qu'ils empruntent et de la vitesse de leur
    déplacement, de même que leur transformation ou décomposition, afin
    d'évaluer la concentration à laquelle les populations humaines ou les
    différents compartiments de l'environnement (eau, air, sol) peuvent
    être exposés.

         Selon le but de l'évaluation, le résultat numérique peut se présenter
    sous la forme d'une estimation de l'intensité, de la vitesse,de la
    durée ou de la fréquence du contact ou encore d'une estimation de la
    dose (quantité de produit qui franchit effectivement la limite). Il
    importe de noter que c'est la dose interne, et non le niveau
    d'exposition externe, qui détermine l'effet toxique d'une exposition
    donnée.

         La caractérisation du risque constitue la phase finale du
    processus d'évaluation du risque. Elle a pour but de faciliter la
    tâche de ceux qui ont la responsabilité de gérer ce risque en leur
    fournissant, en langage ordinaire, les données scientifiques
    essentielles et les principes de base sur lesquels appuyer leurs
    décisions. En particulier, on leur donne une évaluation du risque pour
    la santé humaine dans des situations d'exposition appropriées. La
    caractérisation du risque revient donc à évaluer et à intégrer les
    données scientifiques disponibles pour déterminer la nature,
    l'importance - et souvent l'ampleur- du risque biologique ou
    écologique qu'une exposition à tel ou tel produit peut faire courir
    dans des circonstances précises, compte tenu des incertitudes qui lui
    sont attachées.

         Par "gestion du risque" on entend l'ensemble des activités à
    mettre en oeuvre pour pouvoir décider si le risque associé à une
    substance donnée appelle une élimination ou une réduction. Les
    stratégies et les options qui s'offrent en la matière peuvent être
    classées en gros selon leur nature en réglementaires, non
    réglementaires, économiques, conseillées, ou technologiques, les unes
    n'excluant pas forcément les autres. Ainsi, les mandats législatifs
    (les directives réglementaires), les considérations politiques, les
    valeurs socioéconomiques, le coût, la faisabilité technique, les
    populations exposées au risque, la durée et l'ampleur du risque et les
    conséquences possibles sur les échanges commerciaux internationaux,
    constituent toute une panoplie de facteurs dont il pourra être tenu
    compte dans la politique ou la réglementation finale. Les déterminants
    fondamentaux de la décision tels que la taille de la population, les
    ressources, les dépenses à envisager pour atteindre les objectifs de
    même que la valeur scientifique de l'évaluation du risque et des
    options opérationnelles ultérieures varient considérablement d'un
    contexte à l'autre. Il est également admis que la gestion des risques
    est une procédure complexe et de nature pluridisciplinaire, qui se
    présente rarement sous une forme codifiée ou uniforme, qu'elle est
    souvent peu structurée, mais qu'elle est néanmoins susceptible de
    prendre en compte des données changeantes émanant des sources les plus
    diverses. On estime de plus en plus que la perception du risque et le
    problème de la communication sont aussi des éléments importants à
    prendre en considération si l'on veut que les décisions soient
    acceptées par le public le plus large possible.

         Les produits chimiques sont devenus indispensables à l'Homme,
    qu'il s'agisse de lui permettre de mener à bien ses activités et son
    développement, de prévenir et de combattre de nombreuses maladies et
    d'accroître les rendements agricoles. En dépit de tous ces avantages,

    les produits chimiques, surtout s'ils sont mal utilisés, peuvent avoir
    des effets néfastes sur la santé humaine et sur l'environnement.
    L'utilisation généralisée de ces produits dans l'ensemble du monde
    augmente le risque d'effets indésirables. On peut s'attendre à ce que
    les industries chimiques poursuivent leur croissance dans les pays
    développés comme dans les pays en développement. Compte tenu de cela,
    l'évaluation et la gestion des risques résultant de l'exposition aux
    produits chimiques apparaissent comme des priorités de tout premier
    plan dans la recherche d'un développement durable.

    1.  RESUMEN

         El control de los riesgos de exposición a productos químicos
    (seguridad química) requiere en primer lugar una evaluación
    científica, idealmente cuantitativa, de los efectos potenciales con
    determinadas concentraciones de exposición (evaluación del riesgo).
    Tomando como base los resultados de la evaluación del riesgo y
    teniendo en cuenta otros factores, se puede comenzar un proceso de
    adopción de decisiones encaminado a eliminar o, si esto no fuera
    posible, reducir al mínimo el riesgo de exposición a los productos
    químicos objeto de examen (evaluación del riesgo).

         La evaluación del riesgo es un marco conceptual que proporciona
    el mecanismo que permite un examen estructurado de la información de
    interés para la estimación de los resultados en la salud o en el medio
    ambiente. En la realización de las evaluaciones del riesgo, el modelo
    de la Academia Nacional de Ciencias ha resultado un instrumento útil
    (US NAS, 1983). En este modelo el proceso de evaluación del riesgo se
    divide en cuatro etapas distintas: identificación del peligro,
    evaluación de la relación dosis-respuesta, evaluación de la exposición
    y caracterización del riesgo.

         La identificación del peligro tiene por objeto evaluar la
    importancia de las pruebas relativas a los efectos adversos en el ser
    humano, basándose en la evaluación de todos los datos disponibles
    sobre la toxicidad y el mecanismo de acción. Está concebida para
    abordar fundamentalmente dos cuestiones:1) si un agente puede
    representar un peligro para la salud de los seres humanos y 2) en qué
    circunstancias puede manifestarse un peligro identificado. La
    identificación del peligro se basa en el análisis de diversos datos,
    que pueden ir desde las observaciones en el ser humano hasta el
    análisis de las relaciones existentes entre la estructura y la
    actividad. El resultado de la práctica de identificación del peligro
    es un dictamen científico en cuanto a si el producto químico evaluado
    puede, en determinadas condiciones de exposición, causar un efecto
    adverso en la salud de los seres humanos. En general, se observa
    toxicidad en un órgano destinatario o en más. Con frecuencia se
    detectan efectos finales múltiples tras la exposición a un producto
    químico concreto. Se determina el efecto crítico, que normalmente es
    el primer efecto adverso importante que se produce al aumentar la
    dosis.

         La evaluación de la relación dosis-respuesta es el proceso de
    caracterización de la relación existente entre la dosis de un producto
    administrado o recibido y la incidencia de un efecto adverso en la
    salud. En la mayor parte de los tipos de efectos tóxicos (es decir,
    específicos de órganos, neurológicos/del comportamiento, inmunitarios,
    carcinogénesis no genotóxica, en la reproducción o en el desarrollo),
    se suele considerar que existe una dosis o concentración por debajo de
    la cual no se producen efectos adversos (es decir, un umbral). Para
    otros tipos de efectos tóxicos, se supone que existe alguna
    probabilidad de peligro en todas las concentraciones de exposición (es

    decir, que no existe un umbral). En la actualidad, el último supuesto
    se aplica fundamentalmente a la mutagénesis y la carcinogénesis
    genotóxica.

         Si se supone la existencia de un umbral (por ejemplo, para los
    efectos no neoplásicos y para los carcinógenos no genotóxicos),
    normalmente se estima que existe un nivel de exposición por debajo del
    cual no hay efectos adversos, basado en la concentración sin efectos
    adversos observados (NOAEL) (aproximación del umbral) y en factores de
    incertidumbre. Otra posibilidad consiste en examinar la magnitud en la
    cual la concentración sin efectos adversos observados (o efectos
    mínimos) (NOAEL o LOAEL) es superior a la exposición estimada (es
    decir, el "margen de seguridad"), teniendo en cuenta distintas fuentes
    de incertidumbre. Anteriormente, este método se ha descrito con
    frecuencia como una "evaluación de la seguridad". Por consiguiente, es
    fundamental la concentración que se puede considerar como una primera
    aproximación del umbral, es decir la NOAEL. Sin embargo, en la
    evaluación cuantitativa de la relación dosis-respuesta se propone cada
    vez más el uso de la "dosis de referencia", estimación derivada de un
    modelo (o su límite de confianza más bajo) de un nivel de incidencia
    determinado (por ejemplo, del 5%) para el efecto crítico.

         No hay un consenso claro sobre la metodología apropiada para la
    evaluación del riesgo de los productos químicos sin umbral para el
    efecto crítico (es decir, carcinógenos genotóxicos y mutágenos de
    células germinales). Es más, en tales casos se han adoptado diversos
    métodos basados fundamentalmente en la caracterización de la relación
    dosis-respuesta. Por consiguiente, los puntos críticos de los datos
    son los que definen la pendiente de la relación dosis-respuesta (más
    que la NOAEL, que es la primera aproximación de un umbral).

         La tercera etapa en el proceso de evaluación del riesgo es la
    evaluación de la exposición, que tiene por objeto determinar la
    naturaleza y la amplitud del contacto experimentado o previsto con las
    sustancias químicas en distintas condiciones. Se pueden utilizar
    numerosos métodos para realizar las evaluaciones de la exposición. En
    general, los métodos incluyen técnicas indirectas y directas, que
    comprenden la medición de las concentraciones en el medio ambiente y
    las exposiciones personales, así como biomarcadores. También se
    utilizan con frecuencia cuestionarios y modelos. La evaluación de la
    exposición requiere la determinación de las emisiones, las rutas y las
    velocidades de desplazamiento de una sustancia y su transformación o
    degradación, a fin de estimar las concentraciones a las cuales pueden
    estar expuestas poblaciones humanas o las distintas esferas del medio
    ambiente (agua, suelo y aire).

         En función de la finalidad de una evaluación de la exposición, el
    resultado numérico puede ser una estimación de la intensidad, la
    velocidad, la duración o la frecuencia de la exposición o la dosis por
    contacto (cantidad resultante que realmente cruza la frontera). Para
    la evaluación del riesgo basada en la relación dosis-respuesta, el
    resultado normalmente incluye una estimación de la dosis. Es

    importante señalar que es la dosis interna, no el nivel exposición
    externa, la que determina el resultado toxicológico de una exposición
    determinada.

         La caracterización del riesgo es la última etapa de la evaluación
    del riesgo. Está concebida para prestar asistencia a los especialistas
    en gestión del riesgo mediante el suministro, en lenguaje sencillo, de
    pruebas científicas esenciales y de los fundamentos en relación con el
    riesgo que necesitan para adoptar una decisión. En la caracterización
    del riesgo se proporcionan estimaciones del riesgo para la salud
    humana en los modelos de exposición pertinentes. Así pues, una
    caracterización del riesgo es una evaluación e integración de las
    pruebas científicas disponibles utilizadas para estimar la naturaleza,
    la importancia y con frecuencia la magnitud del riesgo humano y/o para
    el medio ambiente, incluidas las incertidumbres pendientes, que
    razonablemente se puede estimar que se derivan de la exposición a un
    agente concreto del medio ambiente en circunstancias específicas.

         El término "gestión del riesgo" comprende todas las actividades
    precisas para adoptar una decisión sobre si un riesgo asociado
    requiere la eliminación o una reducción necesaria. Las
    estrategias/opciones de gestión del riesgo se pueden clasificar a
    grandes rasgos como reglamentarias, no reglamentarias, económicas,
    consultivas o tecnológicas, que no son excluyentes entre sí. De esta
    manera, los mandatos legislativos (orientación reglamentaria), los
    aspectos políticos, los valores económicos, el costo, la viabilidad
    técnica, las poblaciones con riesgo, la duración y la magnitud del
    riesgo, la comparación de los riesgos y las posibles repercusiones en
    el comercio entre los países pueden considerarse, en general, como un
    amplio abanico de elementos que pueden influir en la formulación final
    de políticas o normas. Los factores fundamentales para decisión, como
    el tamaño de la población, los recursos, los costos del logro de los
    objetivos y la calidad científica de la evaluación del riesgo y las
    posteriores decisiones administrativas, varían enormemente del
    contexto de una decisión al de otra. Se reconoce asimismo que la
    gestión del riesgo es un procedimiento multidisciplinario complejo que
    raramente aparece codificado o uniforme y con frecuencia no está
    estructurado, pero que puede responder a aportaciones en evolución de
    una amplia variedad de fuentes. Cada vez se reconoce con más
    frecuencia que la percepción y la comunicación del riesgo son
    elementos importantes que también hay que tener en cuenta para lograr
    una aceptación pública lo más amplia posible de las decisiones en
    materia de gestión del riesgo.

         Los productos químicos se han convertido en una parte
    indispensable de la vida humana, que sostienen las actividades y el
    desarrollo, previenen y combaten numerosas enfermedades y aumentan la
    productividad agrícola. A pesar de sus ventajas, los productos
    químicos pueden, especialmente cuando se utilizan de manera indebida,
    producir efectos adversos en la salud humana y la integridad del medio
    ambiente. La aplicación generalizada de productos químicos en todo el
    mundo aumenta el potencial de los efectos adversos. Se prevé que

    seguirá aumentando el crecimiento de las industrias químicas, tanto en
    los países en desarrollo como desarrollados. En esta situación, se
    reconoce que la evaluación y la gestión de los riesgos de la
    exposición a productos químicos son una de las prioridades más
    importantes a la hora de aplicar los principios del desarrollo
    sostenible.
    


    See Also:
       Toxicological Abbreviations